CA3128018A1 - Therapeutic compounds and compositions - Google Patents
Therapeutic compounds and compositions Download PDFInfo
- Publication number
- CA3128018A1 CA3128018A1 CA3128018A CA3128018A CA3128018A1 CA 3128018 A1 CA3128018 A1 CA 3128018A1 CA 3128018 A CA3128018 A CA 3128018A CA 3128018 A CA3128018 A CA 3128018A CA 3128018 A1 CA3128018 A1 CA 3128018A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- subject
- compound
- cyclodextrin
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 231
- 239000000203 mixture Substances 0.000 title claims description 314
- 230000001225 therapeutic effect Effects 0.000 title description 16
- 238000000034 method Methods 0.000 claims abstract description 271
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 156
- 235000002639 sodium chloride Nutrition 0.000 claims description 142
- 229920000858 Cyclodextrin Polymers 0.000 claims description 134
- 150000003839 salts Chemical class 0.000 claims description 132
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 122
- 239000000243 solution Substances 0.000 claims description 109
- 230000009424 thromboembolic effect Effects 0.000 claims description 95
- 210000004369 blood Anatomy 0.000 claims description 83
- 239000008280 blood Substances 0.000 claims description 83
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 72
- 238000001990 intravenous administration Methods 0.000 claims description 70
- 238000001802 infusion Methods 0.000 claims description 69
- 239000000872 buffer Substances 0.000 claims description 63
- -1 alkyl cyclodextrin Chemical compound 0.000 claims description 58
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 52
- 238000001356 surgical procedure Methods 0.000 claims description 49
- 239000004067 bulking agent Substances 0.000 claims description 45
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 claims description 43
- 238000011321 prophylaxis Methods 0.000 claims description 42
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 41
- 206010047249 Venous thrombosis Diseases 0.000 claims description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 34
- 208000007536 Thrombosis Diseases 0.000 claims description 33
- 238000000502 dialysis Methods 0.000 claims description 33
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 31
- 229930195725 Mannitol Natural products 0.000 claims description 31
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 31
- 239000000594 mannitol Substances 0.000 claims description 31
- 235000010355 mannitol Nutrition 0.000 claims description 31
- 239000008101 lactose Substances 0.000 claims description 29
- 239000002904 solvent Substances 0.000 claims description 29
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 26
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- 229960002897 heparin Drugs 0.000 claims description 23
- 229920000669 heparin Polymers 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 21
- 230000008569 process Effects 0.000 claims description 20
- 239000001488 sodium phosphate Substances 0.000 claims description 19
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 17
- 206010014522 Embolism venous Diseases 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 17
- 208000004043 venous thromboembolism Diseases 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 16
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 16
- 239000008363 phosphate buffer Substances 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 239000012736 aqueous medium Substances 0.000 claims description 15
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims description 13
- 230000003750 conditioning effect Effects 0.000 claims description 13
- 210000003709 heart valve Anatomy 0.000 claims description 13
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 13
- 238000007920 subcutaneous administration Methods 0.000 claims description 11
- 238000009564 veno-arterial ECMO Methods 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000006213 oxygenation reaction Methods 0.000 claims description 10
- 238000005086 pumping Methods 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 9
- 229920002307 Dextran Polymers 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 9
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 9
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 150000005846 sugar alcohols Chemical class 0.000 claims description 9
- 230000002861 ventricular Effects 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- 239000004386 Erythritol Substances 0.000 claims description 8
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 8
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 8
- 230000000747 cardiac effect Effects 0.000 claims description 8
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 8
- 229940009714 erythritol Drugs 0.000 claims description 8
- 235000019414 erythritol Nutrition 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 235000010356 sorbitol Nutrition 0.000 claims description 8
- 235000000346 sugar Nutrition 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- 238000009565 veno-venous ECMO Methods 0.000 claims description 8
- 239000000811 xylitol Substances 0.000 claims description 8
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 8
- 235000010447 xylitol Nutrition 0.000 claims description 8
- 229960002675 xylitol Drugs 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 239000008121 dextrose Substances 0.000 claims description 7
- 150000002016 disaccharides Chemical class 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 7
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 7
- 150000002772 monosaccharides Chemical class 0.000 claims description 7
- 238000007911 parenteral administration Methods 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 230000035945 sensitivity Effects 0.000 claims description 7
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 6
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 6
- 125000000185 sucrose group Chemical group 0.000 claims description 6
- 125000004964 sulfoalkyl group Chemical group 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000007979 citrate buffer Substances 0.000 claims description 5
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 5
- 235000019800 disodium phosphate Nutrition 0.000 claims description 5
- 230000001143 conditioned effect Effects 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 150000007518 monoprotic acids Chemical group 0.000 claims description 4
- 150000007519 polyprotic acids Chemical class 0.000 claims description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 3
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 3
- 235000019801 trisodium phosphate Nutrition 0.000 claims description 3
- 108010080805 Factor XIa Proteins 0.000 abstract description 36
- 108060005987 Kallikrein Proteins 0.000 abstract description 17
- 102000001399 Kallikrein Human genes 0.000 abstract description 17
- 229940125904 compound 1 Drugs 0.000 description 243
- 208000035475 disorder Diseases 0.000 description 90
- 239000003814 drug Substances 0.000 description 46
- 238000009472 formulation Methods 0.000 description 45
- 238000011084 recovery Methods 0.000 description 33
- 238000004108 freeze drying Methods 0.000 description 32
- 238000011282 treatment Methods 0.000 description 32
- 239000000825 pharmaceutical preparation Substances 0.000 description 30
- 229940126534 drug product Drugs 0.000 description 29
- 239000000047 product Substances 0.000 description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 28
- 206010003658 Atrial Fibrillation Diseases 0.000 description 27
- 208000028867 ischemia Diseases 0.000 description 27
- 230000000302 ischemic effect Effects 0.000 description 27
- 229940124597 therapeutic agent Drugs 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 25
- 238000004128 high performance liquid chromatography Methods 0.000 description 24
- 229960001375 lactose Drugs 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 239000007924 injection Substances 0.000 description 20
- 238000002347 injection Methods 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 208000006011 Stroke Diseases 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 229940097362 cyclodextrins Drugs 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 208000032843 Hemorrhage Diseases 0.000 description 18
- 208000034158 bleeding Diseases 0.000 description 18
- 230000000740 bleeding effect Effects 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- 206010019860 Hereditary angioedema Diseases 0.000 description 17
- 206010020772 Hypertension Diseases 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 239000003981 vehicle Substances 0.000 description 17
- 238000007675 cardiac surgery Methods 0.000 description 16
- 229910052805 deuterium Inorganic materials 0.000 description 16
- 238000001035 drying Methods 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 208000028185 Angioedema Diseases 0.000 description 15
- 230000015271 coagulation Effects 0.000 description 15
- 238000005345 coagulation Methods 0.000 description 15
- 238000013329 compounding Methods 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 230000009467 reduction Effects 0.000 description 15
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 14
- 239000003146 anticoagulant agent Substances 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 201000001320 Atherosclerosis Diseases 0.000 description 13
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 13
- 208000032382 Ischaemic stroke Diseases 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- 238000006722 reduction reaction Methods 0.000 description 13
- 238000001228 spectrum Methods 0.000 description 13
- 230000001052 transient effect Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 208000005189 Embolism Diseases 0.000 description 12
- 108090000190 Thrombin Proteins 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 208000010125 myocardial infarction Diseases 0.000 description 12
- 239000011550 stock solution Substances 0.000 description 12
- 229960004072 thrombin Drugs 0.000 description 12
- 208000035868 Vascular inflammations Diseases 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 229940122036 Factor XIa inhibitor Drugs 0.000 description 10
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 208000020832 chronic kidney disease Diseases 0.000 description 10
- 208000028208 end stage renal disease Diseases 0.000 description 10
- 201000000523 end stage renal failure Diseases 0.000 description 10
- 238000010348 incorporation Methods 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 230000000399 orthopedic effect Effects 0.000 description 10
- 239000008055 phosphate buffer solution Substances 0.000 description 10
- 229910000162 sodium phosphate Inorganic materials 0.000 description 10
- 235000011008 sodium phosphates Nutrition 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 229940127219 anticoagulant drug Drugs 0.000 description 9
- 208000037849 arterial hypertension Diseases 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 238000002513 implantation Methods 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 230000036961 partial effect Effects 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 8
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 8
- 101000975003 Homo sapiens Kallistatin Proteins 0.000 description 8
- 101001077723 Homo sapiens Serine protease inhibitor Kazal-type 6 Proteins 0.000 description 8
- 229940122920 Kallikrein inhibitor Drugs 0.000 description 8
- 102100023012 Kallistatin Human genes 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 210000003414 extremity Anatomy 0.000 description 8
- 238000001631 haemodialysis Methods 0.000 description 8
- 230000000322 hemodialysis Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000013146 percutaneous coronary intervention Methods 0.000 description 8
- 230000002093 peripheral effect Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 206010002388 Angina unstable Diseases 0.000 description 7
- 206010003162 Arterial injury Diseases 0.000 description 7
- 206010003178 Arterial thrombosis Diseases 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 238000012084 abdominal surgery Methods 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 235000021317 phosphate Nutrition 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 229940074410 trehalose Drugs 0.000 description 7
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 101800004538 Bradykinin Proteins 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 6
- 101000701363 Homo sapiens Phospholipid-transporting ATPase IC Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 229940127379 Kallikrein Inhibitors Drugs 0.000 description 6
- 102100035792 Kininogen-1 Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 102100030448 Phospholipid-transporting ATPase IC Human genes 0.000 description 6
- 208000032109 Transient ischaemic attack Diseases 0.000 description 6
- 208000007814 Unstable Angina Diseases 0.000 description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 6
- 230000023555 blood coagulation Effects 0.000 description 6
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 229960002086 dextran Drugs 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 229960004793 sucrose Drugs 0.000 description 6
- 201000010875 transient cerebral ischemia Diseases 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 206010002329 Aneurysm Diseases 0.000 description 5
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 5
- 206010008088 Cerebral artery embolism Diseases 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 229960004853 betadex Drugs 0.000 description 5
- 238000013153 catheter ablation Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000035602 clotting Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000011540 hip replacement Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 201000010849 intracranial embolism Diseases 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 208000037803 restenosis Diseases 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- OENIXTHWZWFYIV-UHFFFAOYSA-N 2-[4-[2-[5-(cyclopentylmethyl)-1h-imidazol-2-yl]ethyl]phenyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CCC(N1)=NC=C1CC1CCCC1 OENIXTHWZWFYIV-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 208000031220 Hemophilia Diseases 0.000 description 4
- 208000009292 Hemophilia A Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010023421 Kidney fibrosis Diseases 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000004695 Polyether sulfone Substances 0.000 description 4
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 4
- 206010061481 Renal injury Diseases 0.000 description 4
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 4
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 4
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- 230000010100 anticoagulation Effects 0.000 description 4
- 210000001765 aortic valve Anatomy 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000003139 buffering effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 230000006623 intrinsic pathway Effects 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 208000037806 kidney injury Diseases 0.000 description 4
- 238000013150 knee replacement Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 229940127066 new oral anticoagluant drug Drugs 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229920006393 polyether sulfone Polymers 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 230000008085 renal dysfunction Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 238000001665 trituration Methods 0.000 description 4
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 4
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 102000005862 Angiotensin II Human genes 0.000 description 3
- 101800000733 Angiotensin-2 Proteins 0.000 description 3
- 200000000007 Arterial disease Diseases 0.000 description 3
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 3
- 206010014513 Embolism arterial Diseases 0.000 description 3
- 102000010911 Enzyme Precursors Human genes 0.000 description 3
- 108010062466 Enzyme Precursors Proteins 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- 108010074864 Factor XI Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010037437 Pulmonary thrombosis Diseases 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 102000012479 Serine Proteases Human genes 0.000 description 3
- 108010022999 Serine Proteases Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 206010042434 Sudden death Diseases 0.000 description 3
- 208000001435 Thromboembolism Diseases 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 229950006323 angiotensin ii Drugs 0.000 description 3
- 239000003416 antiarrhythmic agent Substances 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 238000012865 aseptic processing Methods 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000005388 borosilicate glass Substances 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 238000007919 intrasynovial administration Methods 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000012792 lyophilization process Methods 0.000 description 3
- 239000012931 lyophilized formulation Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000002103 osmometry Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000003331 prothrombotic effect Effects 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000012959 renal replacement therapy Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- 238000002411 thermogravimetry Methods 0.000 description 3
- 201000005060 thrombophlebitis Diseases 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 229960005080 warfarin Drugs 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 208000007257 Budd-Chiari syndrome Diseases 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229910002483 Cu Ka Inorganic materials 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000004803 Di-2ethylhexylphthalate Substances 0.000 description 2
- 206010015769 Extradural haematoma Diseases 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010058423 Haemangioma-thrombocytopenia syndrome Diseases 0.000 description 2
- 206010019713 Hepatic vein thrombosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 208000010299 Kasabach-Merritt syndrome Diseases 0.000 description 2
- 108010059881 Lactase Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000019498 Skin and subcutaneous tissue disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 206010053648 Vascular occlusion Diseases 0.000 description 2
- IGSKYRAPJLTXSO-MRVPVSSYSA-N [(1r)-1-isocyanatoethyl]cyclohexane Chemical compound O=C=N[C@H](C)C1CCCCC1 IGSKYRAPJLTXSO-MRVPVSSYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- LDDQLRUQCUTJBB-UHFFFAOYSA-N ammonium fluoride Chemical compound [NH4+].[F-] LDDQLRUQCUTJBB-UHFFFAOYSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000002253 anti-ischaemic effect Effects 0.000 description 2
- 229940127090 anticoagulant agent Drugs 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 2
- 108010055460 bivalirudin Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 208000015294 blood coagulation disease Diseases 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229960003009 clopidogrel Drugs 0.000 description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000008380 degradant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 238000013171 endarterectomy Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 230000005496 eutectics Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 201000007219 factor XI deficiency Diseases 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- LSLYOANBFKQKPT-UHFFFAOYSA-N fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 229940116108 lactase Drugs 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000020971 positive regulation of blood coagulation Effects 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000013097 stability assessment Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229960005202 streptokinase Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 238000013151 thrombectomy Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 208000021331 vascular occlusion disease Diseases 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 description 1
- WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- CNJLMVZFWLNOEP-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[4.1.0]heptan-5-one Chemical compound O=C1C(C)CCC2C(C)(C)C12 CNJLMVZFWLNOEP-UHFFFAOYSA-N 0.000 description 1
- MNHXYNNKDDXKNP-UHFFFAOYSA-N 4-(3-chlorophenyl)-1,7-diethyl-2-pyrido[2,3-d]pyrimidinone Chemical compound N=1C(=O)N(CC)C2=NC(CC)=CC=C2C=1C1=CC=CC(Cl)=C1 MNHXYNNKDDXKNP-UHFFFAOYSA-N 0.000 description 1
- CVDXFPBVOIERBH-JWQCQUIFSA-N 4-[(4ar,10bs)-9-ethoxy-8-methoxy-2-methyl-3,4,4a,10b-tetrahydro-1h-benzo[c][1,6]naphthyridin-6-yl]-n,n-di(propan-2-yl)benzamide Chemical compound N([C@@H]1CCN(C)C[C@@H]1C=1C=C(C(=CC=11)OC)OCC)=C1C1=CC=C(C(=O)N(C(C)C)C(C)C)C=C1 CVDXFPBVOIERBH-JWQCQUIFSA-N 0.000 description 1
- QCXJEYYXVJIFCE-UHFFFAOYSA-M 4-acetamidobenzoate Chemical compound CC(=O)NC1=CC=C(C([O-])=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-M 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- KYWCWBXGRWWINE-UHFFFAOYSA-N 4-methoxy-N1,N3-bis(3-pyridinylmethyl)benzene-1,3-dicarboxamide Chemical compound COC1=CC=C(C(=O)NCC=2C=NC=CC=2)C=C1C(=O)NCC1=CC=CN=C1 KYWCWBXGRWWINE-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000037403 Blood and lymphatic system disease Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 101100492805 Caenorhabditis elegans atm-1 gene Proteins 0.000 description 1
- 101100191768 Caenorhabditis elegans pbs-4 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 1
- 102100035023 Carboxypeptidase B2 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000035451 General disorders and administration site conditions Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 208000010670 Hemic and Lymphatic disease Diseases 0.000 description 1
- 206010059598 Heparin resistance Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- NBGXQZRRLOGAJF-UHFFFAOYSA-N Maltulose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)(CO)OCC1O NBGXQZRRLOGAJF-UHFFFAOYSA-N 0.000 description 1
- 208000011682 Mitral valve disease Diseases 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 101100172190 Mus musculus Elavl1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 1
- 108050008996 P2Y purinoceptor 1 Proteins 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 description 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 206010073391 Platelet dysfunction Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010057765 Procedural complication Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000032327 Respiratory, thoracic and mediastinal disease Diseases 0.000 description 1
- 206010038980 Retroperitoneal haemorrhage Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- RUOGJYKOQBFJIG-UHFFFAOYSA-N SCH-351591 Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)NC1=C(Cl)C=[N+]([O-])C=C1Cl RUOGJYKOQBFJIG-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 108010056373 SK potentiator Proteins 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 206010042241 Stridor Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000008253 Systolic Heart Failure Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 102000003790 Thrombin receptors Human genes 0.000 description 1
- 108090000166 Thrombin receptors Proteins 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000030451 Vascular dementia disease Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048629 Wound secretion Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- YPFLFUJKZDAXRA-UHFFFAOYSA-N [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate Chemical compound O1C2=CC(OS(=O)(=O)C)=CC=C2C(NC(N)=O)=C1C(=O)C1=CC=C(Cl)C=C1Cl YPFLFUJKZDAXRA-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 208000005707 acquired angioedema Diseases 0.000 description 1
- 229940099983 activase Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940003354 angiomax Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 210000005249 arterial vasculature Anatomy 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 238000011021 bench scale process Methods 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 229910052801 chlorine Chemical group 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- KSPYMJJKQMWWNB-UHFFFAOYSA-N cipamfylline Chemical compound O=C1N(CC2CC2)C(=O)C=2NC(N)=NC=2N1CC1CC1 KSPYMJJKQMWWNB-UHFFFAOYSA-N 0.000 description 1
- 229950002405 cipamfylline Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-M dichloroacetate Chemical compound [O-]C(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-M 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
- 229960002994 dofetilide Drugs 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- XGXOSJSGDNPEEF-NRFANRHFSA-N dsstox_cid_27291 Chemical compound N([C@@H]1N=C(C=2C=3N(C1=O)CCC=3C=C(C=2)N)C=1C=CC=CC=1)C(=O)C1=CC=CN=C1 XGXOSJSGDNPEEF-NRFANRHFSA-N 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940082150 encore Drugs 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 239000002319 fibrinogen receptor antagonist Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- YRSVDSQRGBYVIY-GJZGRUSLSA-N gemopatrilat Chemical compound O=C1N(CC(O)=O)C(C)(C)CCC[C@@H]1NC(=O)[C@@H](S)CC1=CC=CC=C1 YRSVDSQRGBYVIY-GJZGRUSLSA-N 0.000 description 1
- 229950006480 gemopatrilat Drugs 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000024557 hepatobiliary disease Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- BBPRUNPUJIUXSE-DXKRWKNPSA-N ifetroban Chemical compound CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 description 1
- 229950004274 ifetroban Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 108010051044 lanoteplase Proteins 0.000 description 1
- 229950010645 lanoteplase Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229940118179 lovenox Drugs 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000002535 lyotropic effect Effects 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- JCQLYHFGKNRPGE-HFZVAGMNSA-N maltulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-HFZVAGMNSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- VHDUUXNHZLBGHQ-XLVZBRSZSA-N n-cyclohexyl-n-methyl-2-[(e)-[(2-oxo-5,10-dihydro-3h-imidazo[2,1-b]quinazolin-7-yl)-phenylmethylidene]amino]oxyacetamide Chemical compound C=1C=CC=CC=1\C(C=1C=C2CN3CC(=O)N=C3NC2=CC=1)=N/OCC(=O)N(C)C1CCCCC1 VHDUUXNHZLBGHQ-XLVZBRSZSA-N 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-L naphthalene-1,5-disulfonate(2-) Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1S([O-])(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-L 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000002560 nonimmunologic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- JPAWFIIYTJQOKW-UHFFFAOYSA-N olprinone Chemical compound N1C(=O)C(C#N)=CC(C2=CN3C=CN=C3C=C2)=C1C JPAWFIIYTJQOKW-UHFFFAOYSA-N 0.000 description 1
- 229950005421 olprinone Drugs 0.000 description 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
- 229950000973 omapatrilat Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical group [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- RRRUXBQSQLKHEL-UHFFFAOYSA-N piclamilast Chemical compound COC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OC1CCCC1 RRRUXBQSQLKHEL-UHFFFAOYSA-N 0.000 description 1
- 229950005184 piclamilast Drugs 0.000 description 1
- 229960001006 picotamide Drugs 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229960002164 pimobendan Drugs 0.000 description 1
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000001144 powder X-ray diffraction data Methods 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229950010090 pumafentrine Drugs 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108010051412 reteplase Proteins 0.000 description 1
- 229960002917 reteplase Drugs 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229950004118 revizinone Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- 230000005659 seminal clot liquefaction Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000012027 sterile manufacturing Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 206010048627 thoracic outlet syndrome Diseases 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000003558 thrombophilic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- CRKADHVTAQCXRA-UHFFFAOYSA-K trisodium;phosphate;dihydrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O CRKADHVTAQCXRA-UHFFFAOYSA-K 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Provided herein are pharmaceutical compositions comprising compounds that inhibit Factor XIa or kallikrein and methods of use thereof.
Description
THERAPEUTIC COMPOUNDS AND COMPOSITIONS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S.S.N. 62/798,012 filed January 29, 2019, which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S.S.N. 62/798,012 filed January 29, 2019, which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
[0002] Blood coagulation is the first line of defense against blood loss following injury.
The blood coagulation "cascade" involves a number of circulating serine protease zymogens, regulatory cofactors and inhibitors. Each enzyme, once generated from its zymogen, specifically cleaves the next zymogen in the cascade to produce an active protease. This process is repeated until finally thrombin cleaves the fibrinopeptides from fibrinogen to produce fibrin that polymerizes to form a blood clot. Although efficient clotting limits the loss of blood at a site of trauma, it also poses the risk of systemic coagulation resulting in massive thrombosis. Under normal circumstances, hemostasis maintains a balance between clot formation (coagulation) and clot dissolution (fibrinolysis). However, in certain disease states such as acute myocardial infarction and unstable angina, the rupture of an established atherosclerotic plaque results in abnormal thrombus formation in the coronary arterial vasculature.
The blood coagulation "cascade" involves a number of circulating serine protease zymogens, regulatory cofactors and inhibitors. Each enzyme, once generated from its zymogen, specifically cleaves the next zymogen in the cascade to produce an active protease. This process is repeated until finally thrombin cleaves the fibrinopeptides from fibrinogen to produce fibrin that polymerizes to form a blood clot. Although efficient clotting limits the loss of blood at a site of trauma, it also poses the risk of systemic coagulation resulting in massive thrombosis. Under normal circumstances, hemostasis maintains a balance between clot formation (coagulation) and clot dissolution (fibrinolysis). However, in certain disease states such as acute myocardial infarction and unstable angina, the rupture of an established atherosclerotic plaque results in abnormal thrombus formation in the coronary arterial vasculature.
[0003] Diseases that stem from blood coagulation, such as myocardial infarction, unstable angina, atrial fibrillation, stroke, pulmonary embolism, and deep vein thrombosis, are among the leading causes of death in developed countries. Current anticoagulant therapies, such as injectable unfractionated and low molecular weight (LMW) heparin and orally administered warfarin (coumadin), carry the risk of bleeding episodes and display patient-to-patient variability that results in the need for close monitoring and titration of therapeutic doses.
Consequently, there is a large medical need for novel anticoagulation drugs that lack some or all of the side effects of currently available drugs.
Consequently, there is a large medical need for novel anticoagulation drugs that lack some or all of the side effects of currently available drugs.
[0004] Factor XIa is an attractive therapeutic target involved in the pathway associated with these diseases. Increased levels of Factor XIa or Factor XIa activity have been observed in several thromboembolic disorders, including venous thrombosis (Meijers et al., N. Engl. J. Med. 342:696, 2000), acute myocardial infarction (Minnema et al., Arterioscler Thromb Vasc Biol 20:2489, 2000), acute coronary syndrome (Butenas et al., Thromb Haemost 99:142, 2008), coronary artery disease (Butenas et al., Thromb Haemost 99:142, 2008), chronic obstructive pulmonary disease (Jankowski et al., Thromb Res 127:242, 2011), aortic stenosis (Blood Coagul Fibrinolysis, 22:473, 2011), acute cerebrovascular ischemia (Undas et al., Eur J Clin Invest, 42:123, 2012), and systolic heart failure due to ischemic cardiomyopathy (Zabcyk et al., Pol Arch Med Wewn. 120:334, 2010). Patients that lack Factor XI because of a genetic Factor XI deficiency exhibit few, if any, ischemic strokes (Salomon et al., Blood, 111:4113, 2008). At the same time, loss of Factor XIa activity, which leaves one of the pathways that initiate coagulation intact, does not disrupt hemostasis. In humans, Factor XI deficiency can result in a mild-to-moderate bleeding disorder, especially in tissues with high levels of local fibrinolytic activity, such as the urinary tract, nose, oral cavity, and tonsils. Moreover, hemostasis is nearly normal in Factor XI-deficient mice (Gailani, Blood Coagul Fibrinolysis, 8:134, 1997). Furthermore, inhibition of Factor XI has also been found to attenuate arterial hypertension and other diseases and dysfunctions, including vascular inflammation (Kossmann et al. Sci. Transl. Med. 9, eaah4923 (2017)).
[0005] Consequently, compounds that inhibit Factor XIa have the potential to prevent or treat a wide range of disorders while avoiding the side effects and therapeutic challenges that plague drugs that inhibit other components of the coagulation pathway.
Moreover, due to the limited efficacy and adverse side effects of some current therapeutics for the inhibition of undesirable thrombosis (e.g., deep vein thrombosis, hepatic vein thrombosis, and stroke), improved compounds and methods (e.g., those associated with Factor XIa) are needed for preventing or treating undesirable thrombosis.
Moreover, due to the limited efficacy and adverse side effects of some current therapeutics for the inhibition of undesirable thrombosis (e.g., deep vein thrombosis, hepatic vein thrombosis, and stroke), improved compounds and methods (e.g., those associated with Factor XIa) are needed for preventing or treating undesirable thrombosis.
[0006] Another therapeutic target is the enzyme kallikrein. Human plasma kallikrein is a serine protease that may be responsible for activating several downstream factors (e.g., bradykinin and plasmin) that are critical for coagulation and control of e.g., blood pressure, inflammation, and pain. Kallikreins are expressed e.g., in the prostate, epidermis, and the central nervous system (CNS) and may participate in e.g., the regulation of semen liquefaction, cleavage of cellular adhesion proteins, and neuronal plasticity in the CNS.
Moreover, kallikreins may be involved in tumorigenesis and the development of cancer and angioedema, e.g., hereditary angioedema. Overactivation of the kallikrein-kinin pathway can result in a number of disorders, including angioedema, e.g., hereditary angioedema (Schneider et al., J. Allergy Clin. Immunol. 120:2, 416, 2007). To date, there are limited treatment options for HAE (e.g., W02003/076458).
Moreover, kallikreins may be involved in tumorigenesis and the development of cancer and angioedema, e.g., hereditary angioedema. Overactivation of the kallikrein-kinin pathway can result in a number of disorders, including angioedema, e.g., hereditary angioedema (Schneider et al., J. Allergy Clin. Immunol. 120:2, 416, 2007). To date, there are limited treatment options for HAE (e.g., W02003/076458).
[0007] Pharmaceutical compositions comprising a therapeutic agent, e.g., compounds that inhibit Factor Xia or kallikrein described herein, enable administration to a human subject in need by various modes of administration (e.g., parenteral (e.g., intravenous, intramuscular, subcutaneous) delivery). Particularly for intravenous or subcutaneous administration, compositions are generally pH stable or chemically stable, preferably for an extended period of time.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[0008] The present invention relates, in part, to pharmaceutical compositions comprising a compound of Formula (I-A):
?-"Oliro ,-NyN
0 (I-A) also referred to herein as "Compound 1," or a pharmaceutically acceptable salt thereof
?-"Oliro ,-NyN
0 (I-A) also referred to herein as "Compound 1," or a pharmaceutically acceptable salt thereof
[0009] Thus, in an aspect, provided herein is an aqueous pharmaceutical composition comprising a compound of Formula (I-A) ?-01r0 -NyN
0 (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and an excipient.
0 (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and an excipient.
[0010] In some embodiments, the pharmaceutical composition comprises the compound of Formula (I-A), the cyclodextrin, and the excipient. In some embodiments, the cyclodextrin is selected from the group consisting of alkyl cyclodextrin, hydroxyalkyl cyclodextrin, carboxyalkyl cyclodextrin, and sulfoalkyl ether cyclodextrin. In some embodiments, the cyclodextrin is hydroxypropyl 0-cyclodextrin. In some embodiments, the cyclodextrin is sulfobutyl ether 0-cyclodextrin.
[0011] In some embodiments, the excipient is a sugar (e.g., a saccharide (e.g., monosaccharide, disaccharide, or polysaccharide)) or a sugar alcohol. In some embodiments, the excipient is sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, or mannitol, or a combination thereof In some embodiments, the excipient is mannitol. In some embodiments, the excipient is lactose.
[0012] In some embodiments, the pharmaceutical composition further comprises a buffer.
In some embodiments, the buffer is a monoprotic acid or a polyprotic acid or a combination thereof In some embodiments, the buffer is a solution of one or more substances. In some embodiments, the buffer is a solution of a salt of a weak acid and a weak base. In some embodiments, the buffer is a solution of a salt of the weak acid with a strong base. In some embodiments, the buffer is selected from the group consisting of a maleate buffer, a citrate buffer, and a phosphate buffer. In some embodiments, the buffer is a phosphate buffer. In some embodiments, the phosphate buffer is a solution of monosodium phosphate, disodium phosphate, trisodium phosphate, or a combination thereof
In some embodiments, the buffer is a monoprotic acid or a polyprotic acid or a combination thereof In some embodiments, the buffer is a solution of one or more substances. In some embodiments, the buffer is a solution of a salt of a weak acid and a weak base. In some embodiments, the buffer is a solution of a salt of the weak acid with a strong base. In some embodiments, the buffer is selected from the group consisting of a maleate buffer, a citrate buffer, and a phosphate buffer. In some embodiments, the buffer is a phosphate buffer. In some embodiments, the phosphate buffer is a solution of monosodium phosphate, disodium phosphate, trisodium phosphate, or a combination thereof
[0013] In some embodiments, the pharmaceutical compositions described herein further comprises a solubilizing agent. In some embodiments, the solubilizing agent is a polyoxyethylene sorbitan ester (e.g, TWEENO 20) or a polyethylene glycol (e.g., PEG400).
[0014] In some embodiments, the pH is from about 2 to about 8. In some embodiments, the pH is about 6.8.
[0015] In some embodiments, the concentration of the compound of Formula (I-A) is from about 0.1 mg/mL to about 100 mg/mL. For example, the concentration of the compound of Formula (I-A) may be about 10 mg/mL.
[0016] In some embodiments, the concentration of the buffer is from about 1 mM
to about 500 mM. For example, the concentration of the buffer may be about 10 mM. In some embodiments, the buffer is phosphate buffer.
to about 500 mM. For example, the concentration of the buffer may be about 10 mM. In some embodiments, the buffer is phosphate buffer.
[0017] In some embodiments, the cyclodextrin is in an amount of from about 0.1% to about 10% (e.g., about 0.5% to about 6% (e.g., about 0.7% to about 5.6% (e.g., about 2.1 % to about 5%))) by weight relative to weight of the compound of Formula (I-A). For example, the cyclodextrin is in an amount of about 3.5% by weight relative to weight of the compound of Formula (I-A). As another example, the cyclodextrin is in an amount of about 5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is hydroxypropy113-cyclodextrin.
[0018] In some embodiments, the excipient is in an amount of from about 0.1%
to about 10% by weight relative to weight of the compound of Formula (I-A). For example, the excipient is in an amount of about 3% by weight relative to weight of the compound of Formula (I-A). As another example, the excipient is in an amount of about 5%
by weight relative to weight of the compound of Formula (I-A). In some embodiments, the excipient is mannitol. In other embodiments, the excipient is lactose.
to about 10% by weight relative to weight of the compound of Formula (I-A). For example, the excipient is in an amount of about 3% by weight relative to weight of the compound of Formula (I-A). As another example, the excipient is in an amount of about 5%
by weight relative to weight of the compound of Formula (I-A). In some embodiments, the excipient is mannitol. In other embodiments, the excipient is lactose.
[0019] In another aspect, provided herein is pharmaceutical composition comprising particles, wherein the particles comprise a compound of Formula (I-A) ?'\---01r0 ,-NyN
0 (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and a bulking agent.
0 (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and a bulking agent.
[0020] In some embodiments, the cyclodextrin is selected from the group consisting of alkyl cyclodextrin, hydroxyalkyl cyclodextrin, carboxyalkyl cyclodextrin, and sulfoalkyl ether cyclodextrin. In some embodiments, the cyclodextrin is hydroxypropyl 0-cyclodextrin.
In some embodiments, the cyclodextrin is sulfobutyl ether 0-cyclodextrin.
In some embodiments, the cyclodextrin is sulfobutyl ether 0-cyclodextrin.
[0021] In some embodiments, the bulking agent is a sugar (e.g., a saccharide (e.g., monosaccharide, disaccharide, or polysaccharide)) or a sugar alcohol. In some embodiments, the bulking agent is sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, or mannitol, or a combination thereof In some embodiments, the bulking agent is mannitol.
In some embodiments, the bulking agent is lactose.
In some embodiments, the bulking agent is lactose.
[0022] In some embodiments, the bulking agent is a lyoprotectant.
[0023] In some embodiments, the concentration of the compound of Formula (I-A) is from about 0.1 to about 10% by weight of the composition. For example, the concentration of the compound of Formula (I-A) is about 1% by weight of the composition. As another example, the concentration of the compound of Formula (I-A) is about 0.3% by weight of the composition.
[0024] In some embodiments, the cyclodextrin is in an amount of from about 0.1% to about 10% (e.g., about 0.5% to about 6% (e.g., about 0.7% to about 5.6% (e.g., about 2.1 % to about 5%))) by weight relative to weight of the compound of Formula (I-A). For example, the cyclodextrin is in an amount of about 3.5% by weight relative to weight of the compound of Formula (I-A). As another example, the cyclodextrin is in an amount of about 5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is hydroxypropyl 0-cyclodextrin.
[0025] In some embodiments, the bulking agent is in an amount of from about 0.1% to about 10% by weight relative to weight of the compound of Formula (I-A). For example, the bulking agent is in an amount of about 3% by weight relative to weight of the compound of Formula (I-A). As another example, the bulking agent is in an amount of about 5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the bulking agent is mannitol. In other embodiments, the bulking agent is lactose.
[0026] In another aspect, provided herein is a process for preparing an aqueous pharmaceutical composition from the pharmaceutical composition comprising particles, wherein the particles comprise a compound of Formula (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and a bulking agent, the process comprising reconstituting the pharmaceutical composition into an aqueous medium, thereby forming the aqueous composition.
[0027] In some embodiments, the aqueous medium is deionized water. In some embodiments, the aqueous medium comprises sodium chloride. In some embodiments, the aqueous medium comprises about 5% dextrose. In some embodiments, composition is prepared to be suitable for parenteral administration to a subject in need thereof For example, the composition is prepared to be suitable for intramuscular, subcutaneous or intravenous administration to a subject in need thereof
[0028] The compositions described herein can be useful in the treatment, prophylaxis, or reduction in the risk of a disorder described herein. In some embodiments, the methods described herein can include those in which a subject's blood is in contact with an artificial surface.
[0029] Thus, in one aspect, provided herein is a method of treating a thromboembolic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition described herein, wherein the blood of the subject is contacted with an artificial surface.
[0030] In another aspect, provided herein is a method of reducing the risk of a thromboembolic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition described herein, wherein the blood of the subject is contacted with an artificial surface.
[0031] Also provided herein is a method of prophylaxis of a thromboembolic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition described herein, wherein the blood of the subject is contacted with an artificial surface.
[0032] In some embodiments of the methods described herein, the artificial surface is in contact with blood in the subject's circulatory system.
[0033] In some embodiments, the artificial surface is an implantable device, a dialysis catheter, a cardiopulmonary bypass circuit, an artificial heart valve, a ventricular assist device, a small caliber graft, a central venous catheter, or an extracorporeal membrane oxygenation (ECMO) apparatus.
[0034] In some embodiments, the artificial surface causes or is associated with the thromboembolic disorder.
[0035] In some embodiments, the thromboembolic disorder is a venous thromboembolism, deep vein thrombosis, or pulmonary embolism.
[0036] In some embodiments, the thromboembolic disorder is a blood clot.
[0037] In some embodiments, the methods described herein further comprise conditioning the artificial surface with a separate dose of a pharmaceutical composition described herein prior to contacting the artificial surface with blood in the circulatory system of the subject.
[0038] In some embodiments, the methods described herein further comprise conditioning the artificial surface with a separate dose of a pharmaceutical composition described herein prior to or during administration of the pharmaceutical composition to the subject.
[0039] In some embodiments, the methods described herein further comprise conditioning the artificial surface with a separate dose of a pharmaceutical composition described herein prior to and during administration of the pharmaceutical composition to the subject.
[0040] In some embodiments of the methods described herein, the artificial surface is a cardiopulmonary bypass circuit.
[0041] In some embodiments of the methods described herein, the artificial surface is an extracorporeal membrane oxygenation (ECMO) apparatus. In some embodiments, the ECMO
apparatus is venovenous ECMO apparatus or venoarterial ECMO apparatus.
apparatus is venovenous ECMO apparatus or venoarterial ECMO apparatus.
[0042] In another aspect, disclosed herein is a method of preventing or reducing a risk of a thromboembolic disorder in a subject during or after a medical procedure, comprising:
(i) administering to the subject an effective amount of a pharmaceutical composition described herein, before, during, or after the medical procedure; and (ii) contacting blood of the subject with an artificial surface;
thereby preventing or reducing the risk of the thromboembolic disorder during or after the medical procedure.
(i) administering to the subject an effective amount of a pharmaceutical composition described herein, before, during, or after the medical procedure; and (ii) contacting blood of the subject with an artificial surface;
thereby preventing or reducing the risk of the thromboembolic disorder during or after the medical procedure.
[0043] In some embodiments, the artificial surface is conditioned with a pharmaceutical composition described herein prior to administration of the pharmaceutical composition to the subject prior to, during, or after the medical procedure.
[0044] In some embodiments, the pharmaceutical composition for conditioning the artificial surface further comprises a solution, wherein the solution is selected from the group consisting of a saline solution, Ringer's solution, and blood.
[0045] In some embodiments, the thromboembolic disorder is a blood clot.
[0046] In some embodiments, the medical procedure comprises one or more of i) a cardiopulmonary bypass, ii) oxygenation and pumping of blood via extracorporeal membrane oxygenation, iii) assisted pumping of blood (internal or external), iv) dialysis of blood, v) extracorporeal filtration of blood, vi) collection of blood from the subject in a repository for later use in an animal or a human subject, vii) use of venous or arterial intraluminal catheter(s), viii) use of device(s) for diagnostic or interventional cardiac catherisation, ix) use of intravascular device(s), x) use of artificial heart valve(s), and xi) use of artificial graft(s).
[0047] In some embodiments, the medical procedure comprises a cardiopulmonary bypass.
[0048] In some embodiments, the medical procedure comprises an oxygenation and pumping of blood via extracorporeal membrane oxygenation (ECMO). In some embodiments, the ECMO is venovenous ECMO or venoarterial ECMO.
[0049] In some embodiments of the methods described herein, the subject is in contact with the artificial surface for at least 1 day (e.g., about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 2 months, about 3 months, about 6 months, about 9 months, about 1 year).
[0050] In another aspect, provided herein is a method of treating the blood of a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition described herein.
[0051] In some embodiments of the methods described herein, the pharmaceutical composition is administered to the subject intravenously. In other embodiments of the methods described herein, the pharmaceutical composition is administered to the subject subcutaneously. In some embodiments, the pharmaceutical composition is administered to the subject as a continuous intravenous infusion. In some embodiments, the pharmaceutical composition is administered to the subject as a bolus.
[0052] In some embodiments, the subject is a human. In some embodiments, the subject has an elevated risk of a thromboembolic disorder. In some embodiments, the thromboembolic disorder is a result of a complication in surgery. In some embodiments, the subject is sensitive to or has developed sensitivity to heparin. In some embodiments, the subject is resistant to or has developed resistance to heparin.
[0053] In another aspect, the present invention is also directed to a method of reducing the risk of stroke (e.g., ischemia, e.g., a transient ischemic event, large vessel acute ischemic stroke) in a subject that has suffered an ischemic event (e.g., a transient ischemic event), comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the administering reduces the risk of stroke (e.g., large vessel acute ischemic stroke) in a subject as compared to a subject who is not administered with the composition. In some embodiments, the administering reduces the risk of atrial fibrillation in a subject as compared to a subject who is not administered with the composition.
[0054] In one aspect, the present invention is directed to a method of reducing non-central nervous system systemic embolism (e.g., ischemia, e.g., a transient ischemic event) in a subject that has suffered an ischemic event (e.g., a transient ischemic event), comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the administering reduces non-central nervous system systemic embolism in a subject as compared to a subject who is not administered with the composition.
[0055] In one aspect, the present invention is directed to a method of treating deep vein thrombosis comprising administering to the subject that has suffered an ischemic event (e.g., a transient ischemic event), an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0056] In one aspect, the present invention is directed to a method of prophylaxis of deep vein thrombosis comprising administering to the subject that has suffered a deep vein thrombosis (e.g., a subject that has been previously treated for a deep vein thrombosis), an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0057] In one aspect, the present invention is directed to a method of reducing the risk of recurrence of deep vein thrombosis comprising administering to the subject that has suffered a deep vein thrombosis (e.g., a subject that has been previously treated for a deep vein thrombosis), an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the administering reduces the risk of recurrence of deep vein thrombosis in a subject as compared to a subject who is not administered with the composition.
[0058] In one aspect, the present invention is directed to a method of prophylaxis of venous thromboembolism, e.g., deep vein thrombosis or pulmonary embolism in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the subject is undergoing surgery. In some embodiments, the subject is administered the composition described herein before, during, or after surgery. In some embodiments, the subject is undergoing knee or hip replacement surgery.
In some embodiments, the subject is undergoing orthopedic surgery. In some embodiments, the subject is undergoing lung surgery. In some embodiments, the subject is being treated for cancer, e.g., by surgery. In some embodiments, the subject is suffering from a chronic medical condition. In some embodiments, the venous thromboembolism is associated with cancer. In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, in the composition described herein is a primary agent in prophylaxis of the deep vein thrombosis or venous thromboembolism. In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, in the composition described herein is used as an extended therapy.
In some embodiments, the subject is undergoing orthopedic surgery. In some embodiments, the subject is undergoing lung surgery. In some embodiments, the subject is being treated for cancer, e.g., by surgery. In some embodiments, the subject is suffering from a chronic medical condition. In some embodiments, the venous thromboembolism is associated with cancer. In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, in the composition described herein is a primary agent in prophylaxis of the deep vein thrombosis or venous thromboembolism. In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, in the composition described herein is used as an extended therapy.
[0059] In one aspect, the present invention is directed to a method of reducing the risk of venous thromboembolism, e.g., deep vein thrombosis or pulmonary embolism, in a subject, comprising administering to the subject an effective amount of a composition described .. herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the subject is undergoing surgery. In some embodiments, the subject is administered the composition described herein after surgery. In some embodiments, the subject is undergoing knee or hip replacement surgery. In some embodiments, the subject is undergoing orthopedic surgery. In some embodiments, the subject is undergoing lung surgery. In some embodiments, the subject is being treated for cancer, e.g., by surgery. In some embodiments, the subject is suffering from a chronic medical condition. In some embodiments, the thromboembolic disorder is associated with cancer. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof in the composition described herein is a primary agent in reducing the risk of the .. thromboembolic disorder. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof in the composition described herein is used as an extended therapy.
[0060] In one aspect, the present invention is directed to a method of reducing the risk of stroke (e.g., large vessel acute ischemic stroke) or systemic embolism in a subject in need thereof, comprising administering to the subject an effective amount of a composition described herein, e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof In some embodiments, the subject is suffering from atrial fibrillation (e.g., non-valvular atrial fibrillation). In some embodiments, the subject is suffering from a renal disorder (e.g., end-stage renal disease).
[0061] In one aspect, the present invention is directed to a method of prophylaxis of stroke (e.g., large vessel acute ischemic stroke) or systemic embolism in a subject in need thereof, comprising administering to the subject an effective amount of a composition described herein, e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof In some embodiments, the subject is suffering from atrial fibrillation (e.g., non-valvular atrial fibrillation). In some embodiments, the subject is suffering from a renal disorder (e.g., end-stage renal disease).
[0062] In one aspect, the present invention is directed to a method of reducing the risk of recurrence of pulmonary embolism (e.g., symptomatic pulmonary embolism) comprising administering to the subject that has suffered a pulmonary embolism (e.g., a subject that has been previously treated for a pulmonary embolism), an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the administering reduces the risk of recurrence of pulmonary embolism in a subject as compared to a subject who is not administered with the composition.
[0063] In one aspect, the present invention is directed to a method of prophylaxis of pulmonary embolism in a subject that has suffered a pulmonary embolism (e.g., a subject that has been previously treated for a pulmonary embolism), comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0064] In one aspect, the present invention is directed to a method of reducing the risk of recurrence of pulmonary embolism (e.g., symptomatic pulmonary embolism) comprising administering to the subject that has suffered a deep vein thrombosis (e.g., a subject that has been previously treated for a deep vein thrombosis), an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the administering reduces the risk of recurrence of pulmonary embolism in a subject as compared to a subject who is not administered with the composition.
[0065] In one aspect, the present invention is directed to a method of prophylaxis of pulmonary embolism in a subject that has suffered a deep vein thrombosis (e.g., a subject that has been previously treated for a deep vein thrombosis), comprising administering to the subject a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0066] In one aspect, the present invention features a method of treating deep vein thrombosis in a subject that has been previously administered an anticoagulant, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the anticoagulant was administered parenterally for 5-10 days.
[0067] In one aspect, the present invention features a method of treating a pulmonary embolism in a subject that has been previously administered an anticoagulant, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the anticoagulant was administered parenterally for 5-10 days.
[0068] In one aspect, the present invention is directed to a method of treating a subject that has had an ischemic event (e.g., transient ischemia), comprising: a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof) to the subject. In some embodiments, the compound is administered to the subject within 24 hours or less, e.g., 12, 10, 9, 8, 7, 6 hours or less, after the onset of the ischemic event in the subject.
[0069] In one aspect, the present invention is directed to a method of treating a subject that has had an ischemic event (e.g., transient ischemia), comprising:
administering a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof) to the subject. In some embodiments, the composition is administered to the subject within more than 2 hours to 12 hours, e.g., more than 2 hours to 10 hours or less, more than 2 hours to 8 hours or less, after the onset of the ischemic event in the subject.
administering a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof) to the subject. In some embodiments, the composition is administered to the subject within more than 2 hours to 12 hours, e.g., more than 2 hours to 10 hours or less, more than 2 hours to 8 hours or less, after the onset of the ischemic event in the subject.
[0070] In one aspect, the present invention is directed to a method of treating hypertension, e.g., arterial hypertension, in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the hypertension, e.g., arterial hypertension, results in atherosclerosis. In some embodiments, the hypertension is pulmonary arterial hypertension.
[0071] In one aspect, the present invention is directed to a method of reducing the risk of hypertension, e.g., arterial hypertension, in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the hypertension, e.g., arterial hypertension, results in atherosclerosis. In some embodiments, the hypertension is pulmonary arterial hypertension.
[0072] In one aspect, the present invention is directed to a method of prophylaxis of hypertension, e.g., arterial hypertension, in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the hypertension, e.g., arterial hypertension, results in atherosclerosis. In some embodiments, the hypertension is pulmonary arterial hypertension.
.. [0073] In one aspect, the present invention is directed to a method of reducing inflammation in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the inflammation is vascular inflammation. In some embodiments, the vascular inflammation is accompanied by atherosclerosis. In some embodiments, the vascular inflammation is accompanied by a thromboembolic disease in the subject. In some embodiments, the vascular inflammation is angiotensin II-induced vascular inflammation.
[0074] In one aspect, the present invention is directed to a method of preventing vascular leukocyte infiltration in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0075] In one aspect, the present invention is directed to a method of preventing angiotensin II-induced endothelial dysfunction in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0076] In one aspect, the present invention is directed to a method of preventing thrombin propagation in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the thrombin propagation occurs on platelets.
[0077] In one aspect, the present invention is directed to a method of treating hypertension-associated renal dysfunction in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0078] In one aspect, the present invention is directed to a method of prophylaxis of hypertension-associated renal dysfunction in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0079] In one aspect, the present invention is directed to a method of reducing the risk of hypertension-associated renal dysfunction in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0080] In one aspect, the present invention is directed to a method of treating kidney fibrosis in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0081] In one aspect, the present invention is directed to a method of prophylaxis of kidney fibrosis in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0082] In one aspect, the present invention is directed to a method of reducing the risk of kidney fibrosis in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0083] In one aspect, the present invention is directed to a method of treating kidney injury in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0084] In one aspect, the present invention is directed to a method of prophylaxis of kidney injury in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0085] In one aspect, the present invention is directed to a method of reducing the risk of kidney injury in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0086] In one aspect, the present invention is directed to a method of inhibiting Factor XIa in a subject, comprising administering to the subject that has suffered ischemia an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the ischemia is coronary ischemia.
[0087] In some embodiments, the subject is a mammal (e.g., a human).
[0088] In some embodiments, the subject is undergoing surgery (e.g., knee replacement surgery or hip replacement surgery). In some embodiments, the ischemia is coronary ischemia. In some embodiments, the subject is a subject with non-valvular atrial fibrillation.
In some embodiments, the subject has one or more of the following risk factors for stroke: a prior stroke (e.g., ischemic, unknown, hemorrhagic), transient ischemic attack, or non-CNS
systemic embolism. In some embodiments, the subject has one or more of the following risk factors for stroke: 75 years or older of age, hypertension, heart failure or left ventricular ejection fraction (e.g., less than or equal to 35%), or diabetes mellitus.
[0089] In some embodiments, the composition is administered by oral or parenteral (e.g., intravenous) administration. In some embodiments, the composition is administered by oral administration. In some embodiments, the composition is administered by parenteral (e.g., intravenous) administration. In some embodiments, the composition is administered by subcutaneous administration.
[0090] In some embodiments, the composition is administered prior to an ischemic event (e.g., to a subject is at risk of an ischemic event).
[0091] In some embodiments, the composition is administered after an ischemic event (e.g., a transient ischemic event). In some embodiments, the composition is administered about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days or more after an ischemic event (e.g., a transient ischemic event). In some embodiments, the composition is administered about 1, 2, 3, 4, 5, 6, 7, or 8 weeks or more after an ischemic event (e.g., a transient ischemic event).
[0092] In some embodiments, the composition is administered in combination with an additional therapeutic agent. In some embodiments, the additional therapeutic agent is administered after administration of the composition. In some embodiments, the additional therapeutic agent is administered orally. In some embodiments, the additional therapeutic agent is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, or 24 hours or more after administration of the composition. In some embodiments, the additional therapeutic agent is administered at least 1, 2, 3, 4, 5, 6, 7, 14, 21, or 28 days or more after administration of the composition. In some embodiments, the additional therapeutic agent is administered about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days or more after administration of the composition.
[0093] In some embodiments, the additional therapeutic agent is administered chronically (e.g., for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days or more) after administration of the composition.
[0094] In some embodiments, the additional therapeutic agent treats a side effect (e.g., active pathological bleeding or severe hypersensitivity reactions (e.g., anaphylactic reactions), spinal and or epidural hematoma, gastrointestinal disorder (e.g., abdominal pain upper, dyspepsia, toothache), general disorders and administration site conditions (e.g., fatigue), infections and infestations (e.g., sinusitis, urinary tract infection), musculoskeletal and connective tissues disorders (e.g., back pain, osteoarthritis), respiratory, thoracic and mediastinal disorders (e.g., oropharyngeal pain), injury, poisoning, and procedural complications (e.g., wound secretion), musculoskeletal and connective tissues disorders (e.g., pain in extremity, muscle spasm), nervous system disorders (e.g., syncope), skin and subcutaneous tissue disorders (e.g., pruritus, blister), blood and lymphatic system disorders (e.g., agranulocytosis), gastrointestinal disorders (e.g., retroperitoneal hemorrhage), hepatobiliary disorders (e.g., jaundice, cholestasis, cytolytic hepatitis), immune system disorders (e.g., hypersensitivity, anaphylactic reaction, anaphylactic shock, angioedema), nervous system disorders (e.g., cerebral hemorrhage, subdural hematoma, epidural hematoma, hemiparesis), skin and subcutaneous tissue disorders (e.g., Stevens-Johnson syndrome).
[0095] In some embodiments, the additional therapeutic agent is a NSAID (e.g., aspirin or naproxen), platelet aggregation inhibitor (e.g., clopidogrel), or anticoagulant (e.g., warfarin or enoxaparin).
[0096] In some embodiments, the additional therapeutic agent results in an additive therapeutic effect. In some embodiments, the additional therapeutic agent results in a synergistic therapeutic effect.
[0097] In another aspect, the present invention features a method of modulating (e.g., inhibiting) Factor XIa in a patient. The method comprises the step of administering an effective amount of a a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof)to a patient in need thereof, thereby modulating (e.g., inhibiting) Factor XIa.
[0098] In another aspect, the present invention features a method of treating a subject in need thereof for a thromboembolic disorder. The method comprises administering to the subject an effective amount of a a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). The thromboembolic disorder can be arterial cardiovascular thromboembolic disorders, arterial thrombosis, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart; including unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemia (e.g., coronary ischemia, ischemic sudden death, or transient ischemic attack), stroke (e.g., large vessel acute ischemic stroke), atherosclerosis, peripheral occlusive arterial disease, venous thromboembolism, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.
[0099] In another aspect, the present invention features a method of prophylaxis of a thromboembolic disorder in a subject. The method comprises administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). The thromboembolic disorder can be arterial cardiovascular thromboembolic disorders, arterial thrombosis, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart; including unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemia (e.g., coronary ischemia, ischemic sudden death, or transient ischemic attack), stroke (e.g., large vessel acute ischemic stroke), atherosclerosis, peripheral occlusive arterial disease, venous thromboembolism, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.
[0100] In another aspect, the present invention features a method of reducing the risk of a thromboembolic disorder in a subject. The method comprises administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). The thromboembolic disorder can be arterial cardiovascular thromboembolic disorders, arterial thrombosis, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart; including unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemia (e.g., coronary ischemia, ischemic sudden death, or transient ischemic attack), stroke (e.g., large vessel acute ischemic stroke), atherosclerosis, peripheral occlusive arterial disease, venous thromboembolism, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.
[0101] In one aspect, the present invention is directed to a method of treating end-stage renal disease in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0102] In one aspect, the present invention is directed to a method of prophylaxis of end-stage renal disease in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0103] In one aspect, the present invention is directed to a method of reducing the risk of end-stage renal disease in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0104] In another aspect, the present invention features a method of treating a thromboembolic disorder in a subject need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof), wherein the subject is exposed to an artificial surface. In some embodiments, the artificial surface contacts the subject's blood. In some embodiments, the artificial surface is an extracorporeal surface. In some embodiments, the artificial surface is that of an implantable device, e.g., a mechanical valve. In some embodiments, the artificial surface is that of a dialysis catheter. In some embodiments, the artificial surface is that of a cardiopulmonary bypass circuit. In some embodiments, the artificial surface is that of an artificial heart valve. In some embodiments, the artificial surface is that of a ventricular assist device. In some embodiments, the artificial surface is that of a small caliber graft. In some embodiments, the artificial surface is that of a central venous catheter. In some embodiments, the artificial surface is that of an extracorporeal membrane oxygenation (ECMO) apparatus. In some embodiments, the artificial surface causes or is associated with the thromboembolic disorder.
In some embodiments, the thromboembolic disorder is a venous thromboembolism. In some embodiments, the thromboembolic disorder is deep vein thrombosis. In some embodiments, the thromboembolic disorder is pulmonary embolism.
[0105] In another aspect, the present invention features a method of reducing the risk of a thromboembolic disorder in a subject need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof), wherein the subject is exposed to an artificial surface. In some embodiments, the artificial surface contacts the subject's blood. In some embodiments, the artificial surface is an extracorporeal surface. In some embodiments, the artificial surface is that of an implantable device, e.g., a mechanical valve. In some embodiments, the artificial surface is that of a dialysis catheter. In some embodiments, the artificial surface is that of a cardiopulmonary bypass circuit. In some embodiments, the artificial surface is that of an artificial heart valve. In some embodiments, the artificial surface is that of a ventricular assist device. In some embodiments, the artificial surface is that of a small caliber graft. In some embodiments, the artificial surface is that of a central venous catheter. In some embodiments, the artificial surface is that of an extracorporeal membrane oxygenation (ECMO) apparatus. In some embodiments, the artificial surface causes or is associated with the thromboembolic disorder.
In some embodiments, the thromboembolic disorder is a venous thromboembolism. In some embodiments, the thromboembolic disorder is deep vein thrombosis. In some embodiments, the thromboembolic disorder is pulmonary embolism.
[0106] In another aspect, the present invention features a method of prophylaxis of a thromboembolic disorder in a subject need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof), wherein the subject is exposed to an artificial surface. In some embodiments, the artificial surface contacts the subject's blood. In some embodiments, the artificial surface is an extracorporeal surface. In some embodiments, the artificial surface is that of an implantable device, e.g., a mechanical valve. In some embodiments, the artificial surface is that of a dialysis catheter. In some embodiments, the artificial surface is that of a cardiopulmonary bypass circuit. In some embodiments, the artificial surface is that of an artificial heart valve. In some embodiments, the artificial surface is that of a ventricular assist device. In some embodiments, the artificial surface is that of a small caliber graft. In some embodiments, the artificial surface is that of a central venous catheter. In some embodiments, the artificial surface is that of an extracorporeal membrane oxygenation (ECMO) apparatus. In some embodiments, the artificial surface causes or is associated with the thromboembolic disorder.
In some embodiments, the thromboembolic disorder is a venous thromboembolism. In some embodiments, the thromboembolic disorder is deep vein thrombosis. In some embodiments, the thromboembolic disorder is pulmonary embolism.
[0107] In another aspect, the present invention features a method of treating atrial fibrillation, in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the subject is also in need of dialysis, e.g., renal dialysis. In some embodiments, the composition described herein is administered to the subject while the subject is undergoing dialysis. In some embodiments, the composition is administered to the subject before or after receiving dialysis. In some embodiments, the patient has end-stage renal disease. In some __ embodiments, the subject is not in need of dialysis, e.g., renal dialysis.
In some embodiments, the patient is at a high risk for bleeding. In some embodiments, the atrial fibrillation is associated with another thromboembolic disorder, e.g., a blood clot.
[0108] In another aspect, the present invention features a method of reducing the risk of atrial fibrillation, in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the subject is at a high risk of developing atrial fibrillation.
In some embodiments, the subject is also in need of dialysis, e.g., renal dialysis. In some embodiments, the composition described herein is administered to the subject while the subject is undergoing dialysis. In some embodiments, the composition is administered to the subject before or after receiving dialysis. In some embodiments, the patient has end-stage renal disease. In some embodiments, the subject is not in need of dialysis, e.g., renal dialysis.
In some embodiments, the patient is at a high risk for bleeding. In some embodiments, the atrial fibrillation is associated with another thromboembolic disorder, e.g., a blood clot.
[0109] In another aspect, the present invention features a method of prophylaxis of atrial fibrillation, in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the subject is at a high risk of developing atrial fibrillation. In some embodiments, the subject is also in need of dialysis, e.g., renal dialysis. In some embodiments, the composition described herein is administered to the subject while the subject is undergoing dialysis. In some embodiments, the composition is administered to the subject before or after receiving dialysis. In some embodiments, the patient has end-stage renal disease. In some embodiments, the subject is not in need of dialysis, e.g., renal dialysis. In some embodiments, the patient is at a high risk for bleeding. In some embodiments, the atrial fibrillation is associated with another thromboembolic disorder, e.g., a blood clot.
[0110] In another aspect, the present invention features a method of treating heparin-induced thrombocytopenia in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0111] In another aspect, the present invention features a method of reducing the risk of heparin-induced thrombocytopenia in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0112] In another aspect, the present invention features a method of prophylaxis of heparin-induced thrombocytopenia in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0113] In another aspect, the present invention features a method of treating heparin-induced thrombocytopenia thrombosis in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0114] In another aspect, the present invention features a method of reducing the risk of heparin-induced thrombocytopenia thrombosis in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0115] In another aspect, the present invention features a method of prophylaxis of heparin-induced thrombocytopenia thrombosis in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0116] In another aspect, the present invention features a method of prophylaxis of a thromboembolic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof), wherein the subject has cancer or is being with a chemotherapeutic. In some embodiments, the subject is concurrently receiving chemotherapy. In some embodiments, the subject has elevated lactase dehydrogenase levels. In some embodiments, the thromboembolic disorder is venous thromboembolism. In some embodiments, the thromboembolic disorder is deep vein thrombosis. In some embodiments, the thromboembolic disorder is pulmonary embolism.
[0117] In another aspect, the present invention features a method of treating thrombotic microangiopathy in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the thrombotic microangiopathy is hemolytic uremic syndrome (HUS). In some embodiments, the thrombotic microangiopathy is thrombotic thrombocytopenic purpura (TTP).
[0118] In another aspect, the present invention features a method of reducing the risk of thrombotic microangiopathy in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the thrombotic microangiopathy is hemolytic uremic syndrome (HUS). In some embodiments, the thrombotic microangiopathy is thrombotic thrombocytopenic purpura (TTP).
[0119] In another aspect, the present invention features a method of prophylaxis of thrombotic microangiopathy in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the thrombotic microangiopathy is hemolytic uremic syndrome (HUS). In some embodiments, the thrombotic microangiopathy is thrombotic thrombocytopenic purpura (TTP).
[0120] In another aspect, the present invention features a method of prophylaxis of recurrent ischemia in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof), wherein the subject has acute coronary syndrome. In some embodiments, the subject has atrial fibrillation. In some embodiments, the subject does not have atrial fibrillation. In another aspect, the present invention features a method of treating a subject identified as being at risk, e.g., high risk, for stroke (e.g., large vessel acute ischemic stroke) or thrombosis thereby reducing the likelihood of stroke (e.g., large vessel acute ischemic stroke) or thrombosis in the subject. In some embodiments, the subject is further identified as being at risk for bleeding (e.g., excessive bleeding) or sepsis. In some embodiments, the treatment is effective without bleeding liabilities. In some embodiments, the treatment is effective to maintain the patency of infusion ports and lines. In addition, the compositions described herein are useful in the treatment and prevention of other diseases in which the generation of thrombin has been implicated as playing a physiologic role. For example, thrombin has been implicated in contributing to the morbidity and mortality of chronic and degenerative diseases, such as cancer, arthritis, atherosclerosis, vascular dementia, and Alzheimer's disease, by its ability to regulate many different cell types through specific cleavage and activation of a cell surface thrombin receptor, mitogenic effects, diverse cellular functions such as cell proliferation, for example, abnormal proliferation of vascular cells resulting in restenosis or angiogenesis, release of PDGF, and DNA synthesis. Inhibition of Factor XIa effectively blocks thrombin generation and therefore neutralizes any physiologic effects of thrombin on various cell types. The representative indications discussed above include some, but not all, of the potential clinical situations amenable to treatment with a Factor XIa inhibitor.
[0121] In another aspect, the present invention features a method of treating a subject that has edema (e.g., angioedema, e.g., hereditary angioedema), comprising administering an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof) to the subject.
[0122] In another aspect, the present invention features a method of prophylaxis of edema (e.g., angioedema, e.g., hereditary angioedema) in a subject, comprising administering an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof) to the subject.
[0123] In another aspect, the present invention features a method of reducing the risk of edema (e.g., angioedema, e.g., hereditary angioedema) in a subject, comprising administering an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof) to the subject.
[0124] In another aspect, the present invention features a method of inhibiting kallikrein in a subject, comprising administering to the subject with edema (e.g., angioedema, e.g., hereditary angioedema), an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof) to the subject.
[0125] In another aspect, the present invention features a method of treating a thromboembolic consequence or complication in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the thromboembolic consequence or complication is associated with a peripheral vascular intervention (e.g., of the limbs), hemodialysis, catheter ablation, a cerebrovascular intervention, transplantation of an organ (e.g., liver), surgery (e.g., orthopedic surgery, lung surgery, abdominal surgery, or cardiac surgery, (e.g., open-heart surgery)), a trans-catheter aortic valve implantation, a large bore intervention used to treat an aneurysm, a percutaneous coronary intervention, or hemophilia therapy. In some embodiments, the surgery is orthopedic surgery, lung surgery, abdominal surgery, or cardiac surgery. In some embodiments, the cardiac surgery is complex cardiac surgery or lower risk cardiac surgery. In some embodiments, the thromboembolic consequence or complication is associated with a percutaneous coronary intervention.
[0126] In another aspect, the present invention features a method of prophylaxis of a thromboembolic consequence or complication in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the thromboembolic consequence or complication is associated with a peripheral vascular intervention (e.g., of the limbs), hemodialysis, catheter ablation, e.g., catheter ablation for atrial fibrillation, a cerebrovascular intervention, transplantation of an organ (e.g., liver), surgery (e.g., orthopedic surgery, lung surgery, abdominal surgery, or cardiac surgery, (e.g., open-heart surgery)), a trans-catheter aortic valve implantation, a large bore intervention used to treat an aneurysm, a percutaneous coronary intervention, or hemophilia therapy. In some embodiments, the surgery is orthopedic surgery, lung surgery, abdominal surgery, or cardiac surgery. In some embodiments, the cardiac surgery is complex cardiac surgery or lower risk cardiac surgery. In some embodiments, the thromboembolic consequence or complication is associated with a percutaneous coronary intervention.
[0127] In another aspect, the present invention features a method of reducing the risk of a thromboembolic consequence or complication in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the thromboembolic consequence or complication is associated with a peripheral vascular intervention (e.g., of the limbs), hemodialysis, catheter ablationõ e.g., catheter ablation for atrial fibrillation, a cerebrovascular intervention, transplantation of an organ (e.g., liver), surgery (e.g., orthopedic surgery, lung surgery, abdominal surgery, or cardiac surgery, (e.g., open-heart surgery)), a trans-catheter aortic valve implantation, a large bore intervention used to treat an aneurysm, a percutaneous coronary intervention, or hemophilia therapy. In some embodiments, the surgery is orthopedic surgery, lung surgery, abdominal surgery, or cardiac surgery. In some embodiments, the cardiac surgery is complex cardiac surgery or lower risk cardiac surgery. In some embodiments, the thromboembolic consequence or complication is associated with a percutaneous coronary intervention.
[0128] In another aspect, the invention features a method of treating restenosis following arterial injury in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the arterial injury occurs after a cranial artery stenting.
[0129] In another aspect, the present invention features a method of prophylaxis of restenosis following arterial injury in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the arterial injury occurs after a cranial artery stenting.
[0130] In another aspect, the present invention features a method of reducing the risk of restenosis following arterial injury in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the arterial injury occurs after a cranial artery stenting.
[0131] In another aspect, the present invention features a method of treating hepatic vessel thrombosis in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0132] In another aspect, the present invention features a method of prophylaxis of hepatic vessel thrombosis in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0133] In another aspect, the present invention features a method of reducing the risk of hepatic vessel thrombosis in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0134] In another aspect, the present invention features a method of treating a non-ST-elevation myocardial infarction or ST-elevation myocardial infarction), comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0135] In another aspect, the present invention features a method of prophylaxis of a non-ST-elevation myocardial infarction or ST-elevation myocardial infarction in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0136] In another aspect, the present invention features a method of reducing the risk of a non-ST-elevation myocardial infarction or ST-elevation myocardial infarction in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0137] In another aspect, the present invention features a method of maintaining blood vessel patency, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the subject has acute kidney injury. In some embodiments, the subject additionally undergoes continuous renal replacement therapy.
[0138] In some embodiments of any of the foregoing, the composition described herein is administered orally or parenterally. In certain embodiments, the composition described herein is administered parenterally. In certain embodiments, the composition described herein is administered after the subject has discontinued use of a direct oral anticoagulant. In certain embodiments, the subject used the direct oral anticoagulant for up to about 2.5 years.
In certain embodiments, the subject is a mammal, e.g., a human.
[0139] In some embodiments of the methods described herein, the pharmaceutically acceptable salt of Compound 1 is a hydrochloride salt. In some embodiments, the composition is administered to the subject intravenously. In some embodiments, the composition is administered to the subject subcutaneously. In some embodiments, the composition is administered to the subject as a continuous intravenous infusion. In some embodiments, the composition is administered to the subject as a bolus. In some embodiments, the subject is a human. In some embodiments, the subject has an elevated risk of a thromboembolic disorder. In some embodiments, the thromboembolic disorder is a result of a complication in surgery.
[0140] In some embodiments, the subject is sensitive to or has developed sensitivity to heparin. In some embodiments, the subject is resistant to or has developed resistance to heparin. In some embodiments, the subject is in contact with the artificial surface for at least 1 day (e.g., about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 2 months, about 3 months, about 6 months, about 9 months, about 1 year).
BRIEF DESCRIPTION OF THE DRAWINGS
[0141] FIG. 1 depicts an exemplary HPLC chromatogram of Compound 1 including baseline detail.
[0142] FIG. 2A depicts exemplary pH-development data of Compound 1 over the 10-day stability experiment at 4 C.
[0143] FIG. 2B depicts exemplary pH-development data of Compound 1 over the 10-day stability experiment at 40 C.
[0144] FIG. 3A depicts exemplary recovery data of Compound 1 over a 10-day stability assessment at 4 C.
[0145] FIG. 3B depicts exemplary recovery data of Compound 1 over a 10-day stability assessment 40 C.
[0146] FIG. 4A depicts an exemplary powder X-Ray diffractogram of Compound 1=HC1 on scale.
[0147] FIG. 4B depicts an exemplary powder X-Ray diffractogram of Compound 1=HC1 on d-scale.
[0148] FIG. 5 depicts the lyophilization cycle parameters developed for Compound 1.
[0149] FIG. 6 depicts an exemplary monitoring of product temperature and product drying.
[0150] FIG. 7 depicts exemplary long-term stability study of the Compound 1 lyophilized drug product at T = -80 C.
[0151] FIG. 8 depicts exemplary long-term stability study of the Compound 1 lyophilized drug product at T = -20 C.
[0152] FIG. 9 depicts exemplary long-term stability study of the Compound 1 lyophilized drug product at T = 2-8 C.
[0153] FIG. 10 depicts an exemplary chromatograph of 48-hour stability sample of Compound 1 formulation diluted into normal saline.
[0154] FIG. 11 depicts the pressure gradient across membrane oxygenator for cardiopulmonary bypass experiment conducted in the hound model.
[0155] FIG. 12 depicts a comparison of plasma concentrations and activated partial thromboplastin time (aPTT) ratio measured in the hound model.
[0156] FIG. 13 depicts the activated partial thromboplastin time (aPTT) measured in the hound model following Compound 1 administration.
DETAILED DESCRIPTION
[0157] Described herein are pharmaceutical compositions comprising Compound 1 or a pharmaceutically acceptable salt thereof, a cyclodextrin, and an excipient, methods of their use and administration, methods for their preparation, and containers comprising the solutions or mixtures.
Definitions [0158] As used herein, the terms "stabilized" and "stable" solutions described herein (e.g., an aqueous solution comprising Compound 1) refer to solutions that are "chemically stable"
and "physically stable." For example, a solution comprising Compound 1 is chemically stable if Compound 1 does not undergo chemical transformation (e.g., hydrolysis) or degradation (e.g., racemization, epimerization, oxidation).
[0159] "Assay", as used herein, refers to a specific, stability-indicating procedure that determines the content of the drug substance. For example, an assay can be a chromatographic method (e.g., HPLC) involving use of a reference standard.
[0160] "Purity", as used herein, refers to the absence of impurities, for example in a solution or composition, relative to its parent (e.g., at time = 0).
[0161] "Sterilization", as used herein, refers to aseptic fill (e.g., aseptic sterilization) or terminal sterilization.
[0162] A "reconstituted solution," "reconstituted formulation," or "reconstituted drug product" as used herein, refers to a solution which has been prepared by dissolving a lyophilized drug product in a diluent, such that the drug product is dissolved in an aqueous solution suitable for administration (e.g., parenteral administration).
[0163] The term "diluent" as used herein, refers to a pharmaceutically acceptable (e.g., safe and non-toxic for administration to a human) diluting substance useful for the preparation of a reconstituted solution. Exemplary diluents include sterile water for injection (WFI), a pH
buffered solution (e.g., phosphate-buffered saline), sterile saline solution, or dextrose solution (e.g., 5% dextrose).
[0164] The term "osmolarity," as used herein, refers to the total number of dissolved components per liter. Osmolarity is similar to molarity but includes the total number of moles of dissolved species in solution. An osmolarity of 1 Osm/L means there is 1 mole of dissolved components per L of solution. Some solutes, such as ionic solutes that dissociate in solution, will contribute more than 1 mole of dissolved components per mole of solute in the solution. For example, NaCl dissociates into Na+ and Cl- in solution and thus provides 2 moles of dissolved components per 1 mole of dissolved NaCl in solution.
Physiological osmolarity is typically in the range of about 280 mOsm/L to about 310 mOsm/L.
[0165] As used herein, "slurrying" refers to a method wherein a compound as described herein is suspended in a solvent (e.g., polar aprotic solvent or nonpolar solvent) and is collected again (e.g., by filtration) after agitating the suspension.
[0166] As used herein, "crystalline" refers to a solid having a highly regular chemical structure. The molecules are arranged in a regular, periodic manner in the 3-dimensional space of the lattice.
[0167] The term "substantially crystalline" refers to forms that may be at least a particular weight percent crystalline. Particular weight percentages are 70%, 75%, 80%, 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or any percentage between 70% and 100%. In certain embodiments, the particular weight percent of crystallinity is at least 90%. In certain other embodiments, the particular weight percent of .. crystallinity is at least 95%. In some embodiments, Compound 1 can be a substantially crystalline sample of any of the crystalline solid forms described herein.
[0168] The term "substantially pure" relates to the composition of a specific crystalline solid form of Compound 1 that may be at least a particular weight percent free of impurities and/or other solid forms of Compound 1 or a pharmaceutically acceptable salt thereof .. Particular weight percentages are 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage between 70% and 100%. In some embodiments, a crystalline solid form of Compound 1 or a pharmaceutically acceptable salt thereof as described herein is substantially pure at a weight percent between 95% and 100%, e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 99.9%.
[0169] As used herein, and unless otherwise specified, the terms "treat,"
"treating" and "treatment" contemplate an action that occurs while a subject is suffering from the specified disease, disorder or condition, which reduces the severity of the disease, disorder or condition, or retards or slows the progression of the disease, disorder or condition (also, "therapeutic treatment").
[0170] As used herein, and unless otherwise specified, a "therapeutically effective amount"
of a composition is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder or condition, or to delay or minimize one or more symptoms associated with the disease, disorder or condition. A therapeutically effective amount of a composition means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the disease, disorder or condition.
The term "therapeutically effective amount" can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.
[0171] As used herein, and unless otherwise specified, a "prophylactically effective amount" of a composition is an amount sufficient to prevent a disease, disorder or condition, or one or more symptoms associated with the disease, disorder or condition, or prevent its recurrence. A prophylactically effective amount of a composition means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the disease, disorder or condition. The term "prophylactically effective amount" can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
[0172] Disease, disorder, and condition are used interchangeably herein.
[0173] A "subject" to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g, infant, child, adolescent) or adult subject (e.g., young adult, middle¨aged adult or senior adult)) and/or a non-human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and/or dogs. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human animal. In some embodiments, the pediatric subject is between the age of 0 and 18 years old.
In some embodiments, the adult subject is beyond 18 years old.
[0174] As used herein, the term "artificial surface" refers to any non-human or non-animal surface that comes into contact with blood of the subject, for example, during a medical procedure. It can be a vessel for collecting or circulating blood of a subject outside the subject's body. It can also be a stent, valve, intraluminal catheter or a system for pumping blood. By way of non-limiting example such artificial surfaces can be steel, any type of plastic, glass, silicone, rubber, etc. In some embodiments, the artificial surface is exposed to at least 50%. 60%, 70% 80%, 90% or 100% of the blood of subject.
[0175] As used herein, the term "conditioning" or "conditioned" with respect to an artificial surface refers to priming or flushing the artificial surface (e.g., extracorporeal surface) with a composition described herein, already in a priming or flushing solution (e.g., blood, a saline solution, Ringer's solution) or as a separate administration to the artificial surface prior to, during, or after a medical procedure.
Bulking Agent [0176] The term "bulking agent" as used herein, includes agents that provide the structure of the composition (e.g., in lyophilized product) without interacting directly (e.g, chemically) with the pharmaceutical product (e.g, drug product). In addition to providing a pharmaceutically elegant cake, bulking agents may also impart useful qualities in regard to modifying the collapse temperature, providing freeze-thaw protection, and enhancing the active pharmaceutical ingredient (API) stability over long-term storage. Non-limiting examples of bulking agents include a sugar (e.g., a saccharide (e.g., monosaccharide, disaccharide, or polysaccharide)) or a sugar alcohol (e.g., sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, or marmitol, or a combination thereof). Bulking agents may be crystalline (e.g., mannitol, glycine, or sodium chloride) or amorphous (e.g., dextran, hydroxyethyl starch).
[0177] Preferably, the bulking agent applied in pharmaceutical formulation promotes the formation of a cake that is aesthetically acceptable, uniform, or mechanically strong. Bulking agents may also preferably promote ease and speed of reconstitution. Bulking agents may also preferably reduce or prevent cake collapse, eutectic melting, or retention of residual moisture. In some embodiments, the bulking agent is a lyoprotectant.
Buffers [0178] In some embodiments, the aqueous pharmaceutical compositions described herein further comprise a buffer (e.g., a buffer at a pH of between about 6 and about 8 (e.g., between about 6.5 and about 7.0, or about 6.8).
[0179] As used herein, the terms "buffer," "buffer system," or "buffering component"
refers to a compound that, usually in combination with at least one other compound, provides a chemical system in solution that exhibits buffering capacity, that is, the capacity to neutralize, within limits, the pH lowering or raising effects of either strong acids or bases (alkali), respectively, with relatively little or no change in the original pH
(e.g., the pH before being affected by, e.g., strong acid or base). For example, a buffer described herein maintains or controls the pH of a solution to a certain pH range. For example, "buffering capacity" can refer to the millimoles (mM) of strong acid or base (or respectively, hydrogen or hydroxide ions) required to change the pH by one unit when added to one liter (a standard unit) of the buffer solution. From this definition, it is apparent that the smaller the pH change in a solution caused by the addition of a specified quantity of acid or alkali, the greater the buffer capacity of the solution. See, for example, Remington: The Science and Practice of Pharmacy, Mack Publishing Co., Easton, Pennsylvania (19th Edition, 1995), Chapter 17, pages 225-227. The buffer capacity will depend on the kind and concentration of the buffer components.
[0180] In some embodiments, the buffer comprises a monoprotic acid. In some embodiments, the buffer comprises a polyprotic acid (e.g., maleate, citrate, or phosphate). In some embodiments, the buffer is a solution of one or more substances (e.g., a salt of a weak acid and a weak base; a mixture of a weak acid and a salt of the weak acid with a strong base).
[0181] In some embodiments, the buffer is maleate buffer. In some embodiments, the buffer is citrate buffer. In some embodiments, the buffer is phosphate buffer.
Lyoprotectant [0182] The term "lyoprotectant" as used herein, refers to a substance, when combined with the drug product, reduces the chemical and/or physical instability of the drug product upon lyophilization and/or subsequent storage. Exemplary lyoprotectants include sugars and their .. corresponding sugar alcohols, such as sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, and mannitol; amino acids, such as arginine or histidine;
lyotropic salts, such as magnesium sulfate; polyols, such as propylene glycol, glycerol, poly(ethylene glycol), or polypropylene glycol); and combinations thereof Additional exemplary lyoprotectants include gelatin, dextrins, modified starch, and carboxymethyl cellulose. Sugar alcohols are those compounds obtained by reduction of mono- and di-saccharides, such as lactose, trehalose, maltose, lactulose, and maltulose.
Cyclodextrins [0183] Cyclodextrins are cyclic oligosaccharides containing or comprising six (a-cyclodextrin), seven (0-cyclodextrin), eight (y-cyclodextrin), or more a-(1,4)-linked glucose residues. The hydroxyl groups of the cyclodextrins are oriented to the outside of the ring while the glucosidic oxygen and two rings of the non-exchangeable hydrogen atoms are directed towards the interior of the cavity.
[0184] The cyclodextrin may be chemically modified such that some or all of the primary or secondary hydroxyl groups of the macrocycle, or both, are functionalized with a pendant group. Suitable pendant groups include, but are not limited to, sulfinyl, sulfonyl, phosphate, acyl, and Cl-C12 alkyl groups optionally substituted with one or more (e.g., 1, 2, 3, or 4) hydroxy, carboxy, carbonyl, acyl, oxy, oxo; or a combination thereof Methods of modifying these alcohol residues are known in the art, and many cyclodextrin derivatives are commercially available, including sulfo butyl ether 0-cyclodextrins available under the trade name CAPTISOLO from Ligand Pharmaceuticals (La Jolla, CA).
[0185] Cyclodextrins include, but are not limited to, alkyl cyclodextrins, hydroxy alkyl cyclodextrins, such as hydroxy propyl 0-cyclodextrin, carboxy alkyl cyclodextrins and sulfoalkyl ether cyclodextrins, such as sulfo butyl ether 0-cyclodextrin.
[0186] In particular embodiments, the cyclodextrin is beta cyclodextrin having a plurality of charges (e.g., negative or positive) on the surface. In more particular embodiments, the cyclodextrin is a [3-cyclodextrin containing or comprising a plurality of functional groups that are negatively charged at physiological pH. Examples of such functional groups include, but are not limited to, carboxylic acid (carboxylate) groups, sulfonate (R503-), phosphonate groups, phosphinate groups, and amino acids that are negatively charged at physiological pH.
The charged functional groups can be bound directly to the cyclodextrins or can be linked by a spacer, such as an alkylene chain. The number of carbon atoms in the alkylene chain can be varied, but is generally between about 1 and 10 carbons, preferably 1-6 carbons, more preferably 1-4 carbons. Highly sulfated cyclodextrins are described in U.S.
Patent No.
6,316,613.
[0187] In one embodiment, the cyclodextrins is a [3-cyclodextrin functionalized with a plurality of sulfobutyl ether groups. Such a cyclodextrins is sold under the trade name CAPTISOLO.
[0188] CAPTISOLO is a polyanionic beta-cyclodextrin derivative with a sodium sulfonate salt separated from the lipophilic cavity by a butyl ether spacer group, or sulfobutylether (SBE). CAPTISOLO is not a single chemical species, but comprised of a multitude of polymeric structures of varying degrees of substitution and positional/regional isomers dictated and controlled to a uniform pattern by a patented manufacturing process consistently practiced and improved to control impurities.
[0189] CAPTISOLO contains six to seven sulfobutyl ether groups per cyclodextrin molecule. Because of the very low pKa of the sulfonic acid groups, CAPTISOLO
carries multiple negative charges at physiologically compatible pH values. The four-carbon butyl chain coupled with repulsion of the end group negative charges allows for an "extension" of the cyclodextrin cavity. This often results in stronger binding to drug candidates than can be achieved using other modified cyclodextrins. It also provides a potential for ionic charge interactions between the cyclodextrin and a positively charged drug molecule.
In addition, these derivatives impart exceptional solubility and parenteral safety to the molecule. Relative to beta-cyclodextrin, CAPTISOLO provides higher interaction characteristics and superior water solubility in excess of 100 grams/100 ml, a 50-fold improvement.
Solubilizing Agent [0190] The term "solubilizing agent", as used herein, describes a substance which is capable of facilitating the dissolution of insoluble or poorly soluble components in a solution containing same. Representative examples of solubilizing agents that are usable in the context of the present invention include, without limitation, TWEENS and spans, e.g., TWEENa) 80 and TWEENt 20. Other solubilizing agents that are usable in the context of embodiments of the invention include, for example, polyoxyethylen.e sorbitan esters, polyox-yethylene sorbitan fatt)., acid ester, polvoxyethylene n-allcyl ethers, polyethylene glycols (e.g., PEG200, PEG300, PEG400, PEG500, PEG600, etc), n-alicyl amine n-oxides, poloxamers, organic solvents, phospholipids and cyclodextrins.
Containers [0191] Also described herein are containers that include an aqueous solution or admixture described herein. Examples of containers include bags (e.g., plastic or polymer bags such as PVC), vials (e.g., a glass vial), bottles, or syringes. In an embodiment, the container is configured to deliver the solution or admixture parenterally (e.g., intramuscular, subcutaneous, or intravenous).
[0192] In some embodiments, the product intended for injection is packed in a suitably sized hermetically sealed glass container. In some embodiments the product is intended to be diluted prior to infusion, and is packaged in a pharmaceutical vial or bottle (e.g. suitably sized, suitable glass or plastic vial or bottle). In some embodiments the product may prepared to be ready for injection and may be packaged in a prefilled syringe or other syringe device (e.g. suitably sized, suitable glass or plastic package) or large volume container (e.g. suitably sized, suitable glass or plastic container) intended to be used for infusion.
In some embodiments, the product is provided in a container that does not leach (e.g., does not introduce (or allow growth of) contamination or impurities in the solution.
Lyophilization [0193] The term "lyophilization" refers to a freeze-drying process in which water is removed from a product by freezing the product and placing it under a vacuum, which allows the ice to change directly from the solid phase to the vapor phase without passing through the liquid phase. The process consists of three separate, unique, and interdependent processes:
freezing, primary drying (sublimation), and secondary drying (desorption).
There are several advantages associated with lyophilization, such as: (i) ease of processing a liquid, which simplifies aseptic handling; (ii) enhanced stability of a dry powder; (iii) removal of water without excessive heating of the product; (iv) enhanced product stability in a dry state; and (v) rapid and easy dissolution of the reconstituted product.
[0194] The lyophilization process generally includes the following steps:
- Dissolving the drug and excipients in a suitable solvent, generally water for injection (WFI).
- Sterilizing the bulk solution by passing it through a 0.22 micron bacteria-retentive filter.
- Filling into individual sterile containers and partially stoppering the containers under aseptic conditions.
- Transporting the partially stoppered containers to the lyophilizer and loading into the chamber under aseptic conditions.
- Freezing the solution by placing the partially stoppered containers on cooled shelves in a freeze-drying chamber or pre-freezing in another chamber.
- Applying a vacuum to the chamber and heating the shelves in order to evaporate the water from the frozen state.
- Complete stoppering of the vials usually by hydraulic or screw rod stoppering mechanisms installed in the lyophilizers.
Compounds [0195] The present invention relates, in part, to pharmaceutical compositions comprising a compound of Formula (I-A):
N. ?'\---01r0 ,¨NyN
0 (I-A) also referred to herein as "Compound 1," or a pharmaceutically acceptable salt thereof In some embodiments, the pharmaceutically acceptable salt of Compound 1 is a hydrochloride salt.
[0196] In some embodiments, a compound described herein is formed into a salt.
A
compound described herein can be administered as a free acid, a zwitterion or as a salt. A
salt can also be formed between a cation and a negatively charged substituent on a compound described herein, the deprotonated carboxylic acid moiety of Compound 1 for example.
Suitable cationic counterions include sodium ions, potassium ions, magnesium ions, calcium ion, and ammonium ions (e.g., a tetraalkyl ammonium cation such as tetramethylammonium ion). In acid addition salts, a salt can be formed between an anion and a positively charged substituent (e.g., amino group) or basic substituent (e.g., pyridyl) on a compound described herein. Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, and acetate.
[0197] Pharmaceutically acceptable salts of the compounds described herein (e.g., a pharmaceutically acceptable salt of Compound 1) also include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, 4-acetamidobenzoate, adipate, alginate, 4-aminosalicylate, aspartate, ascorbate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, carbonate, cinnamate, cyclamate, decanoate, decanedioate, 2,2-dichloroacetate, digluconate, dodecylsulfate, ethanesulfonate, ethane-1,2-disulfonate, formate, fumarate, galactarate, glucoheptanoate, gluconate, glucoheptonate, glucoronate, glutamate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 1-hydroxy-2-naphthoate, 2-hydroxyethanesulfonate, isobutyrate, lactate, lactobionate, laurate, malate, maleate, malonate, mandelate, methanesulfonate, naphthalene-1,5-disulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, octanoate, oleate, oxalate, 2-oxoglutarate, palmitate, palmoate, pectinate, 3-phenylpropionate, phosphate, phosphonate, picrate, pivalate, propionate, pyroglutamate, salicylate, sebacate, succinate, stearate, sulfate, tartrate, thiocyanate, toluenesulfonate, tosylate, and undecanoate.
[0198] Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and (alkyl)4N + salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
[0199] As used herein, the compounds of this invention, including the Compound 1, are defined to include pharmaceutically acceptable derivatives or prodrugs thereof A
"pharmaceutically acceptable derivative or prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention. Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood), or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species. Preferred prodrugs include derivatives where a group which enhances aqueous solubility or active transport through the gut membrane is appended to the structure of formulae described herein.
[0200] Any formula or a compound described herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds, isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, 3H, 13c, 14C, 15N, 18F 51p, 32p, 35s, 36C1, 1251 respectively. The invention includes various isotopically labeled compounds as defined herein, for example, those into which radioactive isotopes, such as 3H, 13C, and 14C are present. Such isotopically labelled compounds are useful in metabolic studies (with 14C), reaction kinetic studies (with, for example 'H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an I-8F or labeled compound may be particularly desirable for PET or SPECT studies, isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
[0201] Further, substitution with heavier isotopes, particularly deuterium (i.e., 2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of a formula described herein. The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope If a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5%
deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5%
deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95%
deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99%
deuterium incorporation), or at least 8633.3 (99.5% deuterium incorporation).
[0202] Isotopically-labelled compounds described herein can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g, D20, D6-acetone, D6-DMSO.
[0203] Any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)- (S)- or (RS)- configuration, in certain embodiments, each asymmetric atom has at least 50 %
enantiomeric excess, at least 60 % enantiomeric excess, at least 70 %
enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the (R)- or (S)-configuration. Substituents at atoms with unsaturated bonds may, if possible, be present in cis-(Z)- or trans-(E)- form Accordingly, as used herein a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereorners, optical isomers (antipodes), racemates or mixtures thereof Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography or fractional crystallization.
[0204] Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. An acidic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, (+)-0,01-Di-p-toluoyl-D-tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
[0205] The compounds described herein (e.g., Compound 1) may also be represented in multiple tautomeric forms. In such instances, the invention expressly includes all tautomeric forms of the compounds described herein. All crystal forms of the compounds described herein are expressly included in this invention.
Methods of Synthesizing Compounds .. [0206] The compounds described herein can be synthesized by conventional methods using commercially available starting materials and reagents. For example, compounds can be synthesized utilizing the methods set forth in U.S. Patent No. 7,501,404, or as described in the methods described herein.
[0207] Compounds described herein can be purified using various techniques in the art of synthetic organic chemistry. A compound described herein can be purified using one or more chromatographic methods, e.g., column chromatography or HPLC. A compound described herein can be purified by a purification method that is not chromatography, e.g., recrystallization or slurrying. In one embodiment, a compound described herein can be purified using recrystallization. In another embodiment, a compound described herein can also be purified by slurrying.
[0208] In some embodiments, a compound described herein that has been purified by chromatography can also be purified by a recrystallization. A compound described herein .. can also be purified by slurrying (or re-slurrying) the compound with one or more solvents, e.g., a slurry described herein. A compound described herein can also be purified by trituration with one or more solvents, e.g., a trituration described herein.
For example, a compound described herein that has been purified by chromatography can also be purified by trituration. In a chemical reactor, the trituration process may be affected by suspension or .. resuspension of a solid product in a solvent or mixture of solvents with mechanical stirring.
In an embodiment, a compound described herein can also be purified by precipitation from a solution using one or more anti-solvents. For example, a compound described herein that has been purified by chromatography can also be purified by precipitation. In one embodiment, a compound described herein is purified by simulated moving bed (SMB) chromatography. In one embodiment, a compound described herein is purified by supercritical fluid chromatography, e.g., supercritical fluid chromatography with liquid carbon dioxide. In one embodiment, a compound described herein is purified by chiral chromatography e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
Methods of Treatment, Prophylaxis, or Reduction of Risk [0209] The compounds described herein (e.g., Compound 1 or a pharmaceutically acceptable salt thereof) can inhibit Factor XIa or kallikrein. In some embodiments, the compounds described herein (e.g., Compound 1 or a pharmaceutically acceptable salt thereof) can inhibit both Factor XIa and kallikrein. As a result, these compounds can be useful in the .. treatment, prophylaxis, or reduction in the risk of a disorder described herein.
[0210] Exemplary disorders include thrombotic events associated with coronary artery and cerebrovascular disease, venous or arterial thrombosis, coagulation syndromes, ischemia (e.g., coronary ischemia) and angina (stable and unstable), deep vein thrombosis (DVT), hepatic vein thrombosis, disseminated intravascular coagulopathy, Kasabach-Merritt syndrome, pulmonary embolism, myocardial infarction (e.g., ST-elevation myocardial infarction or non-ST-elevation myocardial infarction (e.g., non-ST-elevation myocardial infarction before catheterization), cerebral infarction, cerebral thrombosis, transient ischemic attacks, atrial fibrillation (e.g., non-valvular atrial fibrillation), cerebral embolism, thromboembolic complications of surgery (e.g., hip or knee replacement, orthopedic surgery, cardiac surgery, lung surgery, abdominal surgery, or endarterectomy) and peripheral arterial occlusion and may also be useful in treating or preventing myocardial infarction, stroke (e.g., large vessel acute ischemic stroke), angina and other consequences of atherosclerotic plaque .. rupture. The compounds of the invention possessing Factor XIa or kallikrein inhibition activity may also be useful in preventing thromboembolic disorders, e.g., venous thromboembolisms, in cancer patients, including those receiving chemotherapy and/or those with elevated lactase dehydrogenase (LDH) levels, and to prevent thromboembolic events at or following tissue plasminogen activator-based or mechanical restoration of blood vessel patency. The compounds of the invention possessing Factor XIa or kallikrein inhibition activity may also be useful as inhibitors of blood coagulation such as during the preparation, storage and fractionation of whole blood. Additionally, the compounds described herein may be used in acute hospital settings or periprocedurally, where a patient is at risk of a thromboembolic disorder or complication, and also in patients who are in a heightened .. coagulation state, e.g., cancer patients.
[0211] Factor XIa inhibition, according to the present invention, can be a more effective and safer method of inhibiting thrombosis compared to inhibiting other coagulation serine proteases such as thrombin or Factor Xa. Administration of a small molecule Factor XIa inhibitor should have the effect of inhibiting thrombin generation and clot formation with no or substantially no effect on bleeding times and little or no impairment of haemostasis. These results differ substantially from that of other "direct acting" coagulation protease inhibitors (e.g., active-site inhibitors of thrombin and Factor Xa), which demonstrate prolongation of bleeding time and less separation between antithrombotic efficacy and bleeding time prolongation. A preferred method according to the invention comprises administering to a mammal a pharmaceutical composition containing at least one compound of the invention.
[0212] The compounds described herein (e.g., Compound 1 or pharmaceutically acceptable salts thereof) can inhibit kallikrein. As a result, these compounds can be useful in the treatment, prophylaxis, or reduction in the risk of diseases involved in inflammation, such as edema (e.g., cerebral edema, macular edema, and angioedema (e.g., hereditary angioedema)).
.. In some embodiments, the compounds of the invention can be useful in the treatment or prevention of hereditary angioedema. The compounds described herein (e.g., Compound 1) can also be useful in the treatment, prophylaxis, or reduction in the risk of, e.g., stroke, ischemia (e.g., coronary ischemia), and perioperative blood loss for example, Compound 1 or pharmaceutically acceptable salts thereof The methods of the present invention are useful for treating or preventing those conditions which involve the action of Factor XIa or kallikrein. Accordingly, the methods of the present invention are useful in treating consequences of atherosclerotic plaque rupture including cardiovascular diseases associated with the activation of the coagulation cascade in thrombotic or thrombophilic states.
[0213] More particularly, the methods of the present invention can be used in the treatment, prophylaxis, or reduction in the risk of acute coronary syndromes such as coronary artery disease, myocardial infarction, unstable angina (including crescendo angina), ischemia (e.g., ischemia resulting from vascular occlusion), and cerebral infarction. The methods of the present invention further may be useful in the treatment, prophylaxis, or reduction in the risk of stroke (e.g., large vessel acute ischemic stroke) and related cerebral vascular diseases (including cerebrovascular accident, vascular dementia, and transient ischemic attack);
venous thrombosis and thrombo-embolism, such as deep vein thrombosis (DVT) and pulmonary embolism; thrombosis associated with atrial fibrillation, ventricular enlargement, dilated cardiac myopathy, or heart failure; peripheral arterial disease and intermittent claudication; the formation of atherosclerotic plaques and transplant atherosclerosis;
restenosis following arterial injury induced endogenously (by rupture of an atherosclerotic plaque), or exogenously (by invasive cardiological procedures such as vessel wall injury resulting from angioplasty or post-cranial artery stenting); disseminated intravascular coagulopathy, Kasabach-Merritt syndrome, cerebral thrombosis, and cerebral embolism.
[0214] Additionally, the methods of the present invention can be used in the treatment, prophylaxis (e.g., preventing), or reduction in the risk of thromboembolic consequences or complications associated with cancer, thrombectomy, surgery (e.g., hip replacement, orthopedic surgery), endarterectomy, introduction of artificial heart valves, peripheral vascular interventions (e.g., of the limbs), cerebrovascular interventions, large bore interventions used in the treatment of aneurysms, vascular grafts, mechanical organs, and implantation (e.g., trans-catheter aortic valve implantation) or transplantation of organs, (e.g., transplantation of the liver), tissue, or cells); percutaneous coronary interventions; catheter ablation; hemophilia therapy; hemodialysis; medications (such as tissue plasminogen activator or similar agents and surgical restoration of blood vessel patency) in patients suffering myocardial infarction, stroke (e.g., large vessel acute ischemic stroke), pulmonary embolism and like conditions; medications (such as oral contraceptives, hormone replacement, and heparin, e.g., for treating heparin-induced thrombocytopenia); sepsis (such as sepsis related to disseminated intravascular coagulation); pregnancy or childbirth; and another chronic medical condition. The methods of the present invention may be used to treat thrombosis due to confinement (e.g., immobilization, hospitalization, bed rest, or limb immobilization, e.g., with immobilizing casts, etc.). In some embodiments, the thromboembolic consequence or complication is associated with a percutaneous coronary intervention.
[0215] Additionally, the compounds described herein (e.g., Compound 1) or pharmaceutically acceptable salts thereof or compositions thereof can be useful in the treatment, prophylaxis and reduction in the risk of a thromboembolic disorder, e.g., a venous thromboembolism, deep vein thrombosis or pulmonary embolism, or associated complication in a subject, wherein the subject is exposed to an artificial surface. The artificial surface can contact the subject's blood, for example, as an extracorporeal surface or that of an implantable device. Such artificial surfaces include, but are not limited to, those of dialysis catheters, cardiopulmonary bypass circuits, artificial heart valves, e.g., mechanical heart valves (MHVs), ventricular assist devices, small caliber grafts, central venous catheters, extracorporeal membrane oxygenation (ECMO) apparatuses. Further, the thromboembolic disorder or associated complication may be caused by the artificial surface or associated with the artificial surface. For example, foreign surfaces and various components of mechanical heart valves (MHVs) are pro-thrombotic and promote thrombin generation via the intrinsic pathway of coagulation. Further, thrombin and FXa inhibitors are contraindicated with thromboembolic disorders or associated complications caused by artificial surfaces such as those MHVs, as these inhibitors are ineffective at blocking the intrinsic pathway at plasma levels that will not cause heavy bleeding. The compounds of the present invention, which can be used as, for example, Factor XIa inhibitors, are thus contemplated as alternative therapeutics for these purposes.
[0216] The compounds described herein (e.g., Compound 1) or pharmaceutically acceptable salts thereof or compositions thereof can also be useful for the treatment, prophylaxis, or reduction in the risk of atrial fibrillation in a subject in need thereof For example, the subject can have a high risk of developing atrial fibrillation.
The subject can also in need of dialysis, such as renal dialysis. The compounds described herein (e.g., Compound 1) or pharmaceutically acceptable salts thereof or compositions thereof can be administered before, during, or after dialysis. Direct oral anticoagulants (DOACs) currently available on the market, such as certain FXa or thrombin inhibitors, are contraindicated for atrial fibrillation under such a condition. The compounds of the present invention, which can be used as, for example, Factor XIa inhibitors, are thus contemplated as alternative therapeutics for these purposes. Additionally, the subject can be at a high risk of bleeding. In some embodiments, the subject can have end-stage renal disease. In other cases, the subject is not in need of dialysis, such as renal dialysis. Further, the atrial fibrillation can be associated with another thromboembolic disorder such as a blood clot.
[0217] Furthermore, the compounds described herein (e.g., Compound 1) or pharmaceutically acceptable salts thereof or compositions thereof can be used in the treatment, prophylaxis, or reduction in the risk of hypertension, e.g., arterial hypertension, in a subject. In some embodiments, the hypertension, e.g., arterial hypertension, can result in atherosclerosis. In some embodiments, the hypertension can be pulmonary arterial hypertension.
[0218] Furthermore, the compounds described herein (e.g., Compound 1) or pharmaceutically acceptable salts thereof or compositions thereof can be used in the treatment, prophylaxis, or reduction in the risk of disorders such as heparin-induced thrombocytopenia, heparin-induced thrombocytopenia thrombosis, or thrombotic microangiopathy, e.g., hemolytic uremic syndrome (HUS) or thrombotic thrombocytopenic purpura (TTP).
[0219] In some embodiments, the subject is sensitive to or has developed sensitivity to heparin. Heparin-induced thrombocytopenia (HIT) is the development of (a low platelet count), due to the administration of various forms of heparin.
HIT is caused by the formation of abnormal antibodies that activate platelets. HIT can be confirmed with specific blood tests. In some embodiments, the subject is resistant to or has developed resistance to heparin. For example, activated clotting time (ACT) test can be performed on the subject to test for sensitivity or resistance towards heparin. The ACT
test is a measure of the intrinsic pathway of coagulation that detects the presence of fibrin formation. A subject who is sensitive and/or resistant to standard dose of heparin typically do not reach target anticoagulation time. Common correlates of heparin resistance include, but are not limited to, previous heparin and/or nitroglycerin drips and decreased antithrombin III
levels. In some embodiments, the subject has previously been administered an anticoagulant (e.g.
bivalirudin/Angiomax).
[0220] The compounds described herein (e.g., Compound 1) or pharmaceutically acceptable salts thereof or compositions thereof can be used to reduce inflammation in a subject. In some embodiments, the inflammation can be vascular inflammation.
In some embodiments, the vascular inflammation can be accompanied by atherosclerosis.
In some embodiments, the vascular inflammation can be accompanied by a thromboembolic disease in the subject. In some embodiments, the vascular inflammation can be angiotensin II-induced vascular inflammation.
[0221] The compounds described herein (e.g., Compound 1) or pharmaceutically acceptable salts thereof or compositions thereof can be used in the treatment, prophylaxis, or reduction in the risk of renal disorders or dysfunctions, including end-stage renal disease, hypertension-associated renal dysfunction in a subject, kidney fibrosis, and kidney injury.
[0222] The methods of the present invention may also be used to maintain blood vessel potency, for example, in patients undergoing thrombectomy, transluminal coronary angioplasty, or in connection with vascular surgery such as bypass grafting, arterial reconstruction, atherectomy, vascular grafts, stent potency, and organ, tissue or cell implantation and transplantation. The inventive methods may be used to inhibit blood coagulation in connection with the preparation, storage, fractionation, or use of whole blood.
For example, the inventive methods may be used in maintaining whole and fractionated blood in the fluid phase such as required for analytical and biological testing, e.g., for ex vivo platelet and other cell function studies, bioanalytical procedures, and quantitation of blood-containing components, or for maintaining extracorporeal blood circuits, as in a renal replacement solution (e.g., hemodialysis) or surgery (e.g., open-heart surgery, e.g., coronary artery bypass surgery). In some embodiments, the renal replacement solution can be used to treat patients with acute kidney injury. In some embodiments, the renal replacement solution can be continuous renal replacement therapy.
[0223] In addition, the methods of the present invention may be useful in treating and preventing the prothrombotic complications of cancer. The methods may be useful in treating tumor growth, as an adjunct to chemotherapy, for preventing angiogenesis, and for treating cancer, more particularly, cancer of the lung, prostate, colon, breast, ovaries, and bone.
Extracorporeal Membrane Oxygenation (ECMO) [0224] "Extracorporeal membrane oxygenation" (or "ECMO") as used herein, refers to extracorporeal life support with a blood pump, artificial lung, and vascular access cannula, capable of providing circulatory support or generating blood flow rates adapted to support blood oxygenation, and optionally carbon dioxide removal. In venovenous ECMO, extracorporeal gas exchange is provided to blood that has been withdrawn from the venous system; the blood is then reinfused to the venous system. In venoarterial ECMO, gas exchange is provided to blood that is withdrawn from the venous system and then infused directly into the arterial system to provide partial or complete circulatory or cardiac support.
.. Venoarterial ECMO allows for various degrees of respiratory support.
[0225] As used herein, "extracorporeal membrane oxygenation" or "ECMO" refers to extracorporeal life support that provides circulatory support or generates blood flow rates adequate to support blood oxygenation. In some embodiments, ECMO comprises removal of carbon dioxide from a subject's blood. In some embodiments, ECMO is performed using an extracorporeal apparatus selected from the group consisting of a blood pump, artificial lung, and vascular access cannula.
[0226] As used herein, "venovenous ECMO" refers to a type of ECMO in which blood is withdrawn from the venous system of a subject into an ECMO apparatus and subjected to gas exchange (including oxygenation of the blood), followed by reinfusion of the withdrawn blood into the subject's venous system. As used herein, "venoarterial ECMO"
refers to a type of ECMO in which blood is withdrawn from the venous system of a subject into an ECMO apparatus and subjected to gas exchange (including oxygenation of the blood), followed by infusion of the withdrawn blood directly into the subject's arterial system. In some embodiments, venoarterial ECMO is performed to provide partial circulatory or cardiac support to a subject in need thereof In some embodiments, venoarterial ECMO is performed to provide complete circulatory or cardiac support to a subject in need thereof [0227] The compounds of the present invention can be used in the treatment, prophylaxis, or reduction in the risk of a thromboembolic disorder in a subject in need thereof, wherein the subject is exposed to an artificial surface such as that of an extracorporeal membrane oxygenation (ECMO) apparatus (vide supra), which can be used as a rescue therapy in response to cardiac or pulmonary failure. The surface of an ECMO apparatus that directly contacts the subject can be a pro-thrombotic surface that can result in a thromboembolic disorder such as a venous thromboembolism, e.g., deep vein thrombosis or pulmonary embolism, leading to difficulties in treating a patient in need of ECMO. Clots in the circuit are the most common mechanical complication (19 %). Major clots can cause oxygenator failure, and pulmonary or systemic emboli.
[0228] ECMO is often administered with a continuous infusion of heparin as an anticoagulant to counter clot formation. However, cannula placement can cause damage to the internal jugular vein, which causes massive internal bleeding. Bleeding occurs in 30 - 40 % of patients receiving ECMO and can be life-threatening. This severe bleeding is due to both the necessary continuous heparin infusion and platelet dysfunction.
Approximately 50%
of reported deaths are due to severe bleeding complications. Aubron et al.
Critical Care, 2013, 17:R73 looked at the factors associated with ECMO outcomes.
[0229] The compounds of the present invention, which can be used as, for example, Factor XIa inhibitors, are thus contemplated as an alternative replacement for heparin in ECMO
therapy. The compounds of the present invention are contemplated as effective agents for blocking the intrinsic pathway at plasma levels that will afford effective anti-coagulation/anti-thrombosis without marked bleeding liabilities. In some embodiments, the subject is sensitive to or has developed sensitivity to heparin. In some embodiments, the subject is resistant to or has developed resistance to heparin.
Ischemia [0230] "Ischemia" or an "ischemic event" is a vascular disease generally involving vascular occlusion or a restriction in blood supply to tissues. Ischemia can cause a shortage of oxygen and glucose needed for cellular metabolism. Ischemia is generally caused by problematic blood vessels that result in damage or dysfunction of tissue. Ischemia can also refer to a local loss in blood or oxygen in a given part of the body resulting from congestion (e.g., .. vasoconstriction, thrombosis, or embolism). Causes include embolism, thrombosis of an atherosclerosis artery, trauma, venous problems, aneurysm, heart conditions (e.g., myocardial infarction, mitral valve disease, chronic arterial fibrillation, cardiomyopathies, and prosthesis), trauma or traumatic injury (e.g., to an extremity producing partial or total vessel occlusion), thoracic outlet syndrome, atherosclerosis, hypoglycemia, tachycardia, hypotension, outside compression of a blood vessel (e.g., by a tumor), sickle cell disease, localized extreme cold (e.g., by frostbite), tourniquet application, glutamate receptor stimulation, arteriovenous malformations, rupture of significant blood vessels supplying a tissue or organ, and anemia.
[0231] A transient ischemic event generally refers to a transient (e.g., short-lived) episode of neurologic dysfunction caused by loss of blood flow (e.g., in the focal brain, spinal cord, or retinal) without acute infarction (e.g., tissue death). In some embodiments, the transient ischemic event lasts for less than 72 hours, 48 hours, 24 hours, 12 hours, 10 hours, 8 hours, 4 hours, 2 hours, 1 hour, 45 minutes, 30 minutes, 20 minutes, 15 minutes, 10 minutes, 5 minutes, 4 minutes, 3 minutes, 2 minutes, or 1 minute.
Angioedema [0232] Angioedema is the rapid swelling of the dermis, subcutaneous tissue, mucosa, and submucosal tissues. Angioedema is typically classified as either hereditary or acquired.
[0233] "Acquired angioedema" can be immunologic, non-immunologic, or idiopathic;
caused by e.g., allergy, as a side effect of medications, e.g., ACE inhibitor medications.
[0234] "Hereditary angioedema" or "HAE" refers to a genetic disorder that results in acute periods of edema (e.g., swelling) that may occur in nearly all parts of the body, including the face, limbs, neck, throat, larynx, extremities, gastrointestinal tract, and genitalia. Attacks of HAE can often be life-threatening, with severity depending on the area affected, e.g., abdominal attacks may result in intestinal obstruction, while swelling of the larynx and upper airway can lead to asphyxiation. Pathogenesis of hereditary angioedema may be related to unopposed activation of the contact pathway by the initial generation of kallikrein or clotting factors (e.g., Factor XII).
[0235] Signs and symptoms include swelling, e.g., of the skill of the face, mucosa of the mouth or throat, and tongue. Itchiness, pain, decreased sensation in the affected areas, urticaria (i.e., hives), or stridor of the airway may also be a sign of angioedema. However, there can be no associated itch, or urticaria, e.g., in hereditary angioedema.
HAE subjects can experience abdominal pain (e.g., abdominal pain lasting one to five days, abdominal attacks increasing a subject's white blood cell count), vomiting, weakness, watery diarrhea, or rash.
[0236] Bradykinin plays an important role in angioedema, particularly hereditary angioedema. Bradykinin is released by various cell types in response to numerous different stimuli and is a pain mediator. Interfering with bradykinin production or degradation can lead to angioedema. In hereditary angioedema, continuous production of enzyme kallikrein can facilitate bradykinin formation. Inhibition of kallikrein can interfere with bradykinin production; and treat or prevent angioedema.
[0237] The methods described herein may comprise administering to a subject in need thereof an effective amount of a pharmaceutical composition described herein.
[0238] In an aspect, the methods described herein can include those in which a subject's blood is in contact with an artificial surface. For example, provided herein is a method of treating a thromboembolic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition described herein, wherein the blood of the subject is contacted with an artificial surface.
[0239] In another aspect, provided herein is a method of reducing the risk of a thromboembolic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition described herein, wherein the blood of the subject is contacted with an artificial surface.
[0240] Also provided herein is a method of prophylaxis of a thromboembolic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition described herein, wherein the blood of the subject is contacted with an artificial surface.
[0241] In some embodiments of the methods described herein, the artificial surface is in contact with blood in the subject's circulatory system.
[0242] In some embodiments, the artificial surface is an implantable device, a dialysis catheter, a cardiopulmonary bypass circuit, an artificial heart valve, a ventricular assist device, a small caliber graft, a central venous catheter, or an extracorporeal membrane oxygenation (ECMO) apparatus.
[0243] In some embodiments, the artificial surface causes or is associated with the thromboembolic disorder.
[0244] In some embodiments, the thromboembolic disorder is a venous thromboembolism, deep vein thrombosis, or pulmonary embolism.
[0245] In some embodiments, the thromboembolic disorder is a blood clot.
[0246] In some embodiments, the methods described herein further comprises conditioning the artificial surface with a separate dose of a pharmaceutical composition described herein prior to contacting the artificial surface with blood in the circulatory system of the subject.
[0247] In some embodiments, the methods described herein further comprises conditioning the artificial surface with a separate dose of a pharmaceutical composition described herein prior to or during administration of the pharmaceutical composition to the subject.
[0248] In some embodiments, the methods described herein further comprises conditioning the artificial surface with a separate dose of a pharmaceutical composition described herein prior to and during administration of the pharmaceutical composition to the subject.
[0249] In some embodiments of the methods described herein, the artificial surface is a cardiopulmonary bypass circuit.
[0250] In some embodiments of the methods described herein, the artificial surface is an extracorporeal membrane oxygenation (ECMO) apparatus. In some embodiments, the ECMO
apparatus is venovenous ECMO apparatus or venoarterial ECMO apparatus.
[0251] In another aspect, disclosed herein is a method of preventing or reducing a risk of a thromboembolic disorder in a subject during or after a medical procedure, comprising:
(i) administering to the subject an effective amount of a pharmaceutical composition described herein, before, during, or after the medical procedure; and (ii) contacting blood of the subject with an artificial surface;
thereby preventing or reducing the risk of the thromboembolic disorder during or after the medical procedure.
[0252] In some embodiments, the artificial surface is conditioned with a pharmaceutical composition described herein prior to administration of the pharmaceutical composition to the subject prior to, during, or after the medical procedure.
[0253] In some embodiments, the pharmaceutical composition for conditioning the artificial surface further comprises a solution, wherein the solution is selected from the group consisting of a saline solution, Ringer's solution, and blood.
[0254] In some embodiments, the thromboembolic disorder is a blood clot.
[0255] In some embodiments, the medical procedure comprises one or more of i) a cardiopulmonary bypass, ii) oxygenation and pumping of blood via extracorporeal membrane oxygenation, iii) assisted pumping of blood (internal or external), iv) dialysis of blood, v) extracorporeal filtration of blood, vi) collection of blood from the subject in a repository for later use in an animal or a human subject, vii) use of venous or arterial intraluminal catheter(s), viii) use of device(s) for diagnostic or interventional cardiac catherisation, ix) use of intravascular device(s), x) use of artificial heart valve(s), and xi) use of artificial graft(s).
[0256] In some embodiments, the medical procedure comprises a cardiopulmonary bypass.
[0257] In some embodiments, the medical procedure comprises an oxygenation and pumping of blood via extracorporeal membrane oxygenation (ECMO). In some embodiments, the ECMO is venovenous ECMO or venoarterial ECMO.
[0258] In some embodiments of the methods described herein, the subject is in contact with the artificial surface for at least 1 day (e.g., about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 2 months, about 3 months, about 6 months, about 9 months, about 1 year).
[0259] In another aspect, provided herein is a method of treating the blood of a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition described herein.
[0260] In some embodiments of the methods described herein, the pharmaceutical composition is administered to the subject intravenously. In other embodiments of the methods described herein, the pharmaceutical composition is administered to the subject subcutaneously. In some embodiments, the pharmaceutical composition is administered to the subject as a continuous intravenous infusion. In some embodiments, the pharmaceutical composition is administered to the subject as a bolus.
[0261] In some embodiments, the subject is a human. In some embodiments, the subject has an elevated risk of a thromboembolic disorder. In some embodiments, the thromboembolic disorder is a result of a complication in surgery. In some embodiments, the subject is sensitive to or has developed sensitivity to heparin. In some embodiments, the subject is resistant to or has developed resistance to heparin.
Pharmaceutical Compositions [0262] The compositions described herein include the compound described herein (e.g., Compound 1 or a pharmaceutically acceptable salt thereof) as well as additional therapeutic agents, if present, in amounts effective for achieving the treatment of a disease or disease symptoms (e.g., such as a disease associated with Factor XIa or kallikrein).
[0263] Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions provided herewith include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-a-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as a-, (3-, and y-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-P-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.
[0264] The pharmaceutical compositions may be in the form of a solid composition (e.g., lyophilized composition) that can be reconstituted by addition of a compatible reconstitution diluent prior to parenteral administration or in the form of a frozen composition adapted to be thaws and, if desired, diluted with a compatible diluent prior to parenteral administration. In some embodiments, the pharmaceutical composition includes particles or a powder (e.g., lyophilized composition) dissolved in an aqueous medium, (e.g., a saline solution, dextrose solution) in a unit dosage IV bag or bottle at a concentration suitable for intravenous administration to a subject. In some embodiments, ingredients of a pharmaceutical composition suitable for intravenous administration are separated from each other in a single container, e.g., a powder comprising a compound described herein or a pharmaceutically acceptable salt thereof, is separated from an aqueous medium such as a saline solution. In this latter example, the various components are separated by a seal that can be broken to contact the ingredients with each other to form the pharmaceutical composition suitable for intravenous administration.
[0265] In an aspect, provided herein is an aqueous pharmaceutical composition comprising a compound of Formula (I-A) 0 (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and an excipient.
[0266] In some embodiments, the pharmaceutical composition comprises the compound of Formula (I-A), the cyclodextrin, and the excipient. In some embodiments, the cyclodextrin is selected from the group consisting of alkyl cyclodextrin, hydroxyalkyl cyclodextrin, carboxyalkyl cyclodextrin, and sulfoalkyl ether cyclodextrin. In some embodiments, the cyclodextrin is hydroxypropyl 3-cyclodextrin. In some embodiments, the cyclodextrin is sulfobutyl ether 3-cyclodextrin.
[0267] In some embodiments, the excipient is a sugar (e.g., a saccharide (e.g., monosaccharide, disaccharide, or polysaccharide)) or a sugar alcohol. For example, the excipient is sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, or mannitol, or a combination thereof In some embodiments, the excipient is mannitol. In some embodiments, the excipient is lactose.
[0268] In some embodiments, the pharmaceutical composition described herein further comprises a buffer. In some embodiments, the buffer is a monoprotic acid or a polyprotic acid or a combination thereof In some embodiments, the buffer is a solution of one or more substances. In some embodiments, the buffer is a solution of a salt of a weak acid and a weak base. In some embodiments, the buffer is a solution of a salt of the weak acid with a strong base. In some embodiments, the buffer is selected from the group consisting of a maleate buffer, a citrate buffer, and a phosphate buffer. In some embodiments, the buffer is a phosphate buffer. In some embodiments, the phosphate buffer is a solution of monosodium phosphate, disodium phosphate, trisodium phosphate, or a combination thereof [0269] In some embodiments, the pharmaceutical composition further comprises a solubilizing agent. In some embodiments, the solubilizing agent is a polyoxyethylene sorbitan ester (e.g, TWEENO 20) or a polyethylene glycol (e.g., PEG400).
[0270] In some embodiments, the solubilizing agent is in an amount of from about 0.01%
to about 1%, about 0.01% to about 0.9%, about 0.01% to about 0.8%, about 0.01%
to about 0.7%, about 0.01% to about 0.6, about 0.01% to about 0.5%, about 0.01% to about 0.4%, about 0.01% to about 0.3%, about 0.01% to about 0.2%, about 0.01% to about 0.1%, or about 0.01% to about 0.05% by weight relative to weight of the compound of Formula (I-A).
[0271] In some embodiments, the pH of the composition is from about 2 to about 8 (e.g., from about 3 to about 7, from about 4 to about 7, from about 5 to about 6, from about 6 to about 7, from about 6 to about 8, from about 5 to about 8, from about 4 to about 8, or from about 3 to about 8). In some embodiments, the pH is from about 6 to about 8.
In some embodiments, the pH is about 6 to about 7. In some embodiments, the pH is about 7. In some embodiments, the pH is about 6.8.
[0272] In some embodiments, the concentration of the compound of Formula (I-A) is from about 0.1 mg/mL to about 100 mg/mL, about 0.1 mg/mL to about 80 mg/mL, about 0.1 mg/mL to about 60 mg/mL, about 0.1 mg/mL to about 40 mg/mL, about 0.1 mg/mL to about 20 mg/mL, about 0.1 mg/mL to about 10 mg/mL, about 1 mg/mL to about 100 mg/mL, about 1 mg/mL to about 80 mg/mL, about 1 mg/mL to about 60 mg/mL, about 1 mg/mL to about mg/mL, about 1 mg/mL to about 20 mg/mL, about 1 mg/mL to about 10 mg/mL, about mg/mL to about 100 mg/mL, about 10 mg/mL to about 80 mg/mL, about 10 mg/mL to about 60 mg/mL, about 10 mg/mL to about 40 mg/mL, about 20 mg/mL to about 100 mg/mL, about 20 mg/mL to about 80 mg/mL, about 20 mg/mL to about 60 mg/mL, about 40 mg/mL
to about 100 mg/mL, about 40 mg/mL to about 80 mg/mL, about 60 mg/mL to about mg/mL, about 60 mg/mL to about 80 mg/mL, or about 80 mg/mL to about 100 mg/mL.
[0273] In some embodiments, the concentration of the compound of Formula (I-A) is about 0.1 mg/mL, about 1 mg/mL, about 2.5 mg/mL, about 5 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35 mg/mL, about mg/mL, about 45 mg/mL, or about 50 mg/mL. In some embodiments, the concentration of the compound of Formula (I-A) is about 10 mg/mL. In some embodiments, the concentration of the compound of Formula (I-A) is about 3 mg/mL. In some embodiments, the concentration of the compound of Formula (I-A) is about 1 mg/mL.
[0274] In some embodiments, the concentration of the buffer is from about 1 mM
to about 500 mM, about 1 mM to about 250 mM, about 1 mM to about 100 mM, about 1 mM to about 50 mM, about 1 mM to about 20 mM, about 1 mM to about 10 mM, 10 mM to about mM, about 10 mM to about 250 mM, about 10 mM to about 100 mM, about 10 mM to about 50 mM, about 10 mM to about 20 mM, about 20 mM to about 500 mM, about 20 mM to about 250 mM, about 20 mM to about 100 mM, about 20 mM to about 50 mM, about 50 mM
to about 500 mM, about 50 mM to about 250 mM, about 50 mM to about 100 mM, about 100 mM to about 500 mM, or about 100 mM to about 250 mM.
[0275] In some embodiments, the concentration of the buffer is about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 40 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 210 mM, about 220 mM, about mM, about 240 mM, about 250 mM, about 300 mM, about 350 mM, about 400 mM, about 450 mM, or about 500 mM. In some embodiments, the concentration of the buffer is about 10 mM.
[0276] In some embodiments, the buffer is a phosphate buffer.
[0277] In some embodiments, the concentration of the phosphate buffer is from about 1 mM to about 500 mM, about 1 mM to about 250 mM, about 1 mM to about 100 mM, about 1 mM to about 50 mM, about 1 mM to about 20 mM, about 1 mM to about 10 mM, 10 mM
to about 500 mM, about 10 mM to about 250 mM, about 10 mM to about 100 mM, about mM to about 50 mM, about 10 mM to about 20 mM, about 20 mM to about 500 mM, about 20 mM to about 250 mM, about 20 mM to about 100 mM, about 20 mM to about 50 mM, about 50 mM to about 500 mM, about 50 mM to about 250 mM, about 50 mM to about mM, about 100 mM to about 500 mM, or about 100 mM to about 250 mM.
[0278] In some embodiments, the concentration of the phosphate buffer is about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 40 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM, about mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 210 mM, about 220 mM, about 230 mM, about 240 mM, about 250 mM, about 300 mM, about 350 mM, about mM, about 450 mM, or about 500 mM. In some embodiments, the concentration of the phosphate buffer is about 10 mM.
[0279] In some embodiments, the cyclodextrin is in an amount of from about 0.1% to about 10%, about 0.1% to about 7.5%, about 0.1% to about 5%, about 0.1% to about 3.5%, about 0.1% to about 1%, about 1% to about 10%, about 1% to about 7.5%, about 1% to about 5%, about 3% to about 10%, about 3% to about 7.5%, or about 3% to about 5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of about 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5% or 5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of from about 0.1% to about 10% (e.g., about 0.5% to about 6% (e.g., about 0.7% to about 5.6% (e.g., about 2.1 % to about 5%))) by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of about 3.5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of about 5% by weight relative to weight of the compound of Formula (I-A).
[0280] In some embodiments, the cyclodextrin is hydroxypropyl 0-cyclodextrin.
[0281] In some embodiments, the excipient is in an amount of from about 0.1%
to about 10%, about 0.1% to about 7.5%, about 0.1% to about 5%, about 0.1% to about 3.5%, about 0.1% to about 1%, about 1% to about 30%, about 1% to about 20%, about 1% to about 10%, about 1% to about 7.5%, about 1% to about 5%, about 3% to about 10%, about 3%
to about 7.5%, about 3% to about 5%, about 3% to about 20%, about 3% to about 30%, about 5% to about 20%, or about 5% to about 30% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the excipient is in an amount of about 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 10%, 20%, or 30% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the excipient is in an amount of about 3% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the excipient is an amount of about 5% by weight relative to weight of the compound of Formula (I-A).
[0282] In some embodiments, the excipient agent is mannitol. In some embodiments, the excipient is lactose.
[0283] In another aspect, provided herein is a lyophilized formulation comprising of a composition which prior to lyophilization corresponds to an aqueous pharmaceutical composition described herein (e.g., an aqueous pharmaceutical composition comprising a compound of Formula (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and an excipient). In some embodiments, the lyophilized formulation as described herein is reconstituted in an aqueous medium, thereby preparing an aqueous pharmaceutical solution suitable for parenteral administration to a subject in need thereof [0284] In another aspect, provided herein is a pharmaceutical composition comprising particles, wherein the particles comprise a compound of Formula (I-A) ?"-Oiro ,-NyN
0 (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and a bulking agent.
[0285] In some embodiments, the pharmaceutical composition comprises the compound of Formula (I-A), the cyclodextrin, and the bulking agent. In some embodiments, the cyclodextrin is selected from the group consisting of alkyl cyclodextrin, hydroxyalkyl cyclodextrin, carboxyalkyl cyclodextrin, and sulfoalkyl ether cyclodextrin. In some embodiments, the cyclodextrin is hydroxypropyl 0-cyclodextrin. In some embodiments, the cyclodextrin is sulfobutyl ether 0-cyclodextrin.
[0286] In some embodiments, the bulking agent is a sugar (e.g., a saccharide (e.g., monosaccharide, disaccharide, or polysaccharide)) or a sugar alcohol. In some embodiments, the bulking agent is sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, or mannitol, or a combination thereof In some embodiments, the bulking agent is mannitol.
In some embodiments, the bulking agent is lactose.
[0287] In some embodiments, the bulking agent is a lyoprotectant.
[0288] In some embodiments, the concentration of the compound of Formula (I-A) is from about 0.1% to about 10%, about 0.1% to about 7.5%, about 0.1% to about 5%, about 0.1% to about 3.5%, about 0.1% to about 1%, about 1% to about 10%, about 1% to about 7.5%, about 1% to about 5%, about 3% to about 10%, about 3% to about 7.5%, or about 3% to about 5%
by weight of the composition. In some embodiments, the concentration of the compound of Formula (I-A) is about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% by weight of the composition. In some embodiments, the concentration of the compound of Formula (I-A) is about 1% by weight of the composition. In some embodiments, the concentration of the compound of Formula (I-A) is about 0.3% by weight of the composition.
[0289] In some embodiments, the cyclodextrin is in an amount of from about 0.1% to about 10%, about 0.1% to about 7.5%, about 0.1% to about 5%, about 0.1% to about 3.5%, about 0.1% to about 1%, about 1% to about 10%, about 1% to about 7.5%, about 1% to about 5%, about 3% to about 10%, about 3% to about 7.5%, or about 3% to about 5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of about 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5% or 5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of from about 0.1% to about 10% (e.g., about 0.5% to about 6% (e.g., about 0.7% to about 5.6% (e.g., about 2.1 % to about 5%))) by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of about 3.5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of about 5% by weight relative to weight of the compound of Formula (I-A).
[0290] In some embodiments, the cyclodextrin is hydroxypropyl 0-cyclodextrin.
[0291] In some embodiments, the excipient is in an amount of from about 0.1%
to about 10%, about 0.1% to about 7.5%, about 0.1% to about 5%, about 0.1% to about 3.5%, about 0.1% to about 1%, about 1% to about 30%, about 1% to about 20%, about 1% to about 10%, about 1% to about 7.5%, about 1% to about 5%, about 3% to about 10%, about 3%
to about 7.5%, about 3% to about 5%, about 3% to about 20%, about 3% to about 30%, about 5% to about 20%, or about 5% to about 30% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the excipient is in an amount of about 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 10%, 20%, or 30% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the excipient is in an amount of about 3% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the excipient is an amount of about 5% by weight relative to weight of the compound of Formula (I-A).
[0292] In some embodiments, the excipient agent is mannitol. In some embodiments, the excipient is lactose.
[0293] In another aspect, provided herein is a process for preparing an aqueous pharmaceutical composition from the pharmaceutical composition described herein (e.g., a pharmaceutical composition comprising particles, wherein the particles comprise a compound of Formula (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and a bulking agent), the process comprising reconstituting the pharmaceutical composition into an aqueous medium, thereby forming the aqueous composition. In some embodiments, the aqueous medium is deionized water. In some embodiments, the aqueous medium comprises sodium chloride. In some embodiments, the aqueous medium comprises about 5% dextrose.
[0294] In some embodiments, the composition is prepared to be suitable for parenteral administration to a subject in need thereof In some embodiments, the composition is prepared to be suitable for intramuscular, subcutaneous or intravenous administration to a subject in need thereof [0295] In some embodiments, the pH of the reconstituted composition is from about 2 to about 8 (e.g., from about 3 to about 7, from about 4 to about 7, from about 5 to about 6, from about 6 to about 7, from about 6 to about 8, from about 5 to about 8, from about 4 to about 8, or from about 3 to about 8). In some embodiments, the pH of the reconstituted composition is from about 6 to about 8. In some embodiments, the pH of the reconstituted composition is about 6 to about 7. In some embodiments, the pH of the reconstituted composition is about 7.
In some embodiments, the pH of the reconstituted composition is about 6.8.
[0296] In some embodiments, the concentration of the compound of Formula (I-A) in the reconstituted composition is from about 0.01 mg/mL to about 100 mg/mL, about 0.01 mg/mL
to about 50 mg/mL, about 0.01 mg/mL to about 10 mg/mL, about 0.01 mg/mL to about 1 mg/mL, about 0.01 mg/mL to about 0.1 mg/mL, about 0.1 mg/mL to about 100 mg/mL, about 0.1 mg/mL to about 80 mg/mL, about 0.1 mg/mL to about 60 mg/mL, about 0.1 mg/mL to about 40 mg/mL, about 0.1 mg/mL to about 20 mg/mL, about 0.1 mg/mL to about 10 mg/mL, about 1 mg/mL to about 100 mg/mL, about 1 mg/mL to about 80 mg/mL, about 1 mg/mL to about 60 mg/mL, about 1 mg/mL to about 40 mg/mL, about 1 mg/mL to about 20 mg/mL, about 1 mg/mL to about 10 mg/mL, about 10 mg/mL to about 100 mg/mL, about 10 mg/mL to about 80 mg/mL, about 10 mg/mL to about 60 mg/mL, about 10 mg/mL to about mg/mL, about 20 mg/mL to about 100 mg/mL, about 20 mg/mL to about 80 mg/mL, about 20 mg/mL to about 60 mg/mL, about 40 mg/mL to about 100 mg/mL, about 40 mg/mL
to about 80 mg/mL, about 60 mg/mL to about 100 mg/mL, about 60 mg/mL to about mg/mL, or about 80 mg/mL to about 100 mg/mL.
[0297] In some embodiments, the concentration of the compound of Formula (I-A) in the reconstituted formulation is about 0.01 mg/mL, 0.03 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.3 mg/mL, 0.5 mg/mL, about 1 mg/mL, about 2.5 mg/mL, about 5 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35 mg/mL, about 40 mg/mL, about 45 mg/mL, or about 50 mg/mL. In some embodiments, the concentration of the compound of Formula (I-A) is about 10 mg/mL. In some embodiments, the concentration of the compound of Formula (I-A) is about 1 mg/mL. In some embodiments, the concentration of the compound of Formula (I-A) is about 0.1 mg/mL. In some embodiments, the concentration of the compound of Formula (I-A) is about 0.3 mg/mL.
In some embodiments, the concentration of the compound of Formula (I-A) is about 0.03 mg/mL.
Routes of Administration [0298] The pharmaceutical compositions provided herewith may be administered orally, rectally, or parenterally (e.g., intravenous infusion, intravenous bolus injection, inhalation, implantation). The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous (e.g., intravenous infusion, intravenous bolus injection), intranasal, inhalation, pulmonary, transdermal, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or other infusion techniques. The pharmaceutical compositions provided herewith may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
[0299] The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous solution or suspension.
This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides.
Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation. In some embodiments, the intravenous pharmaceutical composition comprises a carrier selected from the group consisting of 5% w/w dextrose water ("5DW") and saline.
[0300] The pharmaceutical compositions provided herewith may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying or suspending agents. If desired, certain sweetening or flavoring or coloring or taste masking agents may be added.
[0301] The compounds described herein can, for example, be administered by injection, intravenously (e.g., intravenous infusion, intravenous bolus injection), intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically with a dosage ranging from about 0.5 to about 100 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug. The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions provided herewith will be administered from about 1 to about 6 times per day (e.g., by intravenous bolus injection) or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations contain from about 20% to about 80% active compound.
[0302] In some embodiments, the compound or pharmaceutical composition is administered to the subject intravenously. In some embodiments, the compound or pharmaceutical composition is administered to the subject subcutaneously. In some embodiments, the compound or pharmaceutical composition is administered to the subject as a continuous intravenous infusion. In some embodiments, the compound or pharmaceutical composition is administered to the subject as a bolus. In some embodiments, the compound or pharmaceutical composition is administered to the subject as a bolus followed by a continuous intravenous infusion.
[0303] In some embodiments, a pharmaceutical composition formulated for subcutaneous administration or intravenous administration is administered to a subject from 1 time per day to 6 times per day (e.g., 1 time per day, 2 times per day, or 4 times per day).
Combinations [0304] In carrying out the methods of the present invention, it may be desired to administer the compounds of the invention (e.g., Factor XIa or kallikrein inhibitors) in combination with each other and one or more other agents for achieving a therapeutic benefit such as antithrombotic or anticoagulant agents, anti-hypertensive agents, anti-ischemic agents, anti-arrhythmic agents, platelet function inhibitors, and so forth. For example, the methods of the present invention may be carried out by administering the small molecule Factor XIa or kallikrein inhibitors in combination with a small molecule Factor XIa or kallikrein inhibitor.
More particularly, the inventive methods may be carried out by administering the small molecule Factor XIa or kallikrein inhibitors in combination with aspirin, clopidogrel, ticlopidine or CS-747, warfarin, low molecular weight heparins (such as LOVENOX), GPIIb/GPIIIa blockers, PAI-1 inhibitors such as XR-330 and T-686, P2Y1 and receptor antagonists; thromboxane receptor antagonists (such as ifetroban), prostacyclin mimetics, thromboxane A synthetase inhibitors (such as picotamide), serotonin-2-receptor antagonists (such as ketanserin); compounds that inhibit other coagulation factors such as FVII, FVIII, FIX, FX, prothrombin, TAFI, and fibrinogen, or other compounds that inhibit FXI or kallikrein; fibrinolytics such as TPA, streptokinase, PAI-1 inhibitors, and inhibitors of Eli -2-antiplasmin such as anti-0 -2-antiplasmin antibody fibrinogen receptor antagonists, inhibitors of -1-antitrypsin, hypolipidemic agents, such as HMG-CoA reductase inhibitors (e.g., pravastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, AZ4522, and itavastatin), and microsomal triglyceride transport protein inhibitors (such as disclosed in U.S. Pat. Nos.
5,739,135, 5,712,279 and 5,760,246); antihypertensive agents such as angiotensin-converting enzyme inhibitors (e.g., captopril, lisinopril or fosinopril); angiotensin-II
receptor antagonists (e.g., irbesartan, losartan or valsartan); ACE/NEP inhibitors (e.g., omapatrilat and gemopatrilat); or 0-blockers (such as propranolol, nadolol and carvedilol).
The inventive methods may be carried out by administering the small molecule Factor XIa or kallikrein inhibitors in combination with anti-arrhythmic agents such as for atrial fibrillation, for example, amiodarone or dofetilide. The inventive methods may also be carried out in combination continuous renal replacement therapy for treating, e.g., acute kidney injury.
[0305] In carrying out the methods of the present invention, it may be desired to administer the compounds of the invention (Factor XIa or kallikrein inhibitors) in combination with agents that increase the levels of cAMP or cGMP in cells for a therapeutic benefit. For example, the compounds of the invention may have advantageous effects when used in combination with phosphodiesterase inhibitors, including PDE1 inhibitors (such as those described in Journal of Medicinal Chemistry, Vol. 40, pp. 2196-2210 [19971), inhibitors, PDE3 inhibitors (such as revizinone, pimobendan, or olprinone), PDE4 inhibitors (such as rolipram, cilomilast, or piclamilast), PDE7 inhibitors, or other PDE
inhibitors such as dipyridamole, cilostazol, sildenafil, denbutyline, theophylline (1,2-dimethylxanthine), ARIFLOT.TM. (i.e., cis-4-cyano-4-[3-(cyclopentylox-y)-4-methoxyphenyl1cyclohexane-1-carboxyl- ic acid), arofyline, roflumilast, C-11294A, CDC-801, BAY-19-8004, cipamfylline, SCH351591, YM-976, PD-189659, mesiopram, pumafentrine, CDC-998, IC-485, and KW-4490.
[0306] The inventive methods may be carried out by administering the compounds of the invention in combination with prothrombolytic agents, such as tissue plasminogen activator (natural or recombinant), streptokinase, reteplase, activase, lanoteplase, urokinase, prourokinase, anisolated streptokinase plasminogen activator complex (ASPAC), animal salivary gland plasminogen activators, and the like.
[0307] The inventive methods may be carried out by administering the compounds of the invention in combination with 0-adrenergic agonists such as albuterol, terbutaline, formoterol, salmeterol, bitolterol, pilbuterol, or fenoterol; anticholinergics such as ipratropium bromide; anti-inflammatory cortiocosteroids such as beclomethasone, triamcinolone, budesonide, fluticasone, flunisolide or dexamethasone; and anti-inflammatory agents such as cromolyn, nedocromil, theophylline, zileuton, zafirlukast, monteleukast and pranleukast.
.. [0308] Small molecule Factor XIa or kallikrein inhibitors may act synergistically with one or more of the above agents. Thus, reduced doses of thrombolytic agent(s) may be used, therefore obtaining the benefits of administering these compounds while minimizing potential hemorrhagic and other side effects.
Course of Treatment [0309] The compositions described herein include an effective amount of a compound of the invention (e.g., a Factor XIa or kallikrein inhibitor) optionally in combination with one or more other agents (e.g., an additional therapeutic agent) such as antithrombotic or anticoagulant agents, anti-hypertensive agents, anti-ischemic agents, anti-arrhythmic agents, .. platelet function inhibitors, and so forth for achieving a therapeutic benefit.
[0310] In some embodiments, the additional therapeutic agent is administered following administration of the composition of the invention. In some embodiments, the additional therapeutic agent is administered 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 18 hours, 24 hours, 48 hours, 72 hours or longer after administration of the composition of the invention. In some embodiments, the additional therapeutic agent is administered (e.g., orally) after discharge from a medical facility (e.g., a hospital).
[0311] In some embodiments, the compound of the invention (e.g., a Factor XIa or kallikrein inhibitor) and the additional therapeutic agent are co-formulated into a single composition or dosage. In some embodiments, the compound of the invention (e.g., a Factor XIa or kallikrein inhibitor) and the additional therapeutic agent are administered separately.
In some embodiments, the compound of the invention (e.g., a Factor XIa or kallikrein inhibitor) and the additional therapeutic agent are administered sequentially.
In some embodiments, the compound of the invention (e.g., a Factor XIa or kallikrein inhibitor) and the additional therapeutic agent are administered separately and sequentially.
In general, at least one of the compound of the invention (e.g., a Factor XIa or kallikrein inhibitor) and the additional therapeutic agent is administered parenterally (e.g., intranasally, intramuscularly buccally, inhalation, implantation, transdermal, intravenously (e.g., intravenous infusion, intravenous bolus injection), subcutaneous, intracutaneous, intranasal, pulmonary, transdermal, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or other infusion techniques); orally; or rectally, for example, intramuscular injection or intravenously (e.g., intravenous infusion, intravenous bolus injection)). In some embodiments, compound of the invention is administered parenterally (e.g., intranasally, buccally, intravenously (e.g., intravenous infusion, intravenous bolus injection) or intramuscularly). In some embodiments, the additional therapeutic agent is administered orally. In some embodiments, the compound of the invention (e.g., a Factor XIa or kallikrein inhibitor) is administered parenterally (e.g., intranasally, buccally, intravenously (e.g., intravenous infusion, intravenous bolus injection) or intramuscularly) and the additional therapeutic agent is administered orally.
[0312] In some embodiments, the composition of the invention may be administered once or several times a day. A duration of treatment may follow, for example, once per day for a period of about 1, 2, 3, 4, 5, 6, 7 days or more. In some embodiments, the treatment is chronic (e.g., for a lifetime). In some embodiments, either a single dose in the form of an individual dosage unit or several smaller dosage units or by multiple administrations of subdivided dosages at certain intervals is administered. For instance, a dosage unit can be administered from about 0 hours to about 1 hr, about 1 hr to about 24 hr, about 1 to about 72 hours, about 1 to about 120 hours, or about 24 hours to at least about 120 hours post injury.
Alternatively, the dosage unit can be administered from about 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 30, 40, 48, 72, 96, 120 hours or longer post injury. Subsequent dosage units can be administered any time following the initial administration such that a therapeutic effect is achieved. In some embodiments, the initial dose is administered orally. In some embodiments, doses subsequent to the initial dose are administered parenterally (e.g., intranasally, intramuscularly buccally, inhalation, implantation, transdermal, intravenously (e.g., intravenous infusion, intravenous bolus injection), subcutaneous, intracutaneous, intranasal, pulmonary, transdermal, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or other infusion techniques); orally; or rectally.
[0313] In some embodiments, composition of the invention is administered orally, e.g., as an liquid or solid dosage form for ingestion, for about 5 minutes to about 1 week; about 30 minutes to about 24 hours, about 1 hour to about 12 hours, about 2 hours to about 12 hours, about 4 hours to about 12 hours, about 6 hours to about 12 hours, about 6 hours to about 10 hours; about 5 minutes to about 1 hour, about 5 minutes to about 30 minutes;
about 12 hours to about 1 week, about 24 hours to about 1 week, about 2 days to about 5 days, or about 3 days to about 5 days. In one embodiment, the composition is administered orally as a liquid dosage form. In another embodiment, the composition is administered orally as a solid dosage form.
[0314] Where a subject undergoing therapy exhibits a partial response, or a relapse following completion of the first cycle of the therapy, subsequent courses of therapy may be needed to achieve a partial or complete therapeutic response (e.g., chronic treatment, e.g., for a lifetime).
[0315] In some embodiments, the composition described herein is administered intravenously, e.g., as an intravenous infusion or intravenous bolus injection, for about 5 minutes to about 1 week; about 30 minutes to about 24 hours, about 1 hour to about 12 hours, about 2 hours to about 12 hours, about 4 hours to about 12 hours, about 6 hours to about 12 hours, about 6 hours to about 10 hours; about 5 minutes to about 1 hour, about 5 minutes to about 30 minutes; about 12 hours to about 1 week, about 24 hours to about 1 week, about 2 days to about 5 days, or about 3 days to about 5 days. In one embodiment, the composition described herein is administered as an intravenous infusion for about 5, 10, 15, 30, 45, or 60 minutes or longer; about 1, 2, 4, 6, 8, 10, 12, 16, or 24 hours or longer;
about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days or longer.
Dosages and Dosing Regimens [0316] The effective amount of a composition administered according to the present invention may be determined by one of ordinary skill in the art. The specific dose level and frequency of dosage for any particular subject may vary and will depend upon a variety of factors, including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition.
[0317] Upon improvement of a patient's condition, a maintenance dose of a composition or combination provided herewith may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
EXAMPLES
[0318] In order that the invention described herein may be more fully understood, the following examples are set forth. Starting materials and various intermediates described in the following examples may be obtained from commercial sources, prepared from commercially available organic compounds, or prepared using known synthetic methods. The examples described in this application are offered to illustrate the compounds provided herein and are not to be construed in any way as limiting their scope.
General procedures [0319] All non-aqueous reactions were run under an atmosphere of nitrogen to maintain an anhydrous atmosphere and to maximize yields. All reactions were stirred using an overhead stirring assembly or magnetically, with the aid of a Teflon-coated stir bar.
The description 'drying over' refers to drying of a reaction product solution over a specified drying agent and then filtration of the solution though a suitable filter paper or through a sintered glass funnel.
The descriptions 'was concentrated', 'was concentrated at reduced pressure', or 'evaporated' refers to removal of solvents under reduced pressure using a rotary evaporator.
Chromatography or chromatographed refers to the use of flash column chromatography on silica gel unless otherwise specified. Flash chromatography refers to column chromatography under gas pressure (for example, nitrogen) or a mechanical pump to apply solvent pressure such as with a commercial system as supplied by Biotage or other vendors.
Unless otherwise specified, proton NMR spectra (1H) are measured at 400 MHz and carbon NMR spectra (13C) are measured at 100 MHz in the specified solvent.
[0320] Abbreviations used in the experimental examples are listed in the Abbreviations Table below.
Abbreviation Table MeCN or ACN Acetonitrile EDC 1,2-Dichloroethane DCM Dichloromethane DMAP 4-Dimethylaminopyridine EA Ethyl acetate Ether Diethyl ether hr or h Hours HPLC High-performance liquid chromatography IPA Isopropyl alcohol min Minutes TBME Methyl tert-butyl ether TEA Triethylamine NMR Nuclear magnetic resonance instrument RT Room temperature TFA Trifluoroacetic acid THF Tetrahydrofuran TPP Target product profile Concentrated or Concentration of organic solutions under reduced pressure and concentrated in vacuo generally with the use of a rotary evaporator PMB p-Methoxybenzyl Boc or BOC Tert-butyloxycarbonyl Example 1. Exemplary Synthesis of Compound 1.11C1 [0321] A non-limiting example of the synthesis of (2S,3R)-3-[(2-aminopyridin-4-yOmethy11-1-1[(1R)-1-cyclohexylethyll carbamoyl} -4-oxoazetidine-2-carboxylic acid trifluoroacetate (structure 2 below), tert-buty1(4-bromomethyppyridin-2-y11(4-methoxybenzyl)carbamate (structure 3 below), and (R)-(1-isocyanatoethyl)cyclohexane (structure 8 below) can be found in U.S. Patent No. 9,499,532, which is incorporated herein by reference.
A. Synthesis of Compound 1.11C1 from 2 OH OH
Elra TFA 0 HCI; MeCN; Et20 N N IRly0 N y I y 2 Compound 'MCI
[0322] Acetonitrile (12 mL; 10 vol) was added to (2S,3R)-3-[(2-aminopyridin-4-yOmethy11-1-1[(1R)-1-cyclohexylethylicarbamoy11-4-oxoazetidine-2-carboxylic acid trifluoroacetate (1.23 g; 2.52 mmol) to produce a hazy solution. This mixture was extracted twice with hexane (12 mL); then it was filtered (5 micron) to afford a clear solution. This solution was concentrated to 6 mL (5 volumes) at which point a suspension began to form.
Concentrated HC1 (0.42 mL; 2 equiv) was added. Then ether (2 x 12 mL) was added in two portions to induce formation of a precipitate. The mixture was cooled to ¨1 C
for 15 min.
The solids were collected, rinsed with cold ether and air dried to give (2S,3R)-3-[(2-aminopyridin-4-yOmethy11-1-1[(1 R) - 1-cyclohexylethylicarbamoy11-4-oxoazetidine-2-carboxylic acid hydrochloride 0.82 g (79%) as a white solid.
[0323] A highly purified sample was prepared by slurrying the solid in ether (7.5 volumes).
The product was collected, rinsed with ether and dried at 50 C in vacuo overnight.
[0324] 11-INMR (400 MHz, CD30D) ppm ö 7.79 (1 H, d, J=6.8 Hz), 6.99 (1 H, s), 6.90 (1 H, dd, J=1.5, 6.8 Hz), 6.61 (1H, d J = 8.8), 4.28 (1H, d, J=2.8) 3.70 (2H, m), 3.23 (2H, m) 1.75 (5H, m) 1.40 (1H, m) 1.25 (3H, m) 1.15 (3H, d, J=6.8 Hz) 1.00 (2H, m).
[0325] HPLC retention time: 3.21 min. HPLC conditions: Column, Zorbax 50 mm;
flow =
1.5 mL/min; 240 nm; temp = at 30 C; Solvent A = 1 mL TFA/lL water; Solvent B
= 2.8 mL
TFA/ 4 L MeCN; Gradient elution sequence: time = 0, A:B = 95:5; linear gradient to 2:98 A:B over 6 min; linear gradient back to A:B = 95:5 from 1 min.
B. Synthesis of Compound 1.1-1C1 from 3 Step 1. Preparation of 4: (25,3R)-3-{2-Rtert-butoxycarbonyl)(4-methoxybenzyl) amino]pyridin-4-yl)methyl)-1-(tert-butyl(dimethyl)sily1]-4-oxoazetidine-2-carboxylic acid.
N
NBoc(PMB) Boc(PMB) 0 2.0 M LDA NL
Br -25 C to -5 C ''" OH
¨NTBS
0 )¨NTBS
[0326] A solution of (2S)-1-tert-butyl(dimethyOsily1-4-oxoazetidine-2-carboxylic acid (175 g, 0.763 mol) and THF (2 L) was cooled to -25 C (internal temperature). 2M LDA
solution in THF (800 mL, 2.1 eq.) was added dropwise while maintaining the temperature below -10 C.
The reaction was stirred for 30 min and a gel-like suspension formed. A
solution of tert-buty1(4-bromomethyppyridin-2-y11(4-methoxybenzyl)carbamate (342 g, 0.84 mol, 1.12eq., structure 3) in THF (600 mL) was added dropwise while maintaining the reaction below -5 C
over 2 hr, and then stirred 30 min longer. The reaction was quenched with 1M
aqueous KHSO4 (2 L). The layers were separated and the aqueous layer was extracted with EA (2 L x 2). The combined organic phase was washed with brine (1 L x 2), dried (MgSO4), filtered and concentrated to give (2S,3R)-3-12-[(tert-butoxycarbonyl)(4-methoxybenzypaminolpyridin-4-yOmethyl)-1-(tert-butyl(dimethypsily11-4-oxoazetidine-2-carboxylic acid as an oily product which was used without purification (436 g, ¨70% purity).
Step 2. Preparation of compound 5: 4-Methoxybenzyl(25,3R)-3-(12-1-(tert-butoxy carb onyl)(4-methoxy b enzy Damino] pyri din-4-yllmethyl)-1-Rtert-butyl(dimethyl)sily1]-4-oxoazetidine-2-carboxylate NBoc(PMB) NBoc(PMB) N) 0 EDC, DMAP, DCM N 0 ?LOH __________________________________________________________ 0/
PMBOH
¨NTBS
[0327] The crude (2S,3R)-3-12-Rtert-butoxycarbonyl)(4-methoxybenzypaminolpyridin-4-yOmethyl)-1-(tert-butyl(dimethypsily11-4-oxoazetidine-2-carboxylic acid was dissolved in DCM (2.5 L) and EDC (137 g, 0.714 mol, 1.3 eq.), PMBOH (76.2 g, 0.55 mol, 1 eq. based on 70% purity of the acid reagent) and DMAP (3.4 g, 0.05 eq.). The solution was stirred at overnight at RT. The mixture was extracted with water (500 ml) and brine (500 ml), dried (MgSO4), and concentrated. The crude oily residue was chromatographed (gradient elution with 0% to 50% EA/hexanes) to give 4-methoxybenzyl (25,3R)-3-(12-[(tert-butoxy carb onyl)(4-methoxy b enzy Damino] pyri din-4-yllmethyl)-1-Rtert-butyl(dimethyOsily11-4-oxoazetidine-2-carboxylate as a colorless oil (250 g, 48% yield over two steps).
103281 1H NMR (400 MHz, CDC13) ppm ö 8.24 (1H, d, J=5.5 Hz), 7.55 (1H, s), 7.22 (2H, d, J=8.8 Hz), 7.20 (2H, d, J=8.8 Hz), 6.89 (1H, dd, J=1.4, 5.2 Hz), 6.87 (2H,d, J=8.6 Hz), 6.79 (2H, d, J=8.6 Hz), 5.09 (2H, s), 5.06 (2H, s), 3.81 (3H, s), 3.77 (1H, d, J=3.3 Hz), 3.76 (3H, s), 3.53 (1H, m), 3.06 (1H, dd, J=0.6, 14.6 Hz), 2.99 (1H, dd, J=7.6,14.6 Hz), 1.41 (9H, s), 0.82 (9H, s), 0.19 (3H, s), -0.05 (3H, s).
Step 3. Preparation of compound 6: 4-Methoxybenzyl(25,3R)-3-(12-[(tert-butoxy carb onyl)(4-methoxy b enzyl)amino] pyri din-4-yllmethyl)-4-oxoazeti dine-2-carboxylate NBoc(PMB) 0 NBoc(PMB) o/ NH4F, AcOH
BS _____________________________________________ N) 0 Me0H
0 ,¨NH
[0329] To a solution of 4-methoxybenzyl(2S,3R)-3-(12-[(tert-butoxycarbonyl)(4-methoxybenzypaminolpyridin-4-yllmethyl)-1-[(tert-butyl(dimethypsily11-4-oxoazetidine-2-carboxylate (314 g, 0.465 mol) and methanol (1.5 L) was added first acetic acid (112 g, 1.87 5 mol) and then NH4F (20.6 g, 0.556 mol, pre-dissolved in 1.2 L of methanol). The mixture was stirred 2 hr at RT. The reaction was concentrated. The residue was dissolved in EA (2 L) and saturated aqueous NaHCO3 (2 L) was added. The phases were separated and the organic phase was dried (MgSO4), and concentrated. The oily residue was chromatographed (gradient elution with 0% to 40% EA/hexanes) to give a clear oil which was crystallized from EA/hexanes (1:5) to give 4-methoxybenzyl(2S,3R)-3-(12-Rtert-butoxycarbonyl)(4-methoxybenzypaminolpyridin-4-yllmethyl)-4-oxoazetidine-2-carboxylate as a white solid (200 g, 77% yield).
[0330] 1H NMR (400 MHz, CDC13) ppm ö 8.26 (1H, d, J=5.0 Hz), 7.55 (1H, s), 7.21 (2H, d, J=8.6 Hz), 7.19 (2H, d, J=8.6 Hz), 6.91 (1H, dd, J=1.5, 5.0 Hz), 6.88 (2H, d, J=8.8 Hz), 6.79 (2H, d, J=8.8 Hz), 5.92 (1H, s), 5.10 (2H, s), 5.06 (2H, s), 3.87 (1H, d, J=2.5), 3.81 (3 H, s), 3.76 (3H, s), 3.56 (1H, m), 3.14 (1H, dd, J=5.8, 14.6 Hz), 3.03 (1H, dd, J=8.1, 14.6 Hz),1.42 (9H, s).
Step 4 Preparation of 7: 4-Methoxybenzyl(25,3R)-3421(tert-butoxycarbonyl)(4-methoxybenzyflamlno]pyridin-4-yllmethyl)-1-([(1R)-1-cyclohexylethyl)carbamoyll .. oxoazetidine-2-carboxylate.
NBoc(PMB) DCM, TEA NBoc(PMB) ?Lo N=C=O ?"-0 ,¨NH ,¨N N
0 0 y [0331] To a solution of 4-methoxybenzyl(2S,3R)-3-(12-[(tert-butoxycarbonyl)(4-methoxybenzypaminolpyridin-4-ylImethyl)-4-oxoazetidine-2-carboxylate (210 g, 0.374 mol) and DCM (3 L) was added TEA (188 g, 1.86 mol, 5 eq.) and (R)-(1-isocyanatoethyl)cyclohexane (143 g, 0.933 mol, 2.5 eq, structure 8). The mixture was stirred .. overnight at RT. The reaction was concentrated. The residue was chromatographed (gradient elution with 0% to 40% EA/hexanes) to give 4-methoxybenzyl-(2S,3R)-3-42-Rtert-butoxycarbonyl)(4-methoxy benzypamlnolpyridin-4-ylImethyl)-1-([(1R)-1-cyclohexylethyl)carbamoy11-4-oxoazetidine-2- carboxylate (159 g, 60% yield) as a white foam.
[0332] 111 NMR (400 MHz, CDCI3) ppm ö 8.25 (1H, d, J=5.1 Hz), 7.61 (1H, s), 7.23 (2H, d, J=8.8 Hz), 7.15 (2H, d, J=8.6 Hz), 6.85 (2H, d, J=8.8 Hz), 6.80 (2H, d J=8.6 Hz), 6.23 (1H, d, J=9.1 Hz), 5.12 (1H, d, J=15.9), 5.11 (2H, s), 5.04 (1H, d, J=12.1 Hz), 4.23 (1 H, d, J=2.8 Hz), 3.80 (3 H, s), 3.78 (1H, m), 3.76 (3H, s), 3.45 (1H, m), 3.15 (1H, dd, J=6.5,14.8 Hz), 3.01 (1H, dd, J=8.9,14.8 Hz), 1.74 (4H, m), 1.68 (2H, m), 1.41 (9H, s), 1.35 (1H, m), 1.21 (2H, m), 1.14 (3H, d, J=6.8 Hz), 0.98 (2H, m).
Step 5. Preparation of Compound 1.11C1 C) HCI
NBoc(PMB) 0 1) TFA, 0 Et3SiH
?Lo\F) ________________________________________ N
2) HCI, 0 y MeCN, 0 y TBME
8 Compound 1. HCI
[0333] Trifluoroacetic acid (2.1 L) was added to 4-methoxybenzyl-(25,3R)-3-42-[(tert-butoxycarbonyl)(4-methoxybenzypamlnolpyridin-4-ylImethyl)-1-([(1R)-1-cyclohexylethyl)carbamoy11-4-oxoazetidine-2-carboxylate (283 g, 0.396 mol) giving a red solution. Et3SiH (138 g, 1.18 mol, 3 eq.) was added and the solution became colorless. The reaction was stirred 4 hr at RT. The TFA was removed in vacuo overnight to give (25,3R)-3-[(2-aminopyridin-4-yOmethy11-1-([(1R)-1-cyclohexylethylicarbamoy11-4-oxoazetidine-2-carboxylic acid trifluoroacetate as a white foam.
[0334] Acetonitrile (1.8 L) was added to the crude TFA salt giving a hazy solution. The solution was clarified by filtration and the residue was washed with acetonitrile (100 mL).
The combined acetonitrile solution was extracted with hexanes (1.8 L x 3). The acetonitrile solution was concentrated at reduced pressure to about 900 mL. Concentrated HCI (66 mL, 0.792 mol, 2 eq.) was added slowly to form a suspension. TBME (3 L) was added slowly while stirring. The resulting suspension was cooled to 0 C for 30 min. The solid precipitate was isolated by filtration and rinsed with TBME. The solid was air dried overnight and then dried at 50 C in vacuo for 5 hr to give (2S,3R)-3 [(2-aminopyridin-4-yOmethy11-1-1[(1R)-1-cyclohexylethyllcarbamoy11-4-oxoazetidine-2-carboxylic acid hydrochloride as a white powder (130 g, 80% yield).
111 NMR (400 MHz, D20) ppm ö 7.64 (1H, d, J=6.8 Hz), 6.84 (1H, s), 6.74 (1H, dd, J=1.5,6.8 Hz), 4.22 (1H, d, J=2.8 Hz), 3.75 (1H, m), 3.54 (1H, m), 3.17 (2H, m), 1.58 (5H, m), 1.22 (1H, m), 1.07 (6H, m), 0.89 (2H, m).
Example 2. HPLC method parameters for the analysis of Compound 1 [0335] The HPLC method parameters are summarized in Table 1. A representative chromatogram of Compound 1 is shown in FIG. 1.
Table 1. Summary of method parameters for analysis of Compound 1 Column MAC-Mod Halo C18, 4.6 x 100 mm, 2.7 p.m Mobile Phase A 99.9 % water + 0.1% TFA
Mobile Phase B 99.9 % ACN + 0.1% TFA
Time (mm) % A % B
0.0 80 20 0.1 80 20 5.1 40 60 Pump Gradient Program 5.2 0 100 6.2 0 100 6.3 80 20 Diluent water Flow (mL/min) 1 Column Temperature 35 Injection Volume (ttL) 10 Sample Temperature Room temperature or 5 C
(application dependent) Detection Wavelength 280 Example 3. Experimental setup for testing the equilibrium solubility of Compound 1 in common buffers [0336] The equilibrium solubility of Compound 1 was tested in common buffers (Table 2) at a buffer strength of c(buffer)= 200 mM. For this, samples of Compound 1 with c(Compound 1, target) = 16 mg/mL were prepared in the different buffer solutions (Table 3),
.. [0073] In one aspect, the present invention is directed to a method of reducing inflammation in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the inflammation is vascular inflammation. In some embodiments, the vascular inflammation is accompanied by atherosclerosis. In some embodiments, the vascular inflammation is accompanied by a thromboembolic disease in the subject. In some embodiments, the vascular inflammation is angiotensin II-induced vascular inflammation.
[0074] In one aspect, the present invention is directed to a method of preventing vascular leukocyte infiltration in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0075] In one aspect, the present invention is directed to a method of preventing angiotensin II-induced endothelial dysfunction in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0076] In one aspect, the present invention is directed to a method of preventing thrombin propagation in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the thrombin propagation occurs on platelets.
[0077] In one aspect, the present invention is directed to a method of treating hypertension-associated renal dysfunction in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0078] In one aspect, the present invention is directed to a method of prophylaxis of hypertension-associated renal dysfunction in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0079] In one aspect, the present invention is directed to a method of reducing the risk of hypertension-associated renal dysfunction in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0080] In one aspect, the present invention is directed to a method of treating kidney fibrosis in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0081] In one aspect, the present invention is directed to a method of prophylaxis of kidney fibrosis in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0082] In one aspect, the present invention is directed to a method of reducing the risk of kidney fibrosis in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0083] In one aspect, the present invention is directed to a method of treating kidney injury in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0084] In one aspect, the present invention is directed to a method of prophylaxis of kidney injury in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0085] In one aspect, the present invention is directed to a method of reducing the risk of kidney injury in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0086] In one aspect, the present invention is directed to a method of inhibiting Factor XIa in a subject, comprising administering to the subject that has suffered ischemia an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the ischemia is coronary ischemia.
[0087] In some embodiments, the subject is a mammal (e.g., a human).
[0088] In some embodiments, the subject is undergoing surgery (e.g., knee replacement surgery or hip replacement surgery). In some embodiments, the ischemia is coronary ischemia. In some embodiments, the subject is a subject with non-valvular atrial fibrillation.
In some embodiments, the subject has one or more of the following risk factors for stroke: a prior stroke (e.g., ischemic, unknown, hemorrhagic), transient ischemic attack, or non-CNS
systemic embolism. In some embodiments, the subject has one or more of the following risk factors for stroke: 75 years or older of age, hypertension, heart failure or left ventricular ejection fraction (e.g., less than or equal to 35%), or diabetes mellitus.
[0089] In some embodiments, the composition is administered by oral or parenteral (e.g., intravenous) administration. In some embodiments, the composition is administered by oral administration. In some embodiments, the composition is administered by parenteral (e.g., intravenous) administration. In some embodiments, the composition is administered by subcutaneous administration.
[0090] In some embodiments, the composition is administered prior to an ischemic event (e.g., to a subject is at risk of an ischemic event).
[0091] In some embodiments, the composition is administered after an ischemic event (e.g., a transient ischemic event). In some embodiments, the composition is administered about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days or more after an ischemic event (e.g., a transient ischemic event). In some embodiments, the composition is administered about 1, 2, 3, 4, 5, 6, 7, or 8 weeks or more after an ischemic event (e.g., a transient ischemic event).
[0092] In some embodiments, the composition is administered in combination with an additional therapeutic agent. In some embodiments, the additional therapeutic agent is administered after administration of the composition. In some embodiments, the additional therapeutic agent is administered orally. In some embodiments, the additional therapeutic agent is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, or 24 hours or more after administration of the composition. In some embodiments, the additional therapeutic agent is administered at least 1, 2, 3, 4, 5, 6, 7, 14, 21, or 28 days or more after administration of the composition. In some embodiments, the additional therapeutic agent is administered about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days or more after administration of the composition.
[0093] In some embodiments, the additional therapeutic agent is administered chronically (e.g., for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days or more) after administration of the composition.
[0094] In some embodiments, the additional therapeutic agent treats a side effect (e.g., active pathological bleeding or severe hypersensitivity reactions (e.g., anaphylactic reactions), spinal and or epidural hematoma, gastrointestinal disorder (e.g., abdominal pain upper, dyspepsia, toothache), general disorders and administration site conditions (e.g., fatigue), infections and infestations (e.g., sinusitis, urinary tract infection), musculoskeletal and connective tissues disorders (e.g., back pain, osteoarthritis), respiratory, thoracic and mediastinal disorders (e.g., oropharyngeal pain), injury, poisoning, and procedural complications (e.g., wound secretion), musculoskeletal and connective tissues disorders (e.g., pain in extremity, muscle spasm), nervous system disorders (e.g., syncope), skin and subcutaneous tissue disorders (e.g., pruritus, blister), blood and lymphatic system disorders (e.g., agranulocytosis), gastrointestinal disorders (e.g., retroperitoneal hemorrhage), hepatobiliary disorders (e.g., jaundice, cholestasis, cytolytic hepatitis), immune system disorders (e.g., hypersensitivity, anaphylactic reaction, anaphylactic shock, angioedema), nervous system disorders (e.g., cerebral hemorrhage, subdural hematoma, epidural hematoma, hemiparesis), skin and subcutaneous tissue disorders (e.g., Stevens-Johnson syndrome).
[0095] In some embodiments, the additional therapeutic agent is a NSAID (e.g., aspirin or naproxen), platelet aggregation inhibitor (e.g., clopidogrel), or anticoagulant (e.g., warfarin or enoxaparin).
[0096] In some embodiments, the additional therapeutic agent results in an additive therapeutic effect. In some embodiments, the additional therapeutic agent results in a synergistic therapeutic effect.
[0097] In another aspect, the present invention features a method of modulating (e.g., inhibiting) Factor XIa in a patient. The method comprises the step of administering an effective amount of a a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof)to a patient in need thereof, thereby modulating (e.g., inhibiting) Factor XIa.
[0098] In another aspect, the present invention features a method of treating a subject in need thereof for a thromboembolic disorder. The method comprises administering to the subject an effective amount of a a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). The thromboembolic disorder can be arterial cardiovascular thromboembolic disorders, arterial thrombosis, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart; including unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemia (e.g., coronary ischemia, ischemic sudden death, or transient ischemic attack), stroke (e.g., large vessel acute ischemic stroke), atherosclerosis, peripheral occlusive arterial disease, venous thromboembolism, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.
[0099] In another aspect, the present invention features a method of prophylaxis of a thromboembolic disorder in a subject. The method comprises administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). The thromboembolic disorder can be arterial cardiovascular thromboembolic disorders, arterial thrombosis, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart; including unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemia (e.g., coronary ischemia, ischemic sudden death, or transient ischemic attack), stroke (e.g., large vessel acute ischemic stroke), atherosclerosis, peripheral occlusive arterial disease, venous thromboembolism, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.
[0100] In another aspect, the present invention features a method of reducing the risk of a thromboembolic disorder in a subject. The method comprises administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). The thromboembolic disorder can be arterial cardiovascular thromboembolic disorders, arterial thrombosis, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart; including unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemia (e.g., coronary ischemia, ischemic sudden death, or transient ischemic attack), stroke (e.g., large vessel acute ischemic stroke), atherosclerosis, peripheral occlusive arterial disease, venous thromboembolism, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.
[0101] In one aspect, the present invention is directed to a method of treating end-stage renal disease in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0102] In one aspect, the present invention is directed to a method of prophylaxis of end-stage renal disease in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0103] In one aspect, the present invention is directed to a method of reducing the risk of end-stage renal disease in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0104] In another aspect, the present invention features a method of treating a thromboembolic disorder in a subject need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof), wherein the subject is exposed to an artificial surface. In some embodiments, the artificial surface contacts the subject's blood. In some embodiments, the artificial surface is an extracorporeal surface. In some embodiments, the artificial surface is that of an implantable device, e.g., a mechanical valve. In some embodiments, the artificial surface is that of a dialysis catheter. In some embodiments, the artificial surface is that of a cardiopulmonary bypass circuit. In some embodiments, the artificial surface is that of an artificial heart valve. In some embodiments, the artificial surface is that of a ventricular assist device. In some embodiments, the artificial surface is that of a small caliber graft. In some embodiments, the artificial surface is that of a central venous catheter. In some embodiments, the artificial surface is that of an extracorporeal membrane oxygenation (ECMO) apparatus. In some embodiments, the artificial surface causes or is associated with the thromboembolic disorder.
In some embodiments, the thromboembolic disorder is a venous thromboembolism. In some embodiments, the thromboembolic disorder is deep vein thrombosis. In some embodiments, the thromboembolic disorder is pulmonary embolism.
[0105] In another aspect, the present invention features a method of reducing the risk of a thromboembolic disorder in a subject need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof), wherein the subject is exposed to an artificial surface. In some embodiments, the artificial surface contacts the subject's blood. In some embodiments, the artificial surface is an extracorporeal surface. In some embodiments, the artificial surface is that of an implantable device, e.g., a mechanical valve. In some embodiments, the artificial surface is that of a dialysis catheter. In some embodiments, the artificial surface is that of a cardiopulmonary bypass circuit. In some embodiments, the artificial surface is that of an artificial heart valve. In some embodiments, the artificial surface is that of a ventricular assist device. In some embodiments, the artificial surface is that of a small caliber graft. In some embodiments, the artificial surface is that of a central venous catheter. In some embodiments, the artificial surface is that of an extracorporeal membrane oxygenation (ECMO) apparatus. In some embodiments, the artificial surface causes or is associated with the thromboembolic disorder.
In some embodiments, the thromboembolic disorder is a venous thromboembolism. In some embodiments, the thromboembolic disorder is deep vein thrombosis. In some embodiments, the thromboembolic disorder is pulmonary embolism.
[0106] In another aspect, the present invention features a method of prophylaxis of a thromboembolic disorder in a subject need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof), wherein the subject is exposed to an artificial surface. In some embodiments, the artificial surface contacts the subject's blood. In some embodiments, the artificial surface is an extracorporeal surface. In some embodiments, the artificial surface is that of an implantable device, e.g., a mechanical valve. In some embodiments, the artificial surface is that of a dialysis catheter. In some embodiments, the artificial surface is that of a cardiopulmonary bypass circuit. In some embodiments, the artificial surface is that of an artificial heart valve. In some embodiments, the artificial surface is that of a ventricular assist device. In some embodiments, the artificial surface is that of a small caliber graft. In some embodiments, the artificial surface is that of a central venous catheter. In some embodiments, the artificial surface is that of an extracorporeal membrane oxygenation (ECMO) apparatus. In some embodiments, the artificial surface causes or is associated with the thromboembolic disorder.
In some embodiments, the thromboembolic disorder is a venous thromboembolism. In some embodiments, the thromboembolic disorder is deep vein thrombosis. In some embodiments, the thromboembolic disorder is pulmonary embolism.
[0107] In another aspect, the present invention features a method of treating atrial fibrillation, in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the subject is also in need of dialysis, e.g., renal dialysis. In some embodiments, the composition described herein is administered to the subject while the subject is undergoing dialysis. In some embodiments, the composition is administered to the subject before or after receiving dialysis. In some embodiments, the patient has end-stage renal disease. In some __ embodiments, the subject is not in need of dialysis, e.g., renal dialysis.
In some embodiments, the patient is at a high risk for bleeding. In some embodiments, the atrial fibrillation is associated with another thromboembolic disorder, e.g., a blood clot.
[0108] In another aspect, the present invention features a method of reducing the risk of atrial fibrillation, in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the subject is at a high risk of developing atrial fibrillation.
In some embodiments, the subject is also in need of dialysis, e.g., renal dialysis. In some embodiments, the composition described herein is administered to the subject while the subject is undergoing dialysis. In some embodiments, the composition is administered to the subject before or after receiving dialysis. In some embodiments, the patient has end-stage renal disease. In some embodiments, the subject is not in need of dialysis, e.g., renal dialysis.
In some embodiments, the patient is at a high risk for bleeding. In some embodiments, the atrial fibrillation is associated with another thromboembolic disorder, e.g., a blood clot.
[0109] In another aspect, the present invention features a method of prophylaxis of atrial fibrillation, in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the subject is at a high risk of developing atrial fibrillation. In some embodiments, the subject is also in need of dialysis, e.g., renal dialysis. In some embodiments, the composition described herein is administered to the subject while the subject is undergoing dialysis. In some embodiments, the composition is administered to the subject before or after receiving dialysis. In some embodiments, the patient has end-stage renal disease. In some embodiments, the subject is not in need of dialysis, e.g., renal dialysis. In some embodiments, the patient is at a high risk for bleeding. In some embodiments, the atrial fibrillation is associated with another thromboembolic disorder, e.g., a blood clot.
[0110] In another aspect, the present invention features a method of treating heparin-induced thrombocytopenia in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0111] In another aspect, the present invention features a method of reducing the risk of heparin-induced thrombocytopenia in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0112] In another aspect, the present invention features a method of prophylaxis of heparin-induced thrombocytopenia in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0113] In another aspect, the present invention features a method of treating heparin-induced thrombocytopenia thrombosis in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0114] In another aspect, the present invention features a method of reducing the risk of heparin-induced thrombocytopenia thrombosis in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0115] In another aspect, the present invention features a method of prophylaxis of heparin-induced thrombocytopenia thrombosis in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0116] In another aspect, the present invention features a method of prophylaxis of a thromboembolic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof), wherein the subject has cancer or is being with a chemotherapeutic. In some embodiments, the subject is concurrently receiving chemotherapy. In some embodiments, the subject has elevated lactase dehydrogenase levels. In some embodiments, the thromboembolic disorder is venous thromboembolism. In some embodiments, the thromboembolic disorder is deep vein thrombosis. In some embodiments, the thromboembolic disorder is pulmonary embolism.
[0117] In another aspect, the present invention features a method of treating thrombotic microangiopathy in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the thrombotic microangiopathy is hemolytic uremic syndrome (HUS). In some embodiments, the thrombotic microangiopathy is thrombotic thrombocytopenic purpura (TTP).
[0118] In another aspect, the present invention features a method of reducing the risk of thrombotic microangiopathy in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the thrombotic microangiopathy is hemolytic uremic syndrome (HUS). In some embodiments, the thrombotic microangiopathy is thrombotic thrombocytopenic purpura (TTP).
[0119] In another aspect, the present invention features a method of prophylaxis of thrombotic microangiopathy in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the thrombotic microangiopathy is hemolytic uremic syndrome (HUS). In some embodiments, the thrombotic microangiopathy is thrombotic thrombocytopenic purpura (TTP).
[0120] In another aspect, the present invention features a method of prophylaxis of recurrent ischemia in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof), wherein the subject has acute coronary syndrome. In some embodiments, the subject has atrial fibrillation. In some embodiments, the subject does not have atrial fibrillation. In another aspect, the present invention features a method of treating a subject identified as being at risk, e.g., high risk, for stroke (e.g., large vessel acute ischemic stroke) or thrombosis thereby reducing the likelihood of stroke (e.g., large vessel acute ischemic stroke) or thrombosis in the subject. In some embodiments, the subject is further identified as being at risk for bleeding (e.g., excessive bleeding) or sepsis. In some embodiments, the treatment is effective without bleeding liabilities. In some embodiments, the treatment is effective to maintain the patency of infusion ports and lines. In addition, the compositions described herein are useful in the treatment and prevention of other diseases in which the generation of thrombin has been implicated as playing a physiologic role. For example, thrombin has been implicated in contributing to the morbidity and mortality of chronic and degenerative diseases, such as cancer, arthritis, atherosclerosis, vascular dementia, and Alzheimer's disease, by its ability to regulate many different cell types through specific cleavage and activation of a cell surface thrombin receptor, mitogenic effects, diverse cellular functions such as cell proliferation, for example, abnormal proliferation of vascular cells resulting in restenosis or angiogenesis, release of PDGF, and DNA synthesis. Inhibition of Factor XIa effectively blocks thrombin generation and therefore neutralizes any physiologic effects of thrombin on various cell types. The representative indications discussed above include some, but not all, of the potential clinical situations amenable to treatment with a Factor XIa inhibitor.
[0121] In another aspect, the present invention features a method of treating a subject that has edema (e.g., angioedema, e.g., hereditary angioedema), comprising administering an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof) to the subject.
[0122] In another aspect, the present invention features a method of prophylaxis of edema (e.g., angioedema, e.g., hereditary angioedema) in a subject, comprising administering an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof) to the subject.
[0123] In another aspect, the present invention features a method of reducing the risk of edema (e.g., angioedema, e.g., hereditary angioedema) in a subject, comprising administering an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof) to the subject.
[0124] In another aspect, the present invention features a method of inhibiting kallikrein in a subject, comprising administering to the subject with edema (e.g., angioedema, e.g., hereditary angioedema), an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof) to the subject.
[0125] In another aspect, the present invention features a method of treating a thromboembolic consequence or complication in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the thromboembolic consequence or complication is associated with a peripheral vascular intervention (e.g., of the limbs), hemodialysis, catheter ablation, a cerebrovascular intervention, transplantation of an organ (e.g., liver), surgery (e.g., orthopedic surgery, lung surgery, abdominal surgery, or cardiac surgery, (e.g., open-heart surgery)), a trans-catheter aortic valve implantation, a large bore intervention used to treat an aneurysm, a percutaneous coronary intervention, or hemophilia therapy. In some embodiments, the surgery is orthopedic surgery, lung surgery, abdominal surgery, or cardiac surgery. In some embodiments, the cardiac surgery is complex cardiac surgery or lower risk cardiac surgery. In some embodiments, the thromboembolic consequence or complication is associated with a percutaneous coronary intervention.
[0126] In another aspect, the present invention features a method of prophylaxis of a thromboembolic consequence or complication in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the thromboembolic consequence or complication is associated with a peripheral vascular intervention (e.g., of the limbs), hemodialysis, catheter ablation, e.g., catheter ablation for atrial fibrillation, a cerebrovascular intervention, transplantation of an organ (e.g., liver), surgery (e.g., orthopedic surgery, lung surgery, abdominal surgery, or cardiac surgery, (e.g., open-heart surgery)), a trans-catheter aortic valve implantation, a large bore intervention used to treat an aneurysm, a percutaneous coronary intervention, or hemophilia therapy. In some embodiments, the surgery is orthopedic surgery, lung surgery, abdominal surgery, or cardiac surgery. In some embodiments, the cardiac surgery is complex cardiac surgery or lower risk cardiac surgery. In some embodiments, the thromboembolic consequence or complication is associated with a percutaneous coronary intervention.
[0127] In another aspect, the present invention features a method of reducing the risk of a thromboembolic consequence or complication in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the thromboembolic consequence or complication is associated with a peripheral vascular intervention (e.g., of the limbs), hemodialysis, catheter ablationõ e.g., catheter ablation for atrial fibrillation, a cerebrovascular intervention, transplantation of an organ (e.g., liver), surgery (e.g., orthopedic surgery, lung surgery, abdominal surgery, or cardiac surgery, (e.g., open-heart surgery)), a trans-catheter aortic valve implantation, a large bore intervention used to treat an aneurysm, a percutaneous coronary intervention, or hemophilia therapy. In some embodiments, the surgery is orthopedic surgery, lung surgery, abdominal surgery, or cardiac surgery. In some embodiments, the cardiac surgery is complex cardiac surgery or lower risk cardiac surgery. In some embodiments, the thromboembolic consequence or complication is associated with a percutaneous coronary intervention.
[0128] In another aspect, the invention features a method of treating restenosis following arterial injury in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the arterial injury occurs after a cranial artery stenting.
[0129] In another aspect, the present invention features a method of prophylaxis of restenosis following arterial injury in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the arterial injury occurs after a cranial artery stenting.
[0130] In another aspect, the present invention features a method of reducing the risk of restenosis following arterial injury in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the arterial injury occurs after a cranial artery stenting.
[0131] In another aspect, the present invention features a method of treating hepatic vessel thrombosis in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0132] In another aspect, the present invention features a method of prophylaxis of hepatic vessel thrombosis in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0133] In another aspect, the present invention features a method of reducing the risk of hepatic vessel thrombosis in a subject, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0134] In another aspect, the present invention features a method of treating a non-ST-elevation myocardial infarction or ST-elevation myocardial infarction), comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0135] In another aspect, the present invention features a method of prophylaxis of a non-ST-elevation myocardial infarction or ST-elevation myocardial infarction in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0136] In another aspect, the present invention features a method of reducing the risk of a non-ST-elevation myocardial infarction or ST-elevation myocardial infarction in a subject, comprising administering to the subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof).
[0137] In another aspect, the present invention features a method of maintaining blood vessel patency, comprising administering to a subject an effective amount of a composition described herein (e.g., a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the subject has acute kidney injury. In some embodiments, the subject additionally undergoes continuous renal replacement therapy.
[0138] In some embodiments of any of the foregoing, the composition described herein is administered orally or parenterally. In certain embodiments, the composition described herein is administered parenterally. In certain embodiments, the composition described herein is administered after the subject has discontinued use of a direct oral anticoagulant. In certain embodiments, the subject used the direct oral anticoagulant for up to about 2.5 years.
In certain embodiments, the subject is a mammal, e.g., a human.
[0139] In some embodiments of the methods described herein, the pharmaceutically acceptable salt of Compound 1 is a hydrochloride salt. In some embodiments, the composition is administered to the subject intravenously. In some embodiments, the composition is administered to the subject subcutaneously. In some embodiments, the composition is administered to the subject as a continuous intravenous infusion. In some embodiments, the composition is administered to the subject as a bolus. In some embodiments, the subject is a human. In some embodiments, the subject has an elevated risk of a thromboembolic disorder. In some embodiments, the thromboembolic disorder is a result of a complication in surgery.
[0140] In some embodiments, the subject is sensitive to or has developed sensitivity to heparin. In some embodiments, the subject is resistant to or has developed resistance to heparin. In some embodiments, the subject is in contact with the artificial surface for at least 1 day (e.g., about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 2 months, about 3 months, about 6 months, about 9 months, about 1 year).
BRIEF DESCRIPTION OF THE DRAWINGS
[0141] FIG. 1 depicts an exemplary HPLC chromatogram of Compound 1 including baseline detail.
[0142] FIG. 2A depicts exemplary pH-development data of Compound 1 over the 10-day stability experiment at 4 C.
[0143] FIG. 2B depicts exemplary pH-development data of Compound 1 over the 10-day stability experiment at 40 C.
[0144] FIG. 3A depicts exemplary recovery data of Compound 1 over a 10-day stability assessment at 4 C.
[0145] FIG. 3B depicts exemplary recovery data of Compound 1 over a 10-day stability assessment 40 C.
[0146] FIG. 4A depicts an exemplary powder X-Ray diffractogram of Compound 1=HC1 on scale.
[0147] FIG. 4B depicts an exemplary powder X-Ray diffractogram of Compound 1=HC1 on d-scale.
[0148] FIG. 5 depicts the lyophilization cycle parameters developed for Compound 1.
[0149] FIG. 6 depicts an exemplary monitoring of product temperature and product drying.
[0150] FIG. 7 depicts exemplary long-term stability study of the Compound 1 lyophilized drug product at T = -80 C.
[0151] FIG. 8 depicts exemplary long-term stability study of the Compound 1 lyophilized drug product at T = -20 C.
[0152] FIG. 9 depicts exemplary long-term stability study of the Compound 1 lyophilized drug product at T = 2-8 C.
[0153] FIG. 10 depicts an exemplary chromatograph of 48-hour stability sample of Compound 1 formulation diluted into normal saline.
[0154] FIG. 11 depicts the pressure gradient across membrane oxygenator for cardiopulmonary bypass experiment conducted in the hound model.
[0155] FIG. 12 depicts a comparison of plasma concentrations and activated partial thromboplastin time (aPTT) ratio measured in the hound model.
[0156] FIG. 13 depicts the activated partial thromboplastin time (aPTT) measured in the hound model following Compound 1 administration.
DETAILED DESCRIPTION
[0157] Described herein are pharmaceutical compositions comprising Compound 1 or a pharmaceutically acceptable salt thereof, a cyclodextrin, and an excipient, methods of their use and administration, methods for their preparation, and containers comprising the solutions or mixtures.
Definitions [0158] As used herein, the terms "stabilized" and "stable" solutions described herein (e.g., an aqueous solution comprising Compound 1) refer to solutions that are "chemically stable"
and "physically stable." For example, a solution comprising Compound 1 is chemically stable if Compound 1 does not undergo chemical transformation (e.g., hydrolysis) or degradation (e.g., racemization, epimerization, oxidation).
[0159] "Assay", as used herein, refers to a specific, stability-indicating procedure that determines the content of the drug substance. For example, an assay can be a chromatographic method (e.g., HPLC) involving use of a reference standard.
[0160] "Purity", as used herein, refers to the absence of impurities, for example in a solution or composition, relative to its parent (e.g., at time = 0).
[0161] "Sterilization", as used herein, refers to aseptic fill (e.g., aseptic sterilization) or terminal sterilization.
[0162] A "reconstituted solution," "reconstituted formulation," or "reconstituted drug product" as used herein, refers to a solution which has been prepared by dissolving a lyophilized drug product in a diluent, such that the drug product is dissolved in an aqueous solution suitable for administration (e.g., parenteral administration).
[0163] The term "diluent" as used herein, refers to a pharmaceutically acceptable (e.g., safe and non-toxic for administration to a human) diluting substance useful for the preparation of a reconstituted solution. Exemplary diluents include sterile water for injection (WFI), a pH
buffered solution (e.g., phosphate-buffered saline), sterile saline solution, or dextrose solution (e.g., 5% dextrose).
[0164] The term "osmolarity," as used herein, refers to the total number of dissolved components per liter. Osmolarity is similar to molarity but includes the total number of moles of dissolved species in solution. An osmolarity of 1 Osm/L means there is 1 mole of dissolved components per L of solution. Some solutes, such as ionic solutes that dissociate in solution, will contribute more than 1 mole of dissolved components per mole of solute in the solution. For example, NaCl dissociates into Na+ and Cl- in solution and thus provides 2 moles of dissolved components per 1 mole of dissolved NaCl in solution.
Physiological osmolarity is typically in the range of about 280 mOsm/L to about 310 mOsm/L.
[0165] As used herein, "slurrying" refers to a method wherein a compound as described herein is suspended in a solvent (e.g., polar aprotic solvent or nonpolar solvent) and is collected again (e.g., by filtration) after agitating the suspension.
[0166] As used herein, "crystalline" refers to a solid having a highly regular chemical structure. The molecules are arranged in a regular, periodic manner in the 3-dimensional space of the lattice.
[0167] The term "substantially crystalline" refers to forms that may be at least a particular weight percent crystalline. Particular weight percentages are 70%, 75%, 80%, 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or any percentage between 70% and 100%. In certain embodiments, the particular weight percent of crystallinity is at least 90%. In certain other embodiments, the particular weight percent of .. crystallinity is at least 95%. In some embodiments, Compound 1 can be a substantially crystalline sample of any of the crystalline solid forms described herein.
[0168] The term "substantially pure" relates to the composition of a specific crystalline solid form of Compound 1 that may be at least a particular weight percent free of impurities and/or other solid forms of Compound 1 or a pharmaceutically acceptable salt thereof .. Particular weight percentages are 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage between 70% and 100%. In some embodiments, a crystalline solid form of Compound 1 or a pharmaceutically acceptable salt thereof as described herein is substantially pure at a weight percent between 95% and 100%, e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 99.9%.
[0169] As used herein, and unless otherwise specified, the terms "treat,"
"treating" and "treatment" contemplate an action that occurs while a subject is suffering from the specified disease, disorder or condition, which reduces the severity of the disease, disorder or condition, or retards or slows the progression of the disease, disorder or condition (also, "therapeutic treatment").
[0170] As used herein, and unless otherwise specified, a "therapeutically effective amount"
of a composition is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder or condition, or to delay or minimize one or more symptoms associated with the disease, disorder or condition. A therapeutically effective amount of a composition means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the disease, disorder or condition.
The term "therapeutically effective amount" can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.
[0171] As used herein, and unless otherwise specified, a "prophylactically effective amount" of a composition is an amount sufficient to prevent a disease, disorder or condition, or one or more symptoms associated with the disease, disorder or condition, or prevent its recurrence. A prophylactically effective amount of a composition means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the disease, disorder or condition. The term "prophylactically effective amount" can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
[0172] Disease, disorder, and condition are used interchangeably herein.
[0173] A "subject" to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g, infant, child, adolescent) or adult subject (e.g., young adult, middle¨aged adult or senior adult)) and/or a non-human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and/or dogs. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human animal. In some embodiments, the pediatric subject is between the age of 0 and 18 years old.
In some embodiments, the adult subject is beyond 18 years old.
[0174] As used herein, the term "artificial surface" refers to any non-human or non-animal surface that comes into contact with blood of the subject, for example, during a medical procedure. It can be a vessel for collecting or circulating blood of a subject outside the subject's body. It can also be a stent, valve, intraluminal catheter or a system for pumping blood. By way of non-limiting example such artificial surfaces can be steel, any type of plastic, glass, silicone, rubber, etc. In some embodiments, the artificial surface is exposed to at least 50%. 60%, 70% 80%, 90% or 100% of the blood of subject.
[0175] As used herein, the term "conditioning" or "conditioned" with respect to an artificial surface refers to priming or flushing the artificial surface (e.g., extracorporeal surface) with a composition described herein, already in a priming or flushing solution (e.g., blood, a saline solution, Ringer's solution) or as a separate administration to the artificial surface prior to, during, or after a medical procedure.
Bulking Agent [0176] The term "bulking agent" as used herein, includes agents that provide the structure of the composition (e.g., in lyophilized product) without interacting directly (e.g, chemically) with the pharmaceutical product (e.g, drug product). In addition to providing a pharmaceutically elegant cake, bulking agents may also impart useful qualities in regard to modifying the collapse temperature, providing freeze-thaw protection, and enhancing the active pharmaceutical ingredient (API) stability over long-term storage. Non-limiting examples of bulking agents include a sugar (e.g., a saccharide (e.g., monosaccharide, disaccharide, or polysaccharide)) or a sugar alcohol (e.g., sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, or marmitol, or a combination thereof). Bulking agents may be crystalline (e.g., mannitol, glycine, or sodium chloride) or amorphous (e.g., dextran, hydroxyethyl starch).
[0177] Preferably, the bulking agent applied in pharmaceutical formulation promotes the formation of a cake that is aesthetically acceptable, uniform, or mechanically strong. Bulking agents may also preferably promote ease and speed of reconstitution. Bulking agents may also preferably reduce or prevent cake collapse, eutectic melting, or retention of residual moisture. In some embodiments, the bulking agent is a lyoprotectant.
Buffers [0178] In some embodiments, the aqueous pharmaceutical compositions described herein further comprise a buffer (e.g., a buffer at a pH of between about 6 and about 8 (e.g., between about 6.5 and about 7.0, or about 6.8).
[0179] As used herein, the terms "buffer," "buffer system," or "buffering component"
refers to a compound that, usually in combination with at least one other compound, provides a chemical system in solution that exhibits buffering capacity, that is, the capacity to neutralize, within limits, the pH lowering or raising effects of either strong acids or bases (alkali), respectively, with relatively little or no change in the original pH
(e.g., the pH before being affected by, e.g., strong acid or base). For example, a buffer described herein maintains or controls the pH of a solution to a certain pH range. For example, "buffering capacity" can refer to the millimoles (mM) of strong acid or base (or respectively, hydrogen or hydroxide ions) required to change the pH by one unit when added to one liter (a standard unit) of the buffer solution. From this definition, it is apparent that the smaller the pH change in a solution caused by the addition of a specified quantity of acid or alkali, the greater the buffer capacity of the solution. See, for example, Remington: The Science and Practice of Pharmacy, Mack Publishing Co., Easton, Pennsylvania (19th Edition, 1995), Chapter 17, pages 225-227. The buffer capacity will depend on the kind and concentration of the buffer components.
[0180] In some embodiments, the buffer comprises a monoprotic acid. In some embodiments, the buffer comprises a polyprotic acid (e.g., maleate, citrate, or phosphate). In some embodiments, the buffer is a solution of one or more substances (e.g., a salt of a weak acid and a weak base; a mixture of a weak acid and a salt of the weak acid with a strong base).
[0181] In some embodiments, the buffer is maleate buffer. In some embodiments, the buffer is citrate buffer. In some embodiments, the buffer is phosphate buffer.
Lyoprotectant [0182] The term "lyoprotectant" as used herein, refers to a substance, when combined with the drug product, reduces the chemical and/or physical instability of the drug product upon lyophilization and/or subsequent storage. Exemplary lyoprotectants include sugars and their .. corresponding sugar alcohols, such as sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, and mannitol; amino acids, such as arginine or histidine;
lyotropic salts, such as magnesium sulfate; polyols, such as propylene glycol, glycerol, poly(ethylene glycol), or polypropylene glycol); and combinations thereof Additional exemplary lyoprotectants include gelatin, dextrins, modified starch, and carboxymethyl cellulose. Sugar alcohols are those compounds obtained by reduction of mono- and di-saccharides, such as lactose, trehalose, maltose, lactulose, and maltulose.
Cyclodextrins [0183] Cyclodextrins are cyclic oligosaccharides containing or comprising six (a-cyclodextrin), seven (0-cyclodextrin), eight (y-cyclodextrin), or more a-(1,4)-linked glucose residues. The hydroxyl groups of the cyclodextrins are oriented to the outside of the ring while the glucosidic oxygen and two rings of the non-exchangeable hydrogen atoms are directed towards the interior of the cavity.
[0184] The cyclodextrin may be chemically modified such that some or all of the primary or secondary hydroxyl groups of the macrocycle, or both, are functionalized with a pendant group. Suitable pendant groups include, but are not limited to, sulfinyl, sulfonyl, phosphate, acyl, and Cl-C12 alkyl groups optionally substituted with one or more (e.g., 1, 2, 3, or 4) hydroxy, carboxy, carbonyl, acyl, oxy, oxo; or a combination thereof Methods of modifying these alcohol residues are known in the art, and many cyclodextrin derivatives are commercially available, including sulfo butyl ether 0-cyclodextrins available under the trade name CAPTISOLO from Ligand Pharmaceuticals (La Jolla, CA).
[0185] Cyclodextrins include, but are not limited to, alkyl cyclodextrins, hydroxy alkyl cyclodextrins, such as hydroxy propyl 0-cyclodextrin, carboxy alkyl cyclodextrins and sulfoalkyl ether cyclodextrins, such as sulfo butyl ether 0-cyclodextrin.
[0186] In particular embodiments, the cyclodextrin is beta cyclodextrin having a plurality of charges (e.g., negative or positive) on the surface. In more particular embodiments, the cyclodextrin is a [3-cyclodextrin containing or comprising a plurality of functional groups that are negatively charged at physiological pH. Examples of such functional groups include, but are not limited to, carboxylic acid (carboxylate) groups, sulfonate (R503-), phosphonate groups, phosphinate groups, and amino acids that are negatively charged at physiological pH.
The charged functional groups can be bound directly to the cyclodextrins or can be linked by a spacer, such as an alkylene chain. The number of carbon atoms in the alkylene chain can be varied, but is generally between about 1 and 10 carbons, preferably 1-6 carbons, more preferably 1-4 carbons. Highly sulfated cyclodextrins are described in U.S.
Patent No.
6,316,613.
[0187] In one embodiment, the cyclodextrins is a [3-cyclodextrin functionalized with a plurality of sulfobutyl ether groups. Such a cyclodextrins is sold under the trade name CAPTISOLO.
[0188] CAPTISOLO is a polyanionic beta-cyclodextrin derivative with a sodium sulfonate salt separated from the lipophilic cavity by a butyl ether spacer group, or sulfobutylether (SBE). CAPTISOLO is not a single chemical species, but comprised of a multitude of polymeric structures of varying degrees of substitution and positional/regional isomers dictated and controlled to a uniform pattern by a patented manufacturing process consistently practiced and improved to control impurities.
[0189] CAPTISOLO contains six to seven sulfobutyl ether groups per cyclodextrin molecule. Because of the very low pKa of the sulfonic acid groups, CAPTISOLO
carries multiple negative charges at physiologically compatible pH values. The four-carbon butyl chain coupled with repulsion of the end group negative charges allows for an "extension" of the cyclodextrin cavity. This often results in stronger binding to drug candidates than can be achieved using other modified cyclodextrins. It also provides a potential for ionic charge interactions between the cyclodextrin and a positively charged drug molecule.
In addition, these derivatives impart exceptional solubility and parenteral safety to the molecule. Relative to beta-cyclodextrin, CAPTISOLO provides higher interaction characteristics and superior water solubility in excess of 100 grams/100 ml, a 50-fold improvement.
Solubilizing Agent [0190] The term "solubilizing agent", as used herein, describes a substance which is capable of facilitating the dissolution of insoluble or poorly soluble components in a solution containing same. Representative examples of solubilizing agents that are usable in the context of the present invention include, without limitation, TWEENS and spans, e.g., TWEENa) 80 and TWEENt 20. Other solubilizing agents that are usable in the context of embodiments of the invention include, for example, polyoxyethylen.e sorbitan esters, polyox-yethylene sorbitan fatt)., acid ester, polvoxyethylene n-allcyl ethers, polyethylene glycols (e.g., PEG200, PEG300, PEG400, PEG500, PEG600, etc), n-alicyl amine n-oxides, poloxamers, organic solvents, phospholipids and cyclodextrins.
Containers [0191] Also described herein are containers that include an aqueous solution or admixture described herein. Examples of containers include bags (e.g., plastic or polymer bags such as PVC), vials (e.g., a glass vial), bottles, or syringes. In an embodiment, the container is configured to deliver the solution or admixture parenterally (e.g., intramuscular, subcutaneous, or intravenous).
[0192] In some embodiments, the product intended for injection is packed in a suitably sized hermetically sealed glass container. In some embodiments the product is intended to be diluted prior to infusion, and is packaged in a pharmaceutical vial or bottle (e.g. suitably sized, suitable glass or plastic vial or bottle). In some embodiments the product may prepared to be ready for injection and may be packaged in a prefilled syringe or other syringe device (e.g. suitably sized, suitable glass or plastic package) or large volume container (e.g. suitably sized, suitable glass or plastic container) intended to be used for infusion.
In some embodiments, the product is provided in a container that does not leach (e.g., does not introduce (or allow growth of) contamination or impurities in the solution.
Lyophilization [0193] The term "lyophilization" refers to a freeze-drying process in which water is removed from a product by freezing the product and placing it under a vacuum, which allows the ice to change directly from the solid phase to the vapor phase without passing through the liquid phase. The process consists of three separate, unique, and interdependent processes:
freezing, primary drying (sublimation), and secondary drying (desorption).
There are several advantages associated with lyophilization, such as: (i) ease of processing a liquid, which simplifies aseptic handling; (ii) enhanced stability of a dry powder; (iii) removal of water without excessive heating of the product; (iv) enhanced product stability in a dry state; and (v) rapid and easy dissolution of the reconstituted product.
[0194] The lyophilization process generally includes the following steps:
- Dissolving the drug and excipients in a suitable solvent, generally water for injection (WFI).
- Sterilizing the bulk solution by passing it through a 0.22 micron bacteria-retentive filter.
- Filling into individual sterile containers and partially stoppering the containers under aseptic conditions.
- Transporting the partially stoppered containers to the lyophilizer and loading into the chamber under aseptic conditions.
- Freezing the solution by placing the partially stoppered containers on cooled shelves in a freeze-drying chamber or pre-freezing in another chamber.
- Applying a vacuum to the chamber and heating the shelves in order to evaporate the water from the frozen state.
- Complete stoppering of the vials usually by hydraulic or screw rod stoppering mechanisms installed in the lyophilizers.
Compounds [0195] The present invention relates, in part, to pharmaceutical compositions comprising a compound of Formula (I-A):
N. ?'\---01r0 ,¨NyN
0 (I-A) also referred to herein as "Compound 1," or a pharmaceutically acceptable salt thereof In some embodiments, the pharmaceutically acceptable salt of Compound 1 is a hydrochloride salt.
[0196] In some embodiments, a compound described herein is formed into a salt.
A
compound described herein can be administered as a free acid, a zwitterion or as a salt. A
salt can also be formed between a cation and a negatively charged substituent on a compound described herein, the deprotonated carboxylic acid moiety of Compound 1 for example.
Suitable cationic counterions include sodium ions, potassium ions, magnesium ions, calcium ion, and ammonium ions (e.g., a tetraalkyl ammonium cation such as tetramethylammonium ion). In acid addition salts, a salt can be formed between an anion and a positively charged substituent (e.g., amino group) or basic substituent (e.g., pyridyl) on a compound described herein. Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, and acetate.
[0197] Pharmaceutically acceptable salts of the compounds described herein (e.g., a pharmaceutically acceptable salt of Compound 1) also include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, 4-acetamidobenzoate, adipate, alginate, 4-aminosalicylate, aspartate, ascorbate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, carbonate, cinnamate, cyclamate, decanoate, decanedioate, 2,2-dichloroacetate, digluconate, dodecylsulfate, ethanesulfonate, ethane-1,2-disulfonate, formate, fumarate, galactarate, glucoheptanoate, gluconate, glucoheptonate, glucoronate, glutamate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 1-hydroxy-2-naphthoate, 2-hydroxyethanesulfonate, isobutyrate, lactate, lactobionate, laurate, malate, maleate, malonate, mandelate, methanesulfonate, naphthalene-1,5-disulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, octanoate, oleate, oxalate, 2-oxoglutarate, palmitate, palmoate, pectinate, 3-phenylpropionate, phosphate, phosphonate, picrate, pivalate, propionate, pyroglutamate, salicylate, sebacate, succinate, stearate, sulfate, tartrate, thiocyanate, toluenesulfonate, tosylate, and undecanoate.
[0198] Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and (alkyl)4N + salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
[0199] As used herein, the compounds of this invention, including the Compound 1, are defined to include pharmaceutically acceptable derivatives or prodrugs thereof A
"pharmaceutically acceptable derivative or prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention. Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood), or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species. Preferred prodrugs include derivatives where a group which enhances aqueous solubility or active transport through the gut membrane is appended to the structure of formulae described herein.
[0200] Any formula or a compound described herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds, isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, 3H, 13c, 14C, 15N, 18F 51p, 32p, 35s, 36C1, 1251 respectively. The invention includes various isotopically labeled compounds as defined herein, for example, those into which radioactive isotopes, such as 3H, 13C, and 14C are present. Such isotopically labelled compounds are useful in metabolic studies (with 14C), reaction kinetic studies (with, for example 'H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an I-8F or labeled compound may be particularly desirable for PET or SPECT studies, isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
[0201] Further, substitution with heavier isotopes, particularly deuterium (i.e., 2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of a formula described herein. The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope If a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5%
deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5%
deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95%
deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99%
deuterium incorporation), or at least 8633.3 (99.5% deuterium incorporation).
[0202] Isotopically-labelled compounds described herein can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g, D20, D6-acetone, D6-DMSO.
[0203] Any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)- (S)- or (RS)- configuration, in certain embodiments, each asymmetric atom has at least 50 %
enantiomeric excess, at least 60 % enantiomeric excess, at least 70 %
enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the (R)- or (S)-configuration. Substituents at atoms with unsaturated bonds may, if possible, be present in cis-(Z)- or trans-(E)- form Accordingly, as used herein a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereorners, optical isomers (antipodes), racemates or mixtures thereof Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography or fractional crystallization.
[0204] Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. An acidic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, (+)-0,01-Di-p-toluoyl-D-tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
[0205] The compounds described herein (e.g., Compound 1) may also be represented in multiple tautomeric forms. In such instances, the invention expressly includes all tautomeric forms of the compounds described herein. All crystal forms of the compounds described herein are expressly included in this invention.
Methods of Synthesizing Compounds .. [0206] The compounds described herein can be synthesized by conventional methods using commercially available starting materials and reagents. For example, compounds can be synthesized utilizing the methods set forth in U.S. Patent No. 7,501,404, or as described in the methods described herein.
[0207] Compounds described herein can be purified using various techniques in the art of synthetic organic chemistry. A compound described herein can be purified using one or more chromatographic methods, e.g., column chromatography or HPLC. A compound described herein can be purified by a purification method that is not chromatography, e.g., recrystallization or slurrying. In one embodiment, a compound described herein can be purified using recrystallization. In another embodiment, a compound described herein can also be purified by slurrying.
[0208] In some embodiments, a compound described herein that has been purified by chromatography can also be purified by a recrystallization. A compound described herein .. can also be purified by slurrying (or re-slurrying) the compound with one or more solvents, e.g., a slurry described herein. A compound described herein can also be purified by trituration with one or more solvents, e.g., a trituration described herein.
For example, a compound described herein that has been purified by chromatography can also be purified by trituration. In a chemical reactor, the trituration process may be affected by suspension or .. resuspension of a solid product in a solvent or mixture of solvents with mechanical stirring.
In an embodiment, a compound described herein can also be purified by precipitation from a solution using one or more anti-solvents. For example, a compound described herein that has been purified by chromatography can also be purified by precipitation. In one embodiment, a compound described herein is purified by simulated moving bed (SMB) chromatography. In one embodiment, a compound described herein is purified by supercritical fluid chromatography, e.g., supercritical fluid chromatography with liquid carbon dioxide. In one embodiment, a compound described herein is purified by chiral chromatography e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
Methods of Treatment, Prophylaxis, or Reduction of Risk [0209] The compounds described herein (e.g., Compound 1 or a pharmaceutically acceptable salt thereof) can inhibit Factor XIa or kallikrein. In some embodiments, the compounds described herein (e.g., Compound 1 or a pharmaceutically acceptable salt thereof) can inhibit both Factor XIa and kallikrein. As a result, these compounds can be useful in the .. treatment, prophylaxis, or reduction in the risk of a disorder described herein.
[0210] Exemplary disorders include thrombotic events associated with coronary artery and cerebrovascular disease, venous or arterial thrombosis, coagulation syndromes, ischemia (e.g., coronary ischemia) and angina (stable and unstable), deep vein thrombosis (DVT), hepatic vein thrombosis, disseminated intravascular coagulopathy, Kasabach-Merritt syndrome, pulmonary embolism, myocardial infarction (e.g., ST-elevation myocardial infarction or non-ST-elevation myocardial infarction (e.g., non-ST-elevation myocardial infarction before catheterization), cerebral infarction, cerebral thrombosis, transient ischemic attacks, atrial fibrillation (e.g., non-valvular atrial fibrillation), cerebral embolism, thromboembolic complications of surgery (e.g., hip or knee replacement, orthopedic surgery, cardiac surgery, lung surgery, abdominal surgery, or endarterectomy) and peripheral arterial occlusion and may also be useful in treating or preventing myocardial infarction, stroke (e.g., large vessel acute ischemic stroke), angina and other consequences of atherosclerotic plaque .. rupture. The compounds of the invention possessing Factor XIa or kallikrein inhibition activity may also be useful in preventing thromboembolic disorders, e.g., venous thromboembolisms, in cancer patients, including those receiving chemotherapy and/or those with elevated lactase dehydrogenase (LDH) levels, and to prevent thromboembolic events at or following tissue plasminogen activator-based or mechanical restoration of blood vessel patency. The compounds of the invention possessing Factor XIa or kallikrein inhibition activity may also be useful as inhibitors of blood coagulation such as during the preparation, storage and fractionation of whole blood. Additionally, the compounds described herein may be used in acute hospital settings or periprocedurally, where a patient is at risk of a thromboembolic disorder or complication, and also in patients who are in a heightened .. coagulation state, e.g., cancer patients.
[0211] Factor XIa inhibition, according to the present invention, can be a more effective and safer method of inhibiting thrombosis compared to inhibiting other coagulation serine proteases such as thrombin or Factor Xa. Administration of a small molecule Factor XIa inhibitor should have the effect of inhibiting thrombin generation and clot formation with no or substantially no effect on bleeding times and little or no impairment of haemostasis. These results differ substantially from that of other "direct acting" coagulation protease inhibitors (e.g., active-site inhibitors of thrombin and Factor Xa), which demonstrate prolongation of bleeding time and less separation between antithrombotic efficacy and bleeding time prolongation. A preferred method according to the invention comprises administering to a mammal a pharmaceutical composition containing at least one compound of the invention.
[0212] The compounds described herein (e.g., Compound 1 or pharmaceutically acceptable salts thereof) can inhibit kallikrein. As a result, these compounds can be useful in the treatment, prophylaxis, or reduction in the risk of diseases involved in inflammation, such as edema (e.g., cerebral edema, macular edema, and angioedema (e.g., hereditary angioedema)).
.. In some embodiments, the compounds of the invention can be useful in the treatment or prevention of hereditary angioedema. The compounds described herein (e.g., Compound 1) can also be useful in the treatment, prophylaxis, or reduction in the risk of, e.g., stroke, ischemia (e.g., coronary ischemia), and perioperative blood loss for example, Compound 1 or pharmaceutically acceptable salts thereof The methods of the present invention are useful for treating or preventing those conditions which involve the action of Factor XIa or kallikrein. Accordingly, the methods of the present invention are useful in treating consequences of atherosclerotic plaque rupture including cardiovascular diseases associated with the activation of the coagulation cascade in thrombotic or thrombophilic states.
[0213] More particularly, the methods of the present invention can be used in the treatment, prophylaxis, or reduction in the risk of acute coronary syndromes such as coronary artery disease, myocardial infarction, unstable angina (including crescendo angina), ischemia (e.g., ischemia resulting from vascular occlusion), and cerebral infarction. The methods of the present invention further may be useful in the treatment, prophylaxis, or reduction in the risk of stroke (e.g., large vessel acute ischemic stroke) and related cerebral vascular diseases (including cerebrovascular accident, vascular dementia, and transient ischemic attack);
venous thrombosis and thrombo-embolism, such as deep vein thrombosis (DVT) and pulmonary embolism; thrombosis associated with atrial fibrillation, ventricular enlargement, dilated cardiac myopathy, or heart failure; peripheral arterial disease and intermittent claudication; the formation of atherosclerotic plaques and transplant atherosclerosis;
restenosis following arterial injury induced endogenously (by rupture of an atherosclerotic plaque), or exogenously (by invasive cardiological procedures such as vessel wall injury resulting from angioplasty or post-cranial artery stenting); disseminated intravascular coagulopathy, Kasabach-Merritt syndrome, cerebral thrombosis, and cerebral embolism.
[0214] Additionally, the methods of the present invention can be used in the treatment, prophylaxis (e.g., preventing), or reduction in the risk of thromboembolic consequences or complications associated with cancer, thrombectomy, surgery (e.g., hip replacement, orthopedic surgery), endarterectomy, introduction of artificial heart valves, peripheral vascular interventions (e.g., of the limbs), cerebrovascular interventions, large bore interventions used in the treatment of aneurysms, vascular grafts, mechanical organs, and implantation (e.g., trans-catheter aortic valve implantation) or transplantation of organs, (e.g., transplantation of the liver), tissue, or cells); percutaneous coronary interventions; catheter ablation; hemophilia therapy; hemodialysis; medications (such as tissue plasminogen activator or similar agents and surgical restoration of blood vessel patency) in patients suffering myocardial infarction, stroke (e.g., large vessel acute ischemic stroke), pulmonary embolism and like conditions; medications (such as oral contraceptives, hormone replacement, and heparin, e.g., for treating heparin-induced thrombocytopenia); sepsis (such as sepsis related to disseminated intravascular coagulation); pregnancy or childbirth; and another chronic medical condition. The methods of the present invention may be used to treat thrombosis due to confinement (e.g., immobilization, hospitalization, bed rest, or limb immobilization, e.g., with immobilizing casts, etc.). In some embodiments, the thromboembolic consequence or complication is associated with a percutaneous coronary intervention.
[0215] Additionally, the compounds described herein (e.g., Compound 1) or pharmaceutically acceptable salts thereof or compositions thereof can be useful in the treatment, prophylaxis and reduction in the risk of a thromboembolic disorder, e.g., a venous thromboembolism, deep vein thrombosis or pulmonary embolism, or associated complication in a subject, wherein the subject is exposed to an artificial surface. The artificial surface can contact the subject's blood, for example, as an extracorporeal surface or that of an implantable device. Such artificial surfaces include, but are not limited to, those of dialysis catheters, cardiopulmonary bypass circuits, artificial heart valves, e.g., mechanical heart valves (MHVs), ventricular assist devices, small caliber grafts, central venous catheters, extracorporeal membrane oxygenation (ECMO) apparatuses. Further, the thromboembolic disorder or associated complication may be caused by the artificial surface or associated with the artificial surface. For example, foreign surfaces and various components of mechanical heart valves (MHVs) are pro-thrombotic and promote thrombin generation via the intrinsic pathway of coagulation. Further, thrombin and FXa inhibitors are contraindicated with thromboembolic disorders or associated complications caused by artificial surfaces such as those MHVs, as these inhibitors are ineffective at blocking the intrinsic pathway at plasma levels that will not cause heavy bleeding. The compounds of the present invention, which can be used as, for example, Factor XIa inhibitors, are thus contemplated as alternative therapeutics for these purposes.
[0216] The compounds described herein (e.g., Compound 1) or pharmaceutically acceptable salts thereof or compositions thereof can also be useful for the treatment, prophylaxis, or reduction in the risk of atrial fibrillation in a subject in need thereof For example, the subject can have a high risk of developing atrial fibrillation.
The subject can also in need of dialysis, such as renal dialysis. The compounds described herein (e.g., Compound 1) or pharmaceutically acceptable salts thereof or compositions thereof can be administered before, during, or after dialysis. Direct oral anticoagulants (DOACs) currently available on the market, such as certain FXa or thrombin inhibitors, are contraindicated for atrial fibrillation under such a condition. The compounds of the present invention, which can be used as, for example, Factor XIa inhibitors, are thus contemplated as alternative therapeutics for these purposes. Additionally, the subject can be at a high risk of bleeding. In some embodiments, the subject can have end-stage renal disease. In other cases, the subject is not in need of dialysis, such as renal dialysis. Further, the atrial fibrillation can be associated with another thromboembolic disorder such as a blood clot.
[0217] Furthermore, the compounds described herein (e.g., Compound 1) or pharmaceutically acceptable salts thereof or compositions thereof can be used in the treatment, prophylaxis, or reduction in the risk of hypertension, e.g., arterial hypertension, in a subject. In some embodiments, the hypertension, e.g., arterial hypertension, can result in atherosclerosis. In some embodiments, the hypertension can be pulmonary arterial hypertension.
[0218] Furthermore, the compounds described herein (e.g., Compound 1) or pharmaceutically acceptable salts thereof or compositions thereof can be used in the treatment, prophylaxis, or reduction in the risk of disorders such as heparin-induced thrombocytopenia, heparin-induced thrombocytopenia thrombosis, or thrombotic microangiopathy, e.g., hemolytic uremic syndrome (HUS) or thrombotic thrombocytopenic purpura (TTP).
[0219] In some embodiments, the subject is sensitive to or has developed sensitivity to heparin. Heparin-induced thrombocytopenia (HIT) is the development of (a low platelet count), due to the administration of various forms of heparin.
HIT is caused by the formation of abnormal antibodies that activate platelets. HIT can be confirmed with specific blood tests. In some embodiments, the subject is resistant to or has developed resistance to heparin. For example, activated clotting time (ACT) test can be performed on the subject to test for sensitivity or resistance towards heparin. The ACT
test is a measure of the intrinsic pathway of coagulation that detects the presence of fibrin formation. A subject who is sensitive and/or resistant to standard dose of heparin typically do not reach target anticoagulation time. Common correlates of heparin resistance include, but are not limited to, previous heparin and/or nitroglycerin drips and decreased antithrombin III
levels. In some embodiments, the subject has previously been administered an anticoagulant (e.g.
bivalirudin/Angiomax).
[0220] The compounds described herein (e.g., Compound 1) or pharmaceutically acceptable salts thereof or compositions thereof can be used to reduce inflammation in a subject. In some embodiments, the inflammation can be vascular inflammation.
In some embodiments, the vascular inflammation can be accompanied by atherosclerosis.
In some embodiments, the vascular inflammation can be accompanied by a thromboembolic disease in the subject. In some embodiments, the vascular inflammation can be angiotensin II-induced vascular inflammation.
[0221] The compounds described herein (e.g., Compound 1) or pharmaceutically acceptable salts thereof or compositions thereof can be used in the treatment, prophylaxis, or reduction in the risk of renal disorders or dysfunctions, including end-stage renal disease, hypertension-associated renal dysfunction in a subject, kidney fibrosis, and kidney injury.
[0222] The methods of the present invention may also be used to maintain blood vessel potency, for example, in patients undergoing thrombectomy, transluminal coronary angioplasty, or in connection with vascular surgery such as bypass grafting, arterial reconstruction, atherectomy, vascular grafts, stent potency, and organ, tissue or cell implantation and transplantation. The inventive methods may be used to inhibit blood coagulation in connection with the preparation, storage, fractionation, or use of whole blood.
For example, the inventive methods may be used in maintaining whole and fractionated blood in the fluid phase such as required for analytical and biological testing, e.g., for ex vivo platelet and other cell function studies, bioanalytical procedures, and quantitation of blood-containing components, or for maintaining extracorporeal blood circuits, as in a renal replacement solution (e.g., hemodialysis) or surgery (e.g., open-heart surgery, e.g., coronary artery bypass surgery). In some embodiments, the renal replacement solution can be used to treat patients with acute kidney injury. In some embodiments, the renal replacement solution can be continuous renal replacement therapy.
[0223] In addition, the methods of the present invention may be useful in treating and preventing the prothrombotic complications of cancer. The methods may be useful in treating tumor growth, as an adjunct to chemotherapy, for preventing angiogenesis, and for treating cancer, more particularly, cancer of the lung, prostate, colon, breast, ovaries, and bone.
Extracorporeal Membrane Oxygenation (ECMO) [0224] "Extracorporeal membrane oxygenation" (or "ECMO") as used herein, refers to extracorporeal life support with a blood pump, artificial lung, and vascular access cannula, capable of providing circulatory support or generating blood flow rates adapted to support blood oxygenation, and optionally carbon dioxide removal. In venovenous ECMO, extracorporeal gas exchange is provided to blood that has been withdrawn from the venous system; the blood is then reinfused to the venous system. In venoarterial ECMO, gas exchange is provided to blood that is withdrawn from the venous system and then infused directly into the arterial system to provide partial or complete circulatory or cardiac support.
.. Venoarterial ECMO allows for various degrees of respiratory support.
[0225] As used herein, "extracorporeal membrane oxygenation" or "ECMO" refers to extracorporeal life support that provides circulatory support or generates blood flow rates adequate to support blood oxygenation. In some embodiments, ECMO comprises removal of carbon dioxide from a subject's blood. In some embodiments, ECMO is performed using an extracorporeal apparatus selected from the group consisting of a blood pump, artificial lung, and vascular access cannula.
[0226] As used herein, "venovenous ECMO" refers to a type of ECMO in which blood is withdrawn from the venous system of a subject into an ECMO apparatus and subjected to gas exchange (including oxygenation of the blood), followed by reinfusion of the withdrawn blood into the subject's venous system. As used herein, "venoarterial ECMO"
refers to a type of ECMO in which blood is withdrawn from the venous system of a subject into an ECMO apparatus and subjected to gas exchange (including oxygenation of the blood), followed by infusion of the withdrawn blood directly into the subject's arterial system. In some embodiments, venoarterial ECMO is performed to provide partial circulatory or cardiac support to a subject in need thereof In some embodiments, venoarterial ECMO is performed to provide complete circulatory or cardiac support to a subject in need thereof [0227] The compounds of the present invention can be used in the treatment, prophylaxis, or reduction in the risk of a thromboembolic disorder in a subject in need thereof, wherein the subject is exposed to an artificial surface such as that of an extracorporeal membrane oxygenation (ECMO) apparatus (vide supra), which can be used as a rescue therapy in response to cardiac or pulmonary failure. The surface of an ECMO apparatus that directly contacts the subject can be a pro-thrombotic surface that can result in a thromboembolic disorder such as a venous thromboembolism, e.g., deep vein thrombosis or pulmonary embolism, leading to difficulties in treating a patient in need of ECMO. Clots in the circuit are the most common mechanical complication (19 %). Major clots can cause oxygenator failure, and pulmonary or systemic emboli.
[0228] ECMO is often administered with a continuous infusion of heparin as an anticoagulant to counter clot formation. However, cannula placement can cause damage to the internal jugular vein, which causes massive internal bleeding. Bleeding occurs in 30 - 40 % of patients receiving ECMO and can be life-threatening. This severe bleeding is due to both the necessary continuous heparin infusion and platelet dysfunction.
Approximately 50%
of reported deaths are due to severe bleeding complications. Aubron et al.
Critical Care, 2013, 17:R73 looked at the factors associated with ECMO outcomes.
[0229] The compounds of the present invention, which can be used as, for example, Factor XIa inhibitors, are thus contemplated as an alternative replacement for heparin in ECMO
therapy. The compounds of the present invention are contemplated as effective agents for blocking the intrinsic pathway at plasma levels that will afford effective anti-coagulation/anti-thrombosis without marked bleeding liabilities. In some embodiments, the subject is sensitive to or has developed sensitivity to heparin. In some embodiments, the subject is resistant to or has developed resistance to heparin.
Ischemia [0230] "Ischemia" or an "ischemic event" is a vascular disease generally involving vascular occlusion or a restriction in blood supply to tissues. Ischemia can cause a shortage of oxygen and glucose needed for cellular metabolism. Ischemia is generally caused by problematic blood vessels that result in damage or dysfunction of tissue. Ischemia can also refer to a local loss in blood or oxygen in a given part of the body resulting from congestion (e.g., .. vasoconstriction, thrombosis, or embolism). Causes include embolism, thrombosis of an atherosclerosis artery, trauma, venous problems, aneurysm, heart conditions (e.g., myocardial infarction, mitral valve disease, chronic arterial fibrillation, cardiomyopathies, and prosthesis), trauma or traumatic injury (e.g., to an extremity producing partial or total vessel occlusion), thoracic outlet syndrome, atherosclerosis, hypoglycemia, tachycardia, hypotension, outside compression of a blood vessel (e.g., by a tumor), sickle cell disease, localized extreme cold (e.g., by frostbite), tourniquet application, glutamate receptor stimulation, arteriovenous malformations, rupture of significant blood vessels supplying a tissue or organ, and anemia.
[0231] A transient ischemic event generally refers to a transient (e.g., short-lived) episode of neurologic dysfunction caused by loss of blood flow (e.g., in the focal brain, spinal cord, or retinal) without acute infarction (e.g., tissue death). In some embodiments, the transient ischemic event lasts for less than 72 hours, 48 hours, 24 hours, 12 hours, 10 hours, 8 hours, 4 hours, 2 hours, 1 hour, 45 minutes, 30 minutes, 20 minutes, 15 minutes, 10 minutes, 5 minutes, 4 minutes, 3 minutes, 2 minutes, or 1 minute.
Angioedema [0232] Angioedema is the rapid swelling of the dermis, subcutaneous tissue, mucosa, and submucosal tissues. Angioedema is typically classified as either hereditary or acquired.
[0233] "Acquired angioedema" can be immunologic, non-immunologic, or idiopathic;
caused by e.g., allergy, as a side effect of medications, e.g., ACE inhibitor medications.
[0234] "Hereditary angioedema" or "HAE" refers to a genetic disorder that results in acute periods of edema (e.g., swelling) that may occur in nearly all parts of the body, including the face, limbs, neck, throat, larynx, extremities, gastrointestinal tract, and genitalia. Attacks of HAE can often be life-threatening, with severity depending on the area affected, e.g., abdominal attacks may result in intestinal obstruction, while swelling of the larynx and upper airway can lead to asphyxiation. Pathogenesis of hereditary angioedema may be related to unopposed activation of the contact pathway by the initial generation of kallikrein or clotting factors (e.g., Factor XII).
[0235] Signs and symptoms include swelling, e.g., of the skill of the face, mucosa of the mouth or throat, and tongue. Itchiness, pain, decreased sensation in the affected areas, urticaria (i.e., hives), or stridor of the airway may also be a sign of angioedema. However, there can be no associated itch, or urticaria, e.g., in hereditary angioedema.
HAE subjects can experience abdominal pain (e.g., abdominal pain lasting one to five days, abdominal attacks increasing a subject's white blood cell count), vomiting, weakness, watery diarrhea, or rash.
[0236] Bradykinin plays an important role in angioedema, particularly hereditary angioedema. Bradykinin is released by various cell types in response to numerous different stimuli and is a pain mediator. Interfering with bradykinin production or degradation can lead to angioedema. In hereditary angioedema, continuous production of enzyme kallikrein can facilitate bradykinin formation. Inhibition of kallikrein can interfere with bradykinin production; and treat or prevent angioedema.
[0237] The methods described herein may comprise administering to a subject in need thereof an effective amount of a pharmaceutical composition described herein.
[0238] In an aspect, the methods described herein can include those in which a subject's blood is in contact with an artificial surface. For example, provided herein is a method of treating a thromboembolic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition described herein, wherein the blood of the subject is contacted with an artificial surface.
[0239] In another aspect, provided herein is a method of reducing the risk of a thromboembolic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition described herein, wherein the blood of the subject is contacted with an artificial surface.
[0240] Also provided herein is a method of prophylaxis of a thromboembolic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition described herein, wherein the blood of the subject is contacted with an artificial surface.
[0241] In some embodiments of the methods described herein, the artificial surface is in contact with blood in the subject's circulatory system.
[0242] In some embodiments, the artificial surface is an implantable device, a dialysis catheter, a cardiopulmonary bypass circuit, an artificial heart valve, a ventricular assist device, a small caliber graft, a central venous catheter, or an extracorporeal membrane oxygenation (ECMO) apparatus.
[0243] In some embodiments, the artificial surface causes or is associated with the thromboembolic disorder.
[0244] In some embodiments, the thromboembolic disorder is a venous thromboembolism, deep vein thrombosis, or pulmonary embolism.
[0245] In some embodiments, the thromboembolic disorder is a blood clot.
[0246] In some embodiments, the methods described herein further comprises conditioning the artificial surface with a separate dose of a pharmaceutical composition described herein prior to contacting the artificial surface with blood in the circulatory system of the subject.
[0247] In some embodiments, the methods described herein further comprises conditioning the artificial surface with a separate dose of a pharmaceutical composition described herein prior to or during administration of the pharmaceutical composition to the subject.
[0248] In some embodiments, the methods described herein further comprises conditioning the artificial surface with a separate dose of a pharmaceutical composition described herein prior to and during administration of the pharmaceutical composition to the subject.
[0249] In some embodiments of the methods described herein, the artificial surface is a cardiopulmonary bypass circuit.
[0250] In some embodiments of the methods described herein, the artificial surface is an extracorporeal membrane oxygenation (ECMO) apparatus. In some embodiments, the ECMO
apparatus is venovenous ECMO apparatus or venoarterial ECMO apparatus.
[0251] In another aspect, disclosed herein is a method of preventing or reducing a risk of a thromboembolic disorder in a subject during or after a medical procedure, comprising:
(i) administering to the subject an effective amount of a pharmaceutical composition described herein, before, during, or after the medical procedure; and (ii) contacting blood of the subject with an artificial surface;
thereby preventing or reducing the risk of the thromboembolic disorder during or after the medical procedure.
[0252] In some embodiments, the artificial surface is conditioned with a pharmaceutical composition described herein prior to administration of the pharmaceutical composition to the subject prior to, during, or after the medical procedure.
[0253] In some embodiments, the pharmaceutical composition for conditioning the artificial surface further comprises a solution, wherein the solution is selected from the group consisting of a saline solution, Ringer's solution, and blood.
[0254] In some embodiments, the thromboembolic disorder is a blood clot.
[0255] In some embodiments, the medical procedure comprises one or more of i) a cardiopulmonary bypass, ii) oxygenation and pumping of blood via extracorporeal membrane oxygenation, iii) assisted pumping of blood (internal or external), iv) dialysis of blood, v) extracorporeal filtration of blood, vi) collection of blood from the subject in a repository for later use in an animal or a human subject, vii) use of venous or arterial intraluminal catheter(s), viii) use of device(s) for diagnostic or interventional cardiac catherisation, ix) use of intravascular device(s), x) use of artificial heart valve(s), and xi) use of artificial graft(s).
[0256] In some embodiments, the medical procedure comprises a cardiopulmonary bypass.
[0257] In some embodiments, the medical procedure comprises an oxygenation and pumping of blood via extracorporeal membrane oxygenation (ECMO). In some embodiments, the ECMO is venovenous ECMO or venoarterial ECMO.
[0258] In some embodiments of the methods described herein, the subject is in contact with the artificial surface for at least 1 day (e.g., about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 2 months, about 3 months, about 6 months, about 9 months, about 1 year).
[0259] In another aspect, provided herein is a method of treating the blood of a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition described herein.
[0260] In some embodiments of the methods described herein, the pharmaceutical composition is administered to the subject intravenously. In other embodiments of the methods described herein, the pharmaceutical composition is administered to the subject subcutaneously. In some embodiments, the pharmaceutical composition is administered to the subject as a continuous intravenous infusion. In some embodiments, the pharmaceutical composition is administered to the subject as a bolus.
[0261] In some embodiments, the subject is a human. In some embodiments, the subject has an elevated risk of a thromboembolic disorder. In some embodiments, the thromboembolic disorder is a result of a complication in surgery. In some embodiments, the subject is sensitive to or has developed sensitivity to heparin. In some embodiments, the subject is resistant to or has developed resistance to heparin.
Pharmaceutical Compositions [0262] The compositions described herein include the compound described herein (e.g., Compound 1 or a pharmaceutically acceptable salt thereof) as well as additional therapeutic agents, if present, in amounts effective for achieving the treatment of a disease or disease symptoms (e.g., such as a disease associated with Factor XIa or kallikrein).
[0263] Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions provided herewith include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-a-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as a-, (3-, and y-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-P-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.
[0264] The pharmaceutical compositions may be in the form of a solid composition (e.g., lyophilized composition) that can be reconstituted by addition of a compatible reconstitution diluent prior to parenteral administration or in the form of a frozen composition adapted to be thaws and, if desired, diluted with a compatible diluent prior to parenteral administration. In some embodiments, the pharmaceutical composition includes particles or a powder (e.g., lyophilized composition) dissolved in an aqueous medium, (e.g., a saline solution, dextrose solution) in a unit dosage IV bag or bottle at a concentration suitable for intravenous administration to a subject. In some embodiments, ingredients of a pharmaceutical composition suitable for intravenous administration are separated from each other in a single container, e.g., a powder comprising a compound described herein or a pharmaceutically acceptable salt thereof, is separated from an aqueous medium such as a saline solution. In this latter example, the various components are separated by a seal that can be broken to contact the ingredients with each other to form the pharmaceutical composition suitable for intravenous administration.
[0265] In an aspect, provided herein is an aqueous pharmaceutical composition comprising a compound of Formula (I-A) 0 (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and an excipient.
[0266] In some embodiments, the pharmaceutical composition comprises the compound of Formula (I-A), the cyclodextrin, and the excipient. In some embodiments, the cyclodextrin is selected from the group consisting of alkyl cyclodextrin, hydroxyalkyl cyclodextrin, carboxyalkyl cyclodextrin, and sulfoalkyl ether cyclodextrin. In some embodiments, the cyclodextrin is hydroxypropyl 3-cyclodextrin. In some embodiments, the cyclodextrin is sulfobutyl ether 3-cyclodextrin.
[0267] In some embodiments, the excipient is a sugar (e.g., a saccharide (e.g., monosaccharide, disaccharide, or polysaccharide)) or a sugar alcohol. For example, the excipient is sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, or mannitol, or a combination thereof In some embodiments, the excipient is mannitol. In some embodiments, the excipient is lactose.
[0268] In some embodiments, the pharmaceutical composition described herein further comprises a buffer. In some embodiments, the buffer is a monoprotic acid or a polyprotic acid or a combination thereof In some embodiments, the buffer is a solution of one or more substances. In some embodiments, the buffer is a solution of a salt of a weak acid and a weak base. In some embodiments, the buffer is a solution of a salt of the weak acid with a strong base. In some embodiments, the buffer is selected from the group consisting of a maleate buffer, a citrate buffer, and a phosphate buffer. In some embodiments, the buffer is a phosphate buffer. In some embodiments, the phosphate buffer is a solution of monosodium phosphate, disodium phosphate, trisodium phosphate, or a combination thereof [0269] In some embodiments, the pharmaceutical composition further comprises a solubilizing agent. In some embodiments, the solubilizing agent is a polyoxyethylene sorbitan ester (e.g, TWEENO 20) or a polyethylene glycol (e.g., PEG400).
[0270] In some embodiments, the solubilizing agent is in an amount of from about 0.01%
to about 1%, about 0.01% to about 0.9%, about 0.01% to about 0.8%, about 0.01%
to about 0.7%, about 0.01% to about 0.6, about 0.01% to about 0.5%, about 0.01% to about 0.4%, about 0.01% to about 0.3%, about 0.01% to about 0.2%, about 0.01% to about 0.1%, or about 0.01% to about 0.05% by weight relative to weight of the compound of Formula (I-A).
[0271] In some embodiments, the pH of the composition is from about 2 to about 8 (e.g., from about 3 to about 7, from about 4 to about 7, from about 5 to about 6, from about 6 to about 7, from about 6 to about 8, from about 5 to about 8, from about 4 to about 8, or from about 3 to about 8). In some embodiments, the pH is from about 6 to about 8.
In some embodiments, the pH is about 6 to about 7. In some embodiments, the pH is about 7. In some embodiments, the pH is about 6.8.
[0272] In some embodiments, the concentration of the compound of Formula (I-A) is from about 0.1 mg/mL to about 100 mg/mL, about 0.1 mg/mL to about 80 mg/mL, about 0.1 mg/mL to about 60 mg/mL, about 0.1 mg/mL to about 40 mg/mL, about 0.1 mg/mL to about 20 mg/mL, about 0.1 mg/mL to about 10 mg/mL, about 1 mg/mL to about 100 mg/mL, about 1 mg/mL to about 80 mg/mL, about 1 mg/mL to about 60 mg/mL, about 1 mg/mL to about mg/mL, about 1 mg/mL to about 20 mg/mL, about 1 mg/mL to about 10 mg/mL, about mg/mL to about 100 mg/mL, about 10 mg/mL to about 80 mg/mL, about 10 mg/mL to about 60 mg/mL, about 10 mg/mL to about 40 mg/mL, about 20 mg/mL to about 100 mg/mL, about 20 mg/mL to about 80 mg/mL, about 20 mg/mL to about 60 mg/mL, about 40 mg/mL
to about 100 mg/mL, about 40 mg/mL to about 80 mg/mL, about 60 mg/mL to about mg/mL, about 60 mg/mL to about 80 mg/mL, or about 80 mg/mL to about 100 mg/mL.
[0273] In some embodiments, the concentration of the compound of Formula (I-A) is about 0.1 mg/mL, about 1 mg/mL, about 2.5 mg/mL, about 5 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35 mg/mL, about mg/mL, about 45 mg/mL, or about 50 mg/mL. In some embodiments, the concentration of the compound of Formula (I-A) is about 10 mg/mL. In some embodiments, the concentration of the compound of Formula (I-A) is about 3 mg/mL. In some embodiments, the concentration of the compound of Formula (I-A) is about 1 mg/mL.
[0274] In some embodiments, the concentration of the buffer is from about 1 mM
to about 500 mM, about 1 mM to about 250 mM, about 1 mM to about 100 mM, about 1 mM to about 50 mM, about 1 mM to about 20 mM, about 1 mM to about 10 mM, 10 mM to about mM, about 10 mM to about 250 mM, about 10 mM to about 100 mM, about 10 mM to about 50 mM, about 10 mM to about 20 mM, about 20 mM to about 500 mM, about 20 mM to about 250 mM, about 20 mM to about 100 mM, about 20 mM to about 50 mM, about 50 mM
to about 500 mM, about 50 mM to about 250 mM, about 50 mM to about 100 mM, about 100 mM to about 500 mM, or about 100 mM to about 250 mM.
[0275] In some embodiments, the concentration of the buffer is about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 40 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 210 mM, about 220 mM, about mM, about 240 mM, about 250 mM, about 300 mM, about 350 mM, about 400 mM, about 450 mM, or about 500 mM. In some embodiments, the concentration of the buffer is about 10 mM.
[0276] In some embodiments, the buffer is a phosphate buffer.
[0277] In some embodiments, the concentration of the phosphate buffer is from about 1 mM to about 500 mM, about 1 mM to about 250 mM, about 1 mM to about 100 mM, about 1 mM to about 50 mM, about 1 mM to about 20 mM, about 1 mM to about 10 mM, 10 mM
to about 500 mM, about 10 mM to about 250 mM, about 10 mM to about 100 mM, about mM to about 50 mM, about 10 mM to about 20 mM, about 20 mM to about 500 mM, about 20 mM to about 250 mM, about 20 mM to about 100 mM, about 20 mM to about 50 mM, about 50 mM to about 500 mM, about 50 mM to about 250 mM, about 50 mM to about mM, about 100 mM to about 500 mM, or about 100 mM to about 250 mM.
[0278] In some embodiments, the concentration of the phosphate buffer is about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 40 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM, about mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 210 mM, about 220 mM, about 230 mM, about 240 mM, about 250 mM, about 300 mM, about 350 mM, about mM, about 450 mM, or about 500 mM. In some embodiments, the concentration of the phosphate buffer is about 10 mM.
[0279] In some embodiments, the cyclodextrin is in an amount of from about 0.1% to about 10%, about 0.1% to about 7.5%, about 0.1% to about 5%, about 0.1% to about 3.5%, about 0.1% to about 1%, about 1% to about 10%, about 1% to about 7.5%, about 1% to about 5%, about 3% to about 10%, about 3% to about 7.5%, or about 3% to about 5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of about 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5% or 5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of from about 0.1% to about 10% (e.g., about 0.5% to about 6% (e.g., about 0.7% to about 5.6% (e.g., about 2.1 % to about 5%))) by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of about 3.5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of about 5% by weight relative to weight of the compound of Formula (I-A).
[0280] In some embodiments, the cyclodextrin is hydroxypropyl 0-cyclodextrin.
[0281] In some embodiments, the excipient is in an amount of from about 0.1%
to about 10%, about 0.1% to about 7.5%, about 0.1% to about 5%, about 0.1% to about 3.5%, about 0.1% to about 1%, about 1% to about 30%, about 1% to about 20%, about 1% to about 10%, about 1% to about 7.5%, about 1% to about 5%, about 3% to about 10%, about 3%
to about 7.5%, about 3% to about 5%, about 3% to about 20%, about 3% to about 30%, about 5% to about 20%, or about 5% to about 30% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the excipient is in an amount of about 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 10%, 20%, or 30% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the excipient is in an amount of about 3% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the excipient is an amount of about 5% by weight relative to weight of the compound of Formula (I-A).
[0282] In some embodiments, the excipient agent is mannitol. In some embodiments, the excipient is lactose.
[0283] In another aspect, provided herein is a lyophilized formulation comprising of a composition which prior to lyophilization corresponds to an aqueous pharmaceutical composition described herein (e.g., an aqueous pharmaceutical composition comprising a compound of Formula (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and an excipient). In some embodiments, the lyophilized formulation as described herein is reconstituted in an aqueous medium, thereby preparing an aqueous pharmaceutical solution suitable for parenteral administration to a subject in need thereof [0284] In another aspect, provided herein is a pharmaceutical composition comprising particles, wherein the particles comprise a compound of Formula (I-A) ?"-Oiro ,-NyN
0 (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and a bulking agent.
[0285] In some embodiments, the pharmaceutical composition comprises the compound of Formula (I-A), the cyclodextrin, and the bulking agent. In some embodiments, the cyclodextrin is selected from the group consisting of alkyl cyclodextrin, hydroxyalkyl cyclodextrin, carboxyalkyl cyclodextrin, and sulfoalkyl ether cyclodextrin. In some embodiments, the cyclodextrin is hydroxypropyl 0-cyclodextrin. In some embodiments, the cyclodextrin is sulfobutyl ether 0-cyclodextrin.
[0286] In some embodiments, the bulking agent is a sugar (e.g., a saccharide (e.g., monosaccharide, disaccharide, or polysaccharide)) or a sugar alcohol. In some embodiments, the bulking agent is sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, or mannitol, or a combination thereof In some embodiments, the bulking agent is mannitol.
In some embodiments, the bulking agent is lactose.
[0287] In some embodiments, the bulking agent is a lyoprotectant.
[0288] In some embodiments, the concentration of the compound of Formula (I-A) is from about 0.1% to about 10%, about 0.1% to about 7.5%, about 0.1% to about 5%, about 0.1% to about 3.5%, about 0.1% to about 1%, about 1% to about 10%, about 1% to about 7.5%, about 1% to about 5%, about 3% to about 10%, about 3% to about 7.5%, or about 3% to about 5%
by weight of the composition. In some embodiments, the concentration of the compound of Formula (I-A) is about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% by weight of the composition. In some embodiments, the concentration of the compound of Formula (I-A) is about 1% by weight of the composition. In some embodiments, the concentration of the compound of Formula (I-A) is about 0.3% by weight of the composition.
[0289] In some embodiments, the cyclodextrin is in an amount of from about 0.1% to about 10%, about 0.1% to about 7.5%, about 0.1% to about 5%, about 0.1% to about 3.5%, about 0.1% to about 1%, about 1% to about 10%, about 1% to about 7.5%, about 1% to about 5%, about 3% to about 10%, about 3% to about 7.5%, or about 3% to about 5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of about 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5% or 5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of from about 0.1% to about 10% (e.g., about 0.5% to about 6% (e.g., about 0.7% to about 5.6% (e.g., about 2.1 % to about 5%))) by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of about 3.5% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the cyclodextrin is in an amount of about 5% by weight relative to weight of the compound of Formula (I-A).
[0290] In some embodiments, the cyclodextrin is hydroxypropyl 0-cyclodextrin.
[0291] In some embodiments, the excipient is in an amount of from about 0.1%
to about 10%, about 0.1% to about 7.5%, about 0.1% to about 5%, about 0.1% to about 3.5%, about 0.1% to about 1%, about 1% to about 30%, about 1% to about 20%, about 1% to about 10%, about 1% to about 7.5%, about 1% to about 5%, about 3% to about 10%, about 3%
to about 7.5%, about 3% to about 5%, about 3% to about 20%, about 3% to about 30%, about 5% to about 20%, or about 5% to about 30% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the excipient is in an amount of about 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 10%, 20%, or 30% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the excipient is in an amount of about 3% by weight relative to weight of the compound of Formula (I-A). In some embodiments, the excipient is an amount of about 5% by weight relative to weight of the compound of Formula (I-A).
[0292] In some embodiments, the excipient agent is mannitol. In some embodiments, the excipient is lactose.
[0293] In another aspect, provided herein is a process for preparing an aqueous pharmaceutical composition from the pharmaceutical composition described herein (e.g., a pharmaceutical composition comprising particles, wherein the particles comprise a compound of Formula (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and a bulking agent), the process comprising reconstituting the pharmaceutical composition into an aqueous medium, thereby forming the aqueous composition. In some embodiments, the aqueous medium is deionized water. In some embodiments, the aqueous medium comprises sodium chloride. In some embodiments, the aqueous medium comprises about 5% dextrose.
[0294] In some embodiments, the composition is prepared to be suitable for parenteral administration to a subject in need thereof In some embodiments, the composition is prepared to be suitable for intramuscular, subcutaneous or intravenous administration to a subject in need thereof [0295] In some embodiments, the pH of the reconstituted composition is from about 2 to about 8 (e.g., from about 3 to about 7, from about 4 to about 7, from about 5 to about 6, from about 6 to about 7, from about 6 to about 8, from about 5 to about 8, from about 4 to about 8, or from about 3 to about 8). In some embodiments, the pH of the reconstituted composition is from about 6 to about 8. In some embodiments, the pH of the reconstituted composition is about 6 to about 7. In some embodiments, the pH of the reconstituted composition is about 7.
In some embodiments, the pH of the reconstituted composition is about 6.8.
[0296] In some embodiments, the concentration of the compound of Formula (I-A) in the reconstituted composition is from about 0.01 mg/mL to about 100 mg/mL, about 0.01 mg/mL
to about 50 mg/mL, about 0.01 mg/mL to about 10 mg/mL, about 0.01 mg/mL to about 1 mg/mL, about 0.01 mg/mL to about 0.1 mg/mL, about 0.1 mg/mL to about 100 mg/mL, about 0.1 mg/mL to about 80 mg/mL, about 0.1 mg/mL to about 60 mg/mL, about 0.1 mg/mL to about 40 mg/mL, about 0.1 mg/mL to about 20 mg/mL, about 0.1 mg/mL to about 10 mg/mL, about 1 mg/mL to about 100 mg/mL, about 1 mg/mL to about 80 mg/mL, about 1 mg/mL to about 60 mg/mL, about 1 mg/mL to about 40 mg/mL, about 1 mg/mL to about 20 mg/mL, about 1 mg/mL to about 10 mg/mL, about 10 mg/mL to about 100 mg/mL, about 10 mg/mL to about 80 mg/mL, about 10 mg/mL to about 60 mg/mL, about 10 mg/mL to about mg/mL, about 20 mg/mL to about 100 mg/mL, about 20 mg/mL to about 80 mg/mL, about 20 mg/mL to about 60 mg/mL, about 40 mg/mL to about 100 mg/mL, about 40 mg/mL
to about 80 mg/mL, about 60 mg/mL to about 100 mg/mL, about 60 mg/mL to about mg/mL, or about 80 mg/mL to about 100 mg/mL.
[0297] In some embodiments, the concentration of the compound of Formula (I-A) in the reconstituted formulation is about 0.01 mg/mL, 0.03 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.3 mg/mL, 0.5 mg/mL, about 1 mg/mL, about 2.5 mg/mL, about 5 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35 mg/mL, about 40 mg/mL, about 45 mg/mL, or about 50 mg/mL. In some embodiments, the concentration of the compound of Formula (I-A) is about 10 mg/mL. In some embodiments, the concentration of the compound of Formula (I-A) is about 1 mg/mL. In some embodiments, the concentration of the compound of Formula (I-A) is about 0.1 mg/mL. In some embodiments, the concentration of the compound of Formula (I-A) is about 0.3 mg/mL.
In some embodiments, the concentration of the compound of Formula (I-A) is about 0.03 mg/mL.
Routes of Administration [0298] The pharmaceutical compositions provided herewith may be administered orally, rectally, or parenterally (e.g., intravenous infusion, intravenous bolus injection, inhalation, implantation). The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous (e.g., intravenous infusion, intravenous bolus injection), intranasal, inhalation, pulmonary, transdermal, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or other infusion techniques. The pharmaceutical compositions provided herewith may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
[0299] The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous solution or suspension.
This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides.
Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation. In some embodiments, the intravenous pharmaceutical composition comprises a carrier selected from the group consisting of 5% w/w dextrose water ("5DW") and saline.
[0300] The pharmaceutical compositions provided herewith may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying or suspending agents. If desired, certain sweetening or flavoring or coloring or taste masking agents may be added.
[0301] The compounds described herein can, for example, be administered by injection, intravenously (e.g., intravenous infusion, intravenous bolus injection), intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically with a dosage ranging from about 0.5 to about 100 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug. The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions provided herewith will be administered from about 1 to about 6 times per day (e.g., by intravenous bolus injection) or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations contain from about 20% to about 80% active compound.
[0302] In some embodiments, the compound or pharmaceutical composition is administered to the subject intravenously. In some embodiments, the compound or pharmaceutical composition is administered to the subject subcutaneously. In some embodiments, the compound or pharmaceutical composition is administered to the subject as a continuous intravenous infusion. In some embodiments, the compound or pharmaceutical composition is administered to the subject as a bolus. In some embodiments, the compound or pharmaceutical composition is administered to the subject as a bolus followed by a continuous intravenous infusion.
[0303] In some embodiments, a pharmaceutical composition formulated for subcutaneous administration or intravenous administration is administered to a subject from 1 time per day to 6 times per day (e.g., 1 time per day, 2 times per day, or 4 times per day).
Combinations [0304] In carrying out the methods of the present invention, it may be desired to administer the compounds of the invention (e.g., Factor XIa or kallikrein inhibitors) in combination with each other and one or more other agents for achieving a therapeutic benefit such as antithrombotic or anticoagulant agents, anti-hypertensive agents, anti-ischemic agents, anti-arrhythmic agents, platelet function inhibitors, and so forth. For example, the methods of the present invention may be carried out by administering the small molecule Factor XIa or kallikrein inhibitors in combination with a small molecule Factor XIa or kallikrein inhibitor.
More particularly, the inventive methods may be carried out by administering the small molecule Factor XIa or kallikrein inhibitors in combination with aspirin, clopidogrel, ticlopidine or CS-747, warfarin, low molecular weight heparins (such as LOVENOX), GPIIb/GPIIIa blockers, PAI-1 inhibitors such as XR-330 and T-686, P2Y1 and receptor antagonists; thromboxane receptor antagonists (such as ifetroban), prostacyclin mimetics, thromboxane A synthetase inhibitors (such as picotamide), serotonin-2-receptor antagonists (such as ketanserin); compounds that inhibit other coagulation factors such as FVII, FVIII, FIX, FX, prothrombin, TAFI, and fibrinogen, or other compounds that inhibit FXI or kallikrein; fibrinolytics such as TPA, streptokinase, PAI-1 inhibitors, and inhibitors of Eli -2-antiplasmin such as anti-0 -2-antiplasmin antibody fibrinogen receptor antagonists, inhibitors of -1-antitrypsin, hypolipidemic agents, such as HMG-CoA reductase inhibitors (e.g., pravastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, AZ4522, and itavastatin), and microsomal triglyceride transport protein inhibitors (such as disclosed in U.S. Pat. Nos.
5,739,135, 5,712,279 and 5,760,246); antihypertensive agents such as angiotensin-converting enzyme inhibitors (e.g., captopril, lisinopril or fosinopril); angiotensin-II
receptor antagonists (e.g., irbesartan, losartan or valsartan); ACE/NEP inhibitors (e.g., omapatrilat and gemopatrilat); or 0-blockers (such as propranolol, nadolol and carvedilol).
The inventive methods may be carried out by administering the small molecule Factor XIa or kallikrein inhibitors in combination with anti-arrhythmic agents such as for atrial fibrillation, for example, amiodarone or dofetilide. The inventive methods may also be carried out in combination continuous renal replacement therapy for treating, e.g., acute kidney injury.
[0305] In carrying out the methods of the present invention, it may be desired to administer the compounds of the invention (Factor XIa or kallikrein inhibitors) in combination with agents that increase the levels of cAMP or cGMP in cells for a therapeutic benefit. For example, the compounds of the invention may have advantageous effects when used in combination with phosphodiesterase inhibitors, including PDE1 inhibitors (such as those described in Journal of Medicinal Chemistry, Vol. 40, pp. 2196-2210 [19971), inhibitors, PDE3 inhibitors (such as revizinone, pimobendan, or olprinone), PDE4 inhibitors (such as rolipram, cilomilast, or piclamilast), PDE7 inhibitors, or other PDE
inhibitors such as dipyridamole, cilostazol, sildenafil, denbutyline, theophylline (1,2-dimethylxanthine), ARIFLOT.TM. (i.e., cis-4-cyano-4-[3-(cyclopentylox-y)-4-methoxyphenyl1cyclohexane-1-carboxyl- ic acid), arofyline, roflumilast, C-11294A, CDC-801, BAY-19-8004, cipamfylline, SCH351591, YM-976, PD-189659, mesiopram, pumafentrine, CDC-998, IC-485, and KW-4490.
[0306] The inventive methods may be carried out by administering the compounds of the invention in combination with prothrombolytic agents, such as tissue plasminogen activator (natural or recombinant), streptokinase, reteplase, activase, lanoteplase, urokinase, prourokinase, anisolated streptokinase plasminogen activator complex (ASPAC), animal salivary gland plasminogen activators, and the like.
[0307] The inventive methods may be carried out by administering the compounds of the invention in combination with 0-adrenergic agonists such as albuterol, terbutaline, formoterol, salmeterol, bitolterol, pilbuterol, or fenoterol; anticholinergics such as ipratropium bromide; anti-inflammatory cortiocosteroids such as beclomethasone, triamcinolone, budesonide, fluticasone, flunisolide or dexamethasone; and anti-inflammatory agents such as cromolyn, nedocromil, theophylline, zileuton, zafirlukast, monteleukast and pranleukast.
.. [0308] Small molecule Factor XIa or kallikrein inhibitors may act synergistically with one or more of the above agents. Thus, reduced doses of thrombolytic agent(s) may be used, therefore obtaining the benefits of administering these compounds while minimizing potential hemorrhagic and other side effects.
Course of Treatment [0309] The compositions described herein include an effective amount of a compound of the invention (e.g., a Factor XIa or kallikrein inhibitor) optionally in combination with one or more other agents (e.g., an additional therapeutic agent) such as antithrombotic or anticoagulant agents, anti-hypertensive agents, anti-ischemic agents, anti-arrhythmic agents, .. platelet function inhibitors, and so forth for achieving a therapeutic benefit.
[0310] In some embodiments, the additional therapeutic agent is administered following administration of the composition of the invention. In some embodiments, the additional therapeutic agent is administered 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 18 hours, 24 hours, 48 hours, 72 hours or longer after administration of the composition of the invention. In some embodiments, the additional therapeutic agent is administered (e.g., orally) after discharge from a medical facility (e.g., a hospital).
[0311] In some embodiments, the compound of the invention (e.g., a Factor XIa or kallikrein inhibitor) and the additional therapeutic agent are co-formulated into a single composition or dosage. In some embodiments, the compound of the invention (e.g., a Factor XIa or kallikrein inhibitor) and the additional therapeutic agent are administered separately.
In some embodiments, the compound of the invention (e.g., a Factor XIa or kallikrein inhibitor) and the additional therapeutic agent are administered sequentially.
In some embodiments, the compound of the invention (e.g., a Factor XIa or kallikrein inhibitor) and the additional therapeutic agent are administered separately and sequentially.
In general, at least one of the compound of the invention (e.g., a Factor XIa or kallikrein inhibitor) and the additional therapeutic agent is administered parenterally (e.g., intranasally, intramuscularly buccally, inhalation, implantation, transdermal, intravenously (e.g., intravenous infusion, intravenous bolus injection), subcutaneous, intracutaneous, intranasal, pulmonary, transdermal, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or other infusion techniques); orally; or rectally, for example, intramuscular injection or intravenously (e.g., intravenous infusion, intravenous bolus injection)). In some embodiments, compound of the invention is administered parenterally (e.g., intranasally, buccally, intravenously (e.g., intravenous infusion, intravenous bolus injection) or intramuscularly). In some embodiments, the additional therapeutic agent is administered orally. In some embodiments, the compound of the invention (e.g., a Factor XIa or kallikrein inhibitor) is administered parenterally (e.g., intranasally, buccally, intravenously (e.g., intravenous infusion, intravenous bolus injection) or intramuscularly) and the additional therapeutic agent is administered orally.
[0312] In some embodiments, the composition of the invention may be administered once or several times a day. A duration of treatment may follow, for example, once per day for a period of about 1, 2, 3, 4, 5, 6, 7 days or more. In some embodiments, the treatment is chronic (e.g., for a lifetime). In some embodiments, either a single dose in the form of an individual dosage unit or several smaller dosage units or by multiple administrations of subdivided dosages at certain intervals is administered. For instance, a dosage unit can be administered from about 0 hours to about 1 hr, about 1 hr to about 24 hr, about 1 to about 72 hours, about 1 to about 120 hours, or about 24 hours to at least about 120 hours post injury.
Alternatively, the dosage unit can be administered from about 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 30, 40, 48, 72, 96, 120 hours or longer post injury. Subsequent dosage units can be administered any time following the initial administration such that a therapeutic effect is achieved. In some embodiments, the initial dose is administered orally. In some embodiments, doses subsequent to the initial dose are administered parenterally (e.g., intranasally, intramuscularly buccally, inhalation, implantation, transdermal, intravenously (e.g., intravenous infusion, intravenous bolus injection), subcutaneous, intracutaneous, intranasal, pulmonary, transdermal, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or other infusion techniques); orally; or rectally.
[0313] In some embodiments, composition of the invention is administered orally, e.g., as an liquid or solid dosage form for ingestion, for about 5 minutes to about 1 week; about 30 minutes to about 24 hours, about 1 hour to about 12 hours, about 2 hours to about 12 hours, about 4 hours to about 12 hours, about 6 hours to about 12 hours, about 6 hours to about 10 hours; about 5 minutes to about 1 hour, about 5 minutes to about 30 minutes;
about 12 hours to about 1 week, about 24 hours to about 1 week, about 2 days to about 5 days, or about 3 days to about 5 days. In one embodiment, the composition is administered orally as a liquid dosage form. In another embodiment, the composition is administered orally as a solid dosage form.
[0314] Where a subject undergoing therapy exhibits a partial response, or a relapse following completion of the first cycle of the therapy, subsequent courses of therapy may be needed to achieve a partial or complete therapeutic response (e.g., chronic treatment, e.g., for a lifetime).
[0315] In some embodiments, the composition described herein is administered intravenously, e.g., as an intravenous infusion or intravenous bolus injection, for about 5 minutes to about 1 week; about 30 minutes to about 24 hours, about 1 hour to about 12 hours, about 2 hours to about 12 hours, about 4 hours to about 12 hours, about 6 hours to about 12 hours, about 6 hours to about 10 hours; about 5 minutes to about 1 hour, about 5 minutes to about 30 minutes; about 12 hours to about 1 week, about 24 hours to about 1 week, about 2 days to about 5 days, or about 3 days to about 5 days. In one embodiment, the composition described herein is administered as an intravenous infusion for about 5, 10, 15, 30, 45, or 60 minutes or longer; about 1, 2, 4, 6, 8, 10, 12, 16, or 24 hours or longer;
about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days or longer.
Dosages and Dosing Regimens [0316] The effective amount of a composition administered according to the present invention may be determined by one of ordinary skill in the art. The specific dose level and frequency of dosage for any particular subject may vary and will depend upon a variety of factors, including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition.
[0317] Upon improvement of a patient's condition, a maintenance dose of a composition or combination provided herewith may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
EXAMPLES
[0318] In order that the invention described herein may be more fully understood, the following examples are set forth. Starting materials and various intermediates described in the following examples may be obtained from commercial sources, prepared from commercially available organic compounds, or prepared using known synthetic methods. The examples described in this application are offered to illustrate the compounds provided herein and are not to be construed in any way as limiting their scope.
General procedures [0319] All non-aqueous reactions were run under an atmosphere of nitrogen to maintain an anhydrous atmosphere and to maximize yields. All reactions were stirred using an overhead stirring assembly or magnetically, with the aid of a Teflon-coated stir bar.
The description 'drying over' refers to drying of a reaction product solution over a specified drying agent and then filtration of the solution though a suitable filter paper or through a sintered glass funnel.
The descriptions 'was concentrated', 'was concentrated at reduced pressure', or 'evaporated' refers to removal of solvents under reduced pressure using a rotary evaporator.
Chromatography or chromatographed refers to the use of flash column chromatography on silica gel unless otherwise specified. Flash chromatography refers to column chromatography under gas pressure (for example, nitrogen) or a mechanical pump to apply solvent pressure such as with a commercial system as supplied by Biotage or other vendors.
Unless otherwise specified, proton NMR spectra (1H) are measured at 400 MHz and carbon NMR spectra (13C) are measured at 100 MHz in the specified solvent.
[0320] Abbreviations used in the experimental examples are listed in the Abbreviations Table below.
Abbreviation Table MeCN or ACN Acetonitrile EDC 1,2-Dichloroethane DCM Dichloromethane DMAP 4-Dimethylaminopyridine EA Ethyl acetate Ether Diethyl ether hr or h Hours HPLC High-performance liquid chromatography IPA Isopropyl alcohol min Minutes TBME Methyl tert-butyl ether TEA Triethylamine NMR Nuclear magnetic resonance instrument RT Room temperature TFA Trifluoroacetic acid THF Tetrahydrofuran TPP Target product profile Concentrated or Concentration of organic solutions under reduced pressure and concentrated in vacuo generally with the use of a rotary evaporator PMB p-Methoxybenzyl Boc or BOC Tert-butyloxycarbonyl Example 1. Exemplary Synthesis of Compound 1.11C1 [0321] A non-limiting example of the synthesis of (2S,3R)-3-[(2-aminopyridin-4-yOmethy11-1-1[(1R)-1-cyclohexylethyll carbamoyl} -4-oxoazetidine-2-carboxylic acid trifluoroacetate (structure 2 below), tert-buty1(4-bromomethyppyridin-2-y11(4-methoxybenzyl)carbamate (structure 3 below), and (R)-(1-isocyanatoethyl)cyclohexane (structure 8 below) can be found in U.S. Patent No. 9,499,532, which is incorporated herein by reference.
A. Synthesis of Compound 1.11C1 from 2 OH OH
Elra TFA 0 HCI; MeCN; Et20 N N IRly0 N y I y 2 Compound 'MCI
[0322] Acetonitrile (12 mL; 10 vol) was added to (2S,3R)-3-[(2-aminopyridin-4-yOmethy11-1-1[(1R)-1-cyclohexylethylicarbamoy11-4-oxoazetidine-2-carboxylic acid trifluoroacetate (1.23 g; 2.52 mmol) to produce a hazy solution. This mixture was extracted twice with hexane (12 mL); then it was filtered (5 micron) to afford a clear solution. This solution was concentrated to 6 mL (5 volumes) at which point a suspension began to form.
Concentrated HC1 (0.42 mL; 2 equiv) was added. Then ether (2 x 12 mL) was added in two portions to induce formation of a precipitate. The mixture was cooled to ¨1 C
for 15 min.
The solids were collected, rinsed with cold ether and air dried to give (2S,3R)-3-[(2-aminopyridin-4-yOmethy11-1-1[(1 R) - 1-cyclohexylethylicarbamoy11-4-oxoazetidine-2-carboxylic acid hydrochloride 0.82 g (79%) as a white solid.
[0323] A highly purified sample was prepared by slurrying the solid in ether (7.5 volumes).
The product was collected, rinsed with ether and dried at 50 C in vacuo overnight.
[0324] 11-INMR (400 MHz, CD30D) ppm ö 7.79 (1 H, d, J=6.8 Hz), 6.99 (1 H, s), 6.90 (1 H, dd, J=1.5, 6.8 Hz), 6.61 (1H, d J = 8.8), 4.28 (1H, d, J=2.8) 3.70 (2H, m), 3.23 (2H, m) 1.75 (5H, m) 1.40 (1H, m) 1.25 (3H, m) 1.15 (3H, d, J=6.8 Hz) 1.00 (2H, m).
[0325] HPLC retention time: 3.21 min. HPLC conditions: Column, Zorbax 50 mm;
flow =
1.5 mL/min; 240 nm; temp = at 30 C; Solvent A = 1 mL TFA/lL water; Solvent B
= 2.8 mL
TFA/ 4 L MeCN; Gradient elution sequence: time = 0, A:B = 95:5; linear gradient to 2:98 A:B over 6 min; linear gradient back to A:B = 95:5 from 1 min.
B. Synthesis of Compound 1.1-1C1 from 3 Step 1. Preparation of 4: (25,3R)-3-{2-Rtert-butoxycarbonyl)(4-methoxybenzyl) amino]pyridin-4-yl)methyl)-1-(tert-butyl(dimethyl)sily1]-4-oxoazetidine-2-carboxylic acid.
N
NBoc(PMB) Boc(PMB) 0 2.0 M LDA NL
Br -25 C to -5 C ''" OH
¨NTBS
0 )¨NTBS
[0326] A solution of (2S)-1-tert-butyl(dimethyOsily1-4-oxoazetidine-2-carboxylic acid (175 g, 0.763 mol) and THF (2 L) was cooled to -25 C (internal temperature). 2M LDA
solution in THF (800 mL, 2.1 eq.) was added dropwise while maintaining the temperature below -10 C.
The reaction was stirred for 30 min and a gel-like suspension formed. A
solution of tert-buty1(4-bromomethyppyridin-2-y11(4-methoxybenzyl)carbamate (342 g, 0.84 mol, 1.12eq., structure 3) in THF (600 mL) was added dropwise while maintaining the reaction below -5 C
over 2 hr, and then stirred 30 min longer. The reaction was quenched with 1M
aqueous KHSO4 (2 L). The layers were separated and the aqueous layer was extracted with EA (2 L x 2). The combined organic phase was washed with brine (1 L x 2), dried (MgSO4), filtered and concentrated to give (2S,3R)-3-12-[(tert-butoxycarbonyl)(4-methoxybenzypaminolpyridin-4-yOmethyl)-1-(tert-butyl(dimethypsily11-4-oxoazetidine-2-carboxylic acid as an oily product which was used without purification (436 g, ¨70% purity).
Step 2. Preparation of compound 5: 4-Methoxybenzyl(25,3R)-3-(12-1-(tert-butoxy carb onyl)(4-methoxy b enzy Damino] pyri din-4-yllmethyl)-1-Rtert-butyl(dimethyl)sily1]-4-oxoazetidine-2-carboxylate NBoc(PMB) NBoc(PMB) N) 0 EDC, DMAP, DCM N 0 ?LOH __________________________________________________________ 0/
PMBOH
¨NTBS
[0327] The crude (2S,3R)-3-12-Rtert-butoxycarbonyl)(4-methoxybenzypaminolpyridin-4-yOmethyl)-1-(tert-butyl(dimethypsily11-4-oxoazetidine-2-carboxylic acid was dissolved in DCM (2.5 L) and EDC (137 g, 0.714 mol, 1.3 eq.), PMBOH (76.2 g, 0.55 mol, 1 eq. based on 70% purity of the acid reagent) and DMAP (3.4 g, 0.05 eq.). The solution was stirred at overnight at RT. The mixture was extracted with water (500 ml) and brine (500 ml), dried (MgSO4), and concentrated. The crude oily residue was chromatographed (gradient elution with 0% to 50% EA/hexanes) to give 4-methoxybenzyl (25,3R)-3-(12-[(tert-butoxy carb onyl)(4-methoxy b enzy Damino] pyri din-4-yllmethyl)-1-Rtert-butyl(dimethyOsily11-4-oxoazetidine-2-carboxylate as a colorless oil (250 g, 48% yield over two steps).
103281 1H NMR (400 MHz, CDC13) ppm ö 8.24 (1H, d, J=5.5 Hz), 7.55 (1H, s), 7.22 (2H, d, J=8.8 Hz), 7.20 (2H, d, J=8.8 Hz), 6.89 (1H, dd, J=1.4, 5.2 Hz), 6.87 (2H,d, J=8.6 Hz), 6.79 (2H, d, J=8.6 Hz), 5.09 (2H, s), 5.06 (2H, s), 3.81 (3H, s), 3.77 (1H, d, J=3.3 Hz), 3.76 (3H, s), 3.53 (1H, m), 3.06 (1H, dd, J=0.6, 14.6 Hz), 2.99 (1H, dd, J=7.6,14.6 Hz), 1.41 (9H, s), 0.82 (9H, s), 0.19 (3H, s), -0.05 (3H, s).
Step 3. Preparation of compound 6: 4-Methoxybenzyl(25,3R)-3-(12-[(tert-butoxy carb onyl)(4-methoxy b enzyl)amino] pyri din-4-yllmethyl)-4-oxoazeti dine-2-carboxylate NBoc(PMB) 0 NBoc(PMB) o/ NH4F, AcOH
BS _____________________________________________ N) 0 Me0H
0 ,¨NH
[0329] To a solution of 4-methoxybenzyl(2S,3R)-3-(12-[(tert-butoxycarbonyl)(4-methoxybenzypaminolpyridin-4-yllmethyl)-1-[(tert-butyl(dimethypsily11-4-oxoazetidine-2-carboxylate (314 g, 0.465 mol) and methanol (1.5 L) was added first acetic acid (112 g, 1.87 5 mol) and then NH4F (20.6 g, 0.556 mol, pre-dissolved in 1.2 L of methanol). The mixture was stirred 2 hr at RT. The reaction was concentrated. The residue was dissolved in EA (2 L) and saturated aqueous NaHCO3 (2 L) was added. The phases were separated and the organic phase was dried (MgSO4), and concentrated. The oily residue was chromatographed (gradient elution with 0% to 40% EA/hexanes) to give a clear oil which was crystallized from EA/hexanes (1:5) to give 4-methoxybenzyl(2S,3R)-3-(12-Rtert-butoxycarbonyl)(4-methoxybenzypaminolpyridin-4-yllmethyl)-4-oxoazetidine-2-carboxylate as a white solid (200 g, 77% yield).
[0330] 1H NMR (400 MHz, CDC13) ppm ö 8.26 (1H, d, J=5.0 Hz), 7.55 (1H, s), 7.21 (2H, d, J=8.6 Hz), 7.19 (2H, d, J=8.6 Hz), 6.91 (1H, dd, J=1.5, 5.0 Hz), 6.88 (2H, d, J=8.8 Hz), 6.79 (2H, d, J=8.8 Hz), 5.92 (1H, s), 5.10 (2H, s), 5.06 (2H, s), 3.87 (1H, d, J=2.5), 3.81 (3 H, s), 3.76 (3H, s), 3.56 (1H, m), 3.14 (1H, dd, J=5.8, 14.6 Hz), 3.03 (1H, dd, J=8.1, 14.6 Hz),1.42 (9H, s).
Step 4 Preparation of 7: 4-Methoxybenzyl(25,3R)-3421(tert-butoxycarbonyl)(4-methoxybenzyflamlno]pyridin-4-yllmethyl)-1-([(1R)-1-cyclohexylethyl)carbamoyll .. oxoazetidine-2-carboxylate.
NBoc(PMB) DCM, TEA NBoc(PMB) ?Lo N=C=O ?"-0 ,¨NH ,¨N N
0 0 y [0331] To a solution of 4-methoxybenzyl(2S,3R)-3-(12-[(tert-butoxycarbonyl)(4-methoxybenzypaminolpyridin-4-ylImethyl)-4-oxoazetidine-2-carboxylate (210 g, 0.374 mol) and DCM (3 L) was added TEA (188 g, 1.86 mol, 5 eq.) and (R)-(1-isocyanatoethyl)cyclohexane (143 g, 0.933 mol, 2.5 eq, structure 8). The mixture was stirred .. overnight at RT. The reaction was concentrated. The residue was chromatographed (gradient elution with 0% to 40% EA/hexanes) to give 4-methoxybenzyl-(2S,3R)-3-42-Rtert-butoxycarbonyl)(4-methoxy benzypamlnolpyridin-4-ylImethyl)-1-([(1R)-1-cyclohexylethyl)carbamoy11-4-oxoazetidine-2- carboxylate (159 g, 60% yield) as a white foam.
[0332] 111 NMR (400 MHz, CDCI3) ppm ö 8.25 (1H, d, J=5.1 Hz), 7.61 (1H, s), 7.23 (2H, d, J=8.8 Hz), 7.15 (2H, d, J=8.6 Hz), 6.85 (2H, d, J=8.8 Hz), 6.80 (2H, d J=8.6 Hz), 6.23 (1H, d, J=9.1 Hz), 5.12 (1H, d, J=15.9), 5.11 (2H, s), 5.04 (1H, d, J=12.1 Hz), 4.23 (1 H, d, J=2.8 Hz), 3.80 (3 H, s), 3.78 (1H, m), 3.76 (3H, s), 3.45 (1H, m), 3.15 (1H, dd, J=6.5,14.8 Hz), 3.01 (1H, dd, J=8.9,14.8 Hz), 1.74 (4H, m), 1.68 (2H, m), 1.41 (9H, s), 1.35 (1H, m), 1.21 (2H, m), 1.14 (3H, d, J=6.8 Hz), 0.98 (2H, m).
Step 5. Preparation of Compound 1.11C1 C) HCI
NBoc(PMB) 0 1) TFA, 0 Et3SiH
?Lo\F) ________________________________________ N
2) HCI, 0 y MeCN, 0 y TBME
8 Compound 1. HCI
[0333] Trifluoroacetic acid (2.1 L) was added to 4-methoxybenzyl-(25,3R)-3-42-[(tert-butoxycarbonyl)(4-methoxybenzypamlnolpyridin-4-ylImethyl)-1-([(1R)-1-cyclohexylethyl)carbamoy11-4-oxoazetidine-2-carboxylate (283 g, 0.396 mol) giving a red solution. Et3SiH (138 g, 1.18 mol, 3 eq.) was added and the solution became colorless. The reaction was stirred 4 hr at RT. The TFA was removed in vacuo overnight to give (25,3R)-3-[(2-aminopyridin-4-yOmethy11-1-([(1R)-1-cyclohexylethylicarbamoy11-4-oxoazetidine-2-carboxylic acid trifluoroacetate as a white foam.
[0334] Acetonitrile (1.8 L) was added to the crude TFA salt giving a hazy solution. The solution was clarified by filtration and the residue was washed with acetonitrile (100 mL).
The combined acetonitrile solution was extracted with hexanes (1.8 L x 3). The acetonitrile solution was concentrated at reduced pressure to about 900 mL. Concentrated HCI (66 mL, 0.792 mol, 2 eq.) was added slowly to form a suspension. TBME (3 L) was added slowly while stirring. The resulting suspension was cooled to 0 C for 30 min. The solid precipitate was isolated by filtration and rinsed with TBME. The solid was air dried overnight and then dried at 50 C in vacuo for 5 hr to give (2S,3R)-3 [(2-aminopyridin-4-yOmethy11-1-1[(1R)-1-cyclohexylethyllcarbamoy11-4-oxoazetidine-2-carboxylic acid hydrochloride as a white powder (130 g, 80% yield).
111 NMR (400 MHz, D20) ppm ö 7.64 (1H, d, J=6.8 Hz), 6.84 (1H, s), 6.74 (1H, dd, J=1.5,6.8 Hz), 4.22 (1H, d, J=2.8 Hz), 3.75 (1H, m), 3.54 (1H, m), 3.17 (2H, m), 1.58 (5H, m), 1.22 (1H, m), 1.07 (6H, m), 0.89 (2H, m).
Example 2. HPLC method parameters for the analysis of Compound 1 [0335] The HPLC method parameters are summarized in Table 1. A representative chromatogram of Compound 1 is shown in FIG. 1.
Table 1. Summary of method parameters for analysis of Compound 1 Column MAC-Mod Halo C18, 4.6 x 100 mm, 2.7 p.m Mobile Phase A 99.9 % water + 0.1% TFA
Mobile Phase B 99.9 % ACN + 0.1% TFA
Time (mm) % A % B
0.0 80 20 0.1 80 20 5.1 40 60 Pump Gradient Program 5.2 0 100 6.2 0 100 6.3 80 20 Diluent water Flow (mL/min) 1 Column Temperature 35 Injection Volume (ttL) 10 Sample Temperature Room temperature or 5 C
(application dependent) Detection Wavelength 280 Example 3. Experimental setup for testing the equilibrium solubility of Compound 1 in common buffers [0336] The equilibrium solubility of Compound 1 was tested in common buffers (Table 2) at a buffer strength of c(buffer)= 200 mM. For this, samples of Compound 1 with c(Compound 1, target) = 16 mg/mL were prepared in the different buffer solutions (Table 3),
73 mixed by vortexing and inspected for solid residues. For the cases for which no solid residues were observed the solutions were arbitrarily supplemented with additional solid Compound 1.
This process was repeated (hourly observation) until a solid residue remained readily observable. The samples were rotated at room temperature for 24 h.
Table 2. Buffer conditions and samples subjected to equilibrium solubility analysis c(Compoun c(Compoun Additiona Sample # Buffer System c(Buffer) pH d 1, d 1, [mM] (Buffer FB, Target) FB, Actual) Compoun , Img/mL] [mg/mL] d 1 Solid Actual) Added 100 Phosphoric acid/Sodium 200 2.00 16.0 16.4 Yes phosphate (monobasic) 101 Citric acid/Sodium 200 3.00 16.0 16.4 Yes 102 Citric acid/Sodium 200 4.00 16.0 16.6 No 103 Acetic acid/Sodium 200 5.00 16.0 17.6 No Acetate 104 Sodium phosphate 200 6.00 16.0 17.9 No (monobasic/dibasic) 105 Sodium phosphate 200 7.00 16.0 16.7 No (monobasic/dibasic) 106 Sodium phosphate 200 8.00 16.0 16.6 No (monobasic/dibasic) [0337] The equilibrium solubility samples were cleared by centrifugation (table top centrifuge, rcf = 16,100 x g, 10 min). The supernatant was subjected to HPLC
analysis and assayed in triplicates for Compound 1 concentration using the HPLC method described in Example 2. The pH of the supernatant was measured (Table 3).
Table 3. Equilibrium solubility data in different buffer solutions Dil. Avg. Avg. Avg. Main pH pH Factor CompoundCompoundc(Compound StDev Degradant (Buffer)(Meas.) (HPLC 1 1 1, c(Compound Peak Area Samples) Retention Peak Area FB) 1) as % of Time ImAU21 Img/mL]
Parent Peak [mini Area 2.00 1.29 100 4.12 7552644 158.74 3.6E-03 1.48 3.00 2.72 100 4.21 302520 5.96 6.3E-04 3.46 4.00 3.74 100 4.22 313683 6.20 2.5E-04 3.10 5.00 4.57 100 4.20 374682 7.48 3.8E-04 4.21 7.00 6.33 100 4.20 588211 11.98 1.1E-03 3.01 8.00 6.67 100 4.20 746250 15.31 2.0E-03 6.55 Example 4. Experimental setup for testing the pH-dependent stability and pH-rate profile of Compound 1
This process was repeated (hourly observation) until a solid residue remained readily observable. The samples were rotated at room temperature for 24 h.
Table 2. Buffer conditions and samples subjected to equilibrium solubility analysis c(Compoun c(Compoun Additiona Sample # Buffer System c(Buffer) pH d 1, d 1, [mM] (Buffer FB, Target) FB, Actual) Compoun , Img/mL] [mg/mL] d 1 Solid Actual) Added 100 Phosphoric acid/Sodium 200 2.00 16.0 16.4 Yes phosphate (monobasic) 101 Citric acid/Sodium 200 3.00 16.0 16.4 Yes 102 Citric acid/Sodium 200 4.00 16.0 16.6 No 103 Acetic acid/Sodium 200 5.00 16.0 17.6 No Acetate 104 Sodium phosphate 200 6.00 16.0 17.9 No (monobasic/dibasic) 105 Sodium phosphate 200 7.00 16.0 16.7 No (monobasic/dibasic) 106 Sodium phosphate 200 8.00 16.0 16.6 No (monobasic/dibasic) [0337] The equilibrium solubility samples were cleared by centrifugation (table top centrifuge, rcf = 16,100 x g, 10 min). The supernatant was subjected to HPLC
analysis and assayed in triplicates for Compound 1 concentration using the HPLC method described in Example 2. The pH of the supernatant was measured (Table 3).
Table 3. Equilibrium solubility data in different buffer solutions Dil. Avg. Avg. Avg. Main pH pH Factor CompoundCompoundc(Compound StDev Degradant (Buffer)(Meas.) (HPLC 1 1 1, c(Compound Peak Area Samples) Retention Peak Area FB) 1) as % of Time ImAU21 Img/mL]
Parent Peak [mini Area 2.00 1.29 100 4.12 7552644 158.74 3.6E-03 1.48 3.00 2.72 100 4.21 302520 5.96 6.3E-04 3.46 4.00 3.74 100 4.22 313683 6.20 2.5E-04 3.10 5.00 4.57 100 4.20 374682 7.48 3.8E-04 4.21 7.00 6.33 100 4.20 588211 11.98 1.1E-03 3.01 8.00 6.67 100 4.20 746250 15.31 2.0E-03 6.55 Example 4. Experimental setup for testing the pH-dependent stability and pH-rate profile of Compound 1
74 [0338] The stability Compound 1 was assessed over a 10-day period at several pH-values pH = 2, 3, 4, 5, 6, 7, 8) and at two different temperatures (4 C, 40 C).
Samples of Compound 1 at c(Compound 1) = 0.1 mg/mL were prepared in standard buffers (Table 2) at a buffer strength of c(buffer) = 100 mM and incubated at either T = 4 C or T
=40 C
(exclusion from light during incubation and analysis). The concentration of Compound 1 was assessed in such samples via HPLC analysis at an initial time point (to) and on days 1, 2, 3, 4, 7 and 10 (At = day x 24 h). The pH was monitored at identical time points during the 10-day period.
[0339] Over the 10-day period for both temperatures the pH of the sample solutions (FIG. 2A
& FIG. 2B) was monitored and the recovery (R%) of Compound 1 (FIG. 3A & FIG.
3B) was calculated via:
R% = (c(Compound 1,theor.)) ____________________________________________ = 100 (1) c(Compound1,actual) whereas c(Compound 1, theor.) = 0.1 mg/mL and c(Compound 1, actual) is determined by HPLC analysis via integration of the Compound 1 parent peak areas.
[0340] Compound 1 is stable in buffered aqueous solutions over a broad pH-range (pH = 2-8) when stored in the dark at 4 C. At elevated temperature (T = 40 C, in the dark) significant degradation is observed. The trend of the stability/pH-correlation is clear with Compound 1 tending to be more stable towards a low pH and less stable towards a higher pH.
It can be excluded that the differences observed in stability can be attributed to changes in pH
since the pH-values of the studies solutions remained constant within the 10 days of the experiment. All solutions were clear throughout the course of the experiment;
no precipitation of the drug compound could be observed.
Example 5. Solid state characterization of Compound 1.1-1C1 [0341] An exemplary sample of the solid state of Compound 1=FIC1 was assessed by powder X-ray diffractometry (XPRD) using a Rigaku Miniflex X-ray diffractometer (Cu-Ka source, NaI-Scintillation Counter, U = 30kV, I = 15 mA).
[0342] The solid Compound 1=FIC1 (m = 15-20 mg) was analyzed in a zero-background holder silicon (Si). Scanning was carried out in FT-mode with a 20-scan (20 =
3 ¨>40 , A20 =
0.05 , tcoont = 20s). The obtained diffractogram is displayed in FIG. 4A on a 20-scale and as specimen dimensions in real-space (d-scale) as shown in FIG. 4B. Additionally, representative peaks from an exemplary XRD pattern of Compound 1=FIC1 can be indicated by their values of 20, d-spacing, and relative intensities, for example, in Table 4 below. At low d the indication of a plateau of total reflection indicated the proper sample alignment.
[0343] The defined peak pattern obtained for Compound 1=HC1 shows the drug compound as crystalline, which makes likely that a crystalline drug product will result from solely pairing the drug compound with crystalline excipients like mannitol during a lyophilization process. The use of amorphous excipients on the other hand might shift a crystallization process towards an amorphous drug product potentially comprising enhanced properties regarding reconstitution, dissolution and solubility.
Table 4. Selected experimental powder XRD pattern data for Compound 1=HC1 20 (degrees) d-spacing (A) Relative Intensity (%) 3.744 23.5791 100 7.539 11.7173 13.7 13.295 6.654 11.7 14.343 6.1703 19 16.256 5.4483 24.8 18.751 4.7284 21.2 19.151 4.6307 12.5 20.157 4.4018 17.2 23.539 3.7764 16.6 26.702 3.3358 19.1 Example 6. Experimental setup and details for testing of vehicles [0344] Two additional vehicles: sodium citrate (50 mM) and PBS (commercial) were formulated at different concentrations (Table 5, Table 6). Both vehicles at any concentration were compounded using the appropriate final sodium hydroxide concentration (0.1 M NaOH
stock solution).
Table 5. Compounding information for citrate and PBS formulations Sample c(Compound 1, V Buffer c(HC1) Target final Osml.
FB) Conditions [mL] Stock mM pH
pH [mOsm/
[mg/mL] Conc. kg]
26 0.5 PBS, after 4 10X 7.00 7.00 311 compounding 27 0.5 PBS 4 10X 1.69 6.80 6.78 309 Sample c(Compound 1, V Buffer c(NaOH) Target final Osml.
FB) Conditions [mL] Stock mM pH
pH [mOsm/
[mg/mL] Conc. kg]
28 1.0 Citrate 5 10X 3.75 6.80 7.08 154 29 10.0 Citrate 2 10X 37.5 6.80 6.82 216 Table 6. Concentration and recovery for citrate and PBS formulations (HPLC
analysis) Sample c(Comp Avg. Avg. Avg. StDev. Avg.
# Conditions ound 1, Compou Compou c(Compou c(Compou % pH
FB, nd 1 nd 1Peak nd 1, FB, nd 1, FB, Compoun (Meas.) Theor.) Retentio Area Obs.) Obs.) d 1 Img/mL n Time ImAU2] Img/mL] Recovery [min]
After 0.5 4.21 483261 0.5 1.6E-03 103 7.00 compounding 26 After filtration 0.5 4.21 482115 0.5 2.2E-03 103 n/a 27 After 0.5 4.21 487381 0.5 1.2E-03 104 6.78 compounding 27 After filtration 0.5 4.21 483822 0.5 2.2E-03 103 n/a 28 After 1.0 4.19 505228 1.1 0.00 106 7.08 compounding 28 After filtration, 1.0 4.19 502493 1.1 0.02 105 n/a to 28 t = 12h 1.0 4.19 506190 1.1 0.01 106 7.08 28 t = 12h, 1.0 4.18 500765 1.1 0.00 105 n/a +filtration 28 t = 24h 1.0 4.18 485904 1.0 0.01 101 7.01 28 t = 24h, 1.0 4.19 480614 1.0 0.00 100 n/a +filtration 29 After 10.0 4.18 478936 10.0 0.03 100 6.82 compounding 29 After filtration, 10.0 4.19 467520 9.7 0.03 97 n/a 29 t = 12h 10.0 4.18 472523 9.8 0.04 98 6.86 29 t = 12h, 10.0 4.18 464674 9.6 0.02 96 n/a +filtration 29 t = 24h 10.0 4.18 484808 10.1 0.39 101 6.79 29 t = 24h, 10.0 4.18 465309 9.7 0.01 97 n/a +filtration [0345] The PBS vehicle was compounded to two different pH-values while the citrate vehicle was compounded at different concentrations at the same target pH and tested for its stability over the course of 24 h (rt, exclusion from light). To evaluate the potential occurrence of particles from precipitation, a filtration step (0.2 p.m micro centrifugal filters) was included at each time point.
[0346] In case of Sample #27 the amount of HC1(aq.) (0.1 M stock) added instead of the NaOH-solution was mixed with the 10X PBS buffer and added to the aqueous solution of Compound 1 in a single step.
[0347] In the case of PBS formulations at a low concentration of Compound 1 with c(Compound 1) = 0.5 mg/mL, the concentrations of HC1(aq.) or Na0H(aq.) were carefully determined in iterative compounding titrations (see above). Stability of Compound 1 in citrate buffer was confirmed for at = 24 h; losses are comparable to the degradation generally observed for Compound 1 under the applied conditions (ambient temperature).
Precipitation of Compound 1 was not observed within this time frame.
Example 7. Development of the lyophilization process [0348] A conservative lyophilization cycle (FIG. 5) was developed for lyophilization of the Compound 1 target formulation. The lyophilization cycle comprises an annealing step and a primary drying time of 20 h. During cycle development the annealing temperature as well as the primary drying temperature (shelf temperature) were varied to achieve optimal drying properties and economic use of time. FIG. 5 shows the shelf temperature (Tshelf) of the lyophilizer as well as the exemplary parameters of an early stage formulation of Compound 1 .. with Tg' as the glass transition temperature, T(melt, onset) as the onset temperature of melting and T(freeze) as the freezing temperature of the formulation as measured by differential scanning calorimetry (DSC).
[0349] Due to the evaporation enthalpy of the aqueous phase during the drying process (100 mTorr) the product temperature Tproduct is generally lower than the shelf temperature of the lyophilizer; below a temperature of T = -40 C the water vapor over ice is close to zero.
Variation of the shelf temperature was performed to achieve a slow primary drying with a primary drying temperature below the Tg' (amorphous product) or the eutectic melting temperature (Teu, crystalline product) of the formulation but above a Tproduct > -40 C. During test lyophilizations the product vials were equipped with temperature sensors to record Tproduct, in the final cycle a Tproduct = -38.5 C was observed at Tsheir = -35 C (FIG. 6). The end of primary drying was determined by measuring the water vapor release over time as a function of the pressure differences between the product chamber and the vacuum circuit of the lyophilizer (FIG. 6). It is noted that in the presence of certain excipients (e.g., mannitol) and at certain concentrations of those excipients primary drying can be accomplished well above a Tg' or Teu.
[0350] Parameters of the optimized lyophilization cycle can be found in Table 7. The residual moisture content of lyophilized formulation vehicles was determined by thermogravimetric analysis (TGA) with approximately 1.5-1.7% (w/w).
Table 7. Details of the lyophilization cycle program Step Set Point, Ramp Rate Pressure Step Total Phase Type (Tshelf) 1 C] 1 C/h]
[mTorr] Time Time [h]
[min]
0 Loading 5 atm 1 Freeze Hold 5 0.0 atm 60 1.00 2 Freeze Rate -50 20.0 atm 165 3.75 3 Freeze Hold -50 atm 180 6.75 4 Freeze/Anneal Rate -8 20.0 atm 174 9.65 Freeze/Anneal Hold -8 atm 240 13.65 6 Freeze/Anneal Rate -35 20.0 atm 81 15.00 7 Freeze/Anneal Hold -35 atm 60 16.00 8 Primary Drying Hold -35 100 1200 36.00 Secondary drying Rate 20 2.5 100 1300 57.67 11 Secondary drying Hold 20 100 360 63.67 [0351] The developed lyophilization cycle was successfully applied to Compound formulations.
5 .. Example 8. Exemplary formulations [0352] The target product profile (TPP) was defined as:
= c(Compound 1) = 10 mg/mL
= Sodium phosphate buffer, pH = 6.8, cp = 270-320 mOsm/kg = Minimal number and minimal concentration of excipients (bulking agents, solubilizing 10 agents) that facilitate robust preparation of a lyophilized drug product = Neutralization of the Compound 1=FIC1 during liquid compounding during preparation of the lyophilization fill solutions [0353] A limited formulation matrix of 108 formulations was created. The matrix comprised bulking agents, co-solvents, cyclodextrins at varying concentrations (Table 8); the concentration of sodium phosphate (10 mM) and the API (10 mg/mL) were kept constant.
Table 8. Excipients evaluated in the limited formulation testing matrix Approx. Conc.
Excipient Category [%], w/w Mannitol bulking aent 4.0, 3.5, 3.0, 2.5 Lactose bulking agent 8.0, 7.0, 6.0, 5.0, 1.5 HPPCD bulking/solubilizing 5.0, 2.1, 0.7, 0.0 (encapsulating) agent Captisol bulking/solubilizing (Sulfobutyl ether (encapsulating) agent 5.6, 2.4, 0.8, 0.0 P-cyclodextrin) PEG 400 solubilizing agent 0.05, 0.00 (cosolvent) TWEEN 20 solubilizing agent 0.01, 0.00 (cosolvent) [0354] Formulations always contained mannitol or lactose as a bulking agent and varying amounts of cyclodextrins and cosolvents. Usually the concentration of the bulking agent was varied to maintain an osmolality in the appropriate range. Lyophilization at an increased total volume concordant with a lower concentration of all formulation components compared to the .. final reconstitution strength was evaluated.
[0355] The 108 formulations were compounded from stock solutions including neutralization of Compound 1=FIC1 and lyophilized in triplicates and duplicates on a 1 mL
scale using 5 mL lyophilization vials. The concentration of excipients denoted in percent w/w is relative to the weight of Compound 1. The concentration of excipients denoted in percent (w/w or w/v) can only be considered to be approximate and do not reflect absolute w/w or w/v percentages, since neutralization compounding from stock solutions involves dilutions that do not account for defined mass or volume-ratios.
[0356] The following formulations represent the top, equally well-performing candidates with the mannitol containing formulation providing a more elegant cake structure and the .. lactose formulation achieving a cleaner, less foamy reconstitution.
= Formulation 1: 10 mg/mL Compound 1, 10 mM sodium phosphate, pH = 6.8,5%
HPOCD, 3% Marmitol = Formulation 2: 10 mg/mL Compound 1, 10 mM sodium phosphate, pH = 6.8, 5%
HPOCD, 3% Marmitol, 0.05 % PEG400 = Formulation 3: 10 mg/mL Compound 1, 10 mM sodium phosphate, pH= 6.8,5%
HPOCD, 5% Lactose = Formulation 4: 10 mg/mL Compound 1, 10 mM sodium phosphate, pH= 6.8,5%
HPOCD, 5% Lactose, 0.05 % PEG400 = Formulation 5: 10 mg/mL Compound 1, 10 mM sodium phosphate, pH = 6.8, 3.5%
HPOCD, 3% Mannitol = Formulation 6: 10 mg/mL Compound 1, 10 mM sodium phosphate, pH= 6.8, 3.5%
HPOCD, 5% Lactose Example 9. Preparation of Formulation 5 at an increased bench scale [0357] Formulation 5 was prepared to the target concentration of c(Compound 1) = 10 mg/mL on a 210 mL scale. First, a liquid fill solution was compounded including neutralization of the Compound 1=FIC1 component before lyophilization containers were filled and lyophilization was performed. Amber lyophilization containers at Vcontamer = 20 mL
and a fill volume of Vfitt = 5 mL were applied.
[0358] The fill solution was compounded from the following stock solutions at the given multifold concentration:
i. Aq. Compound 1 stock solution, c(Compound 1) = 40 mg/mL, [4X]
ii. 10 % aq. mannitol stock solution(w/v), [3.33X]
iii. 28% aq. HPPCD stock solution (w/w), [8X]
iv. 500 mM aq. sodium hydroxide stock solution [12.82X]
v. 100 mM aq. sodium phosphate buffer, pH = 6.8 [10X].
[0359] For preparation of the fill solution the residual volume of water to reach the target concentrations was added to the Compound 1 stock solution under constant stirring.
Subsequently the mannitol and HPPCD stock solutions were dispensed into the mixture before the sodium hydroxide stock solution was added to yield a final c(NaOH) = 39 mM. In the last step the 10X sodium phosphate buffer was added and the solution was allowed to cool to ambient temperature.
[0360] The mannitol, HPPCD and buffer stock solutions were filtered (0.2 p.m PES
membrane, 20 mm syringe filter, Acrodisc Supor EKV) prior to compounding without observing any difficulties. The ready-compounded lyophilization fill solution was likewise filtered (0.2 p.m PES membrane, 20 mm syringe filter, Acrodisc Supor EKV) before dispensing into lyophilization vials under best clean conditions.
[0361] The 40 resulting lyophilization vials were arranged densely packed at the center of the lyophilization and placed at the center shelf of the lyophilizer product chamber. Product vials were surrounded by vials filled with buffer solution. The developed lyophilization cycle from Example 7 was applied for lyophilization of the product vials; vials were stoppered manually after vacuum release to ambient air.
Example 10. Reconstitution and reconstitution stability of the lyophilized Compound 1 drug product [0362] The lyophilized Compound 1 drug product was subjected to testing of reconstitution and to stability testing for 6 h after reconstituted with DI water VDtwater =
5 mL.
[0363] The lyophilization cake readily reconstituted within 10-20 s. The solution during reconstitution appeared quite foamy and contained many bubbles, which cleared within approximately 2 min addition of the reconstitution solution. Residual micro-bubbles on the container wall can be removed by vortexing (2 s) or sonication (2 s). The reconstituted solution appears clear and colorless. The pH of the reconstituted solution was measured with pH = 6.81; the osmolality was determined to cp = 295 mOsm/kg. The reconstituted solution was practically free of particulates as determined by liquid particle counting (LPC, HIAC: Vsamme = 5 mL, nmas = 4, 1st run discarded, fammen = 10, Vnommal, container = 2 ml) with a cumulative count of 3200 particles at a size of 10 p.m and 667 particles at a size of 25 p.m.
[0364] The recovery of Compound 1 was monitored for 24 h after reconstitution to test for the in-use stability of the reconstituted solution (Table 9) Table 9. Excipients evaluated in the limited formulation testing matrix c(Compoun Avg. Avg. Avg. StDev. Avg.
Condition d 1, Compoun Compoun c(Compoun c(Compoun % pH
s FB, Theor.) d 1 d 1 Peak d 1, FB, d 1, FB, Compoun (Meas.
Img/mL] Retention Area Obs.) Obs.) d 1 Time ImAU21 [mg/mL] Recovery [min]
Reconst. to 9.65* 4.22 464901 9.65 0.78 100*
6.80 Reconst, 9.65 4.22 456448 9.47 0.12 98 6.79 t=lh Reconst, 9.65 4.22 444244 9.20 0.09 95 6.80 t=2h Reconst, 9.65 4.21 8501104 9.19 0.28 95 6.79 t=4h Reconst, 9.65 4.22 448263 9.28 0.06 96 6.79 t=6h Reconst, 9.65 4.21 434893 8.99 0.01 93 6.85 t=24h *%recovery(Compound 1) 100 %, since Vfm solution = VDIwater, reconst ; #different dilution was applied for preparation of the HPLC sample [0365] The current phosphate-based formulation containing HPPCD and mannitol shows a loss in Compound 1 recovery of approximately 7% over the course of 24 h.
Example 11. Compatibility with infusion vehicles and in use storage of reconstituted Compound 1 formulation [0366] The compatibility of the reconstituted Compound 1 formulation with two infusion vehicles, normal saline (NS) and 5% dextrose in water (D5W) was tested after At = 4 h for two concentration (high/low) at c(Compound 1, target) = 0.1 mg/mL and c(Compound 1, target) = 1.0 mg/mL and at ambient conditions (Table 10). The average values of % recovery are relative to the dilution of the reconstituted drug product into DI water at to.
Table 10. Assessment of compatibility with infusion vehicles c(Compound Avg. Avg. Avg. StDev. Avg.
Conditions 1, Compound Compound c(Compoundc(Compound %
FB, Theor.) 1 1 1, FB, Obs.) 1, FB, Obs.) Compound Img/mL] Retention Peak Area [mg/mL] 1 Time ImAU21 Recovery [min]
Water, to 0.09* 4.22 449346 0.09 6.10-Water, t=4h 0.09 4.22 448417 0.09 4.10-NS, t=4h 0.09 4.21 450839 0.09 5.10-D5W, t=4h 0.09 4.21 445119 0.09 2.10-Water, to 0.92* 4.22 445348 0.92 3.10-Water, t=4h 0.92 4.22 444601 0.92 6.104 NS, t=4h 0.92 4.21 446396 0.92 3.10-D5W, t=4h 0.92 4.21 446458 0.92 1.10'3 *%recovery(Compound 1) d4 100%, since Vfin solution= VDIwater, reconst.;
[0367] Both infusion, NS, and D5W are compatible with the reconstituted Compound 1 drug product at the tested concentrations and within the course of 4 h at ambient temperature and lighting conditions.
Example 12. Compatibility of reconstituted Compound 1 formulation with vials and stoppers [0368] The compatibility of the reconstituted Compound 1 formulation with sterile manufacturing vials and stoppers (Table 17) was tested for a contact time of At = 1 h at c(Compound 1, target) = 10 mg/mL at ambient conditions. The average values of %recovery are relative to the reconstituted drug product that has not been in contact with the tested materials.
Table 11. Assessment of compatibility with vials and stoppers for manufacturing c(Compound Avg. Avg. Avg. StDev. Avg.
Conditions 1, FB, Compound Compoundc(Compoundc(Compound %
Theor.) 1 1 1, FB, Obs.) 1, FB, Obs.) Compound Img/mL] Retention Peak Area [mg/mL] 1 Time ImAU21 Recovery [min]
Reconst. Soln., 9.32* 4.21 450793 9.32 0.02 100*
Vial, t = lh 9.32 4.21 449081 9.28 0.02 100 Stopper, t = lh 9.32 4.20 449072 9.28 0.01 100 *%recovery(Compound 1) d4 100%, since Vol solution = VDIwater, reconst [0369] Table 11 shows the tested vial and stopper material is compatible with the reconstituted Compound 1 drug product at the tested concentrations and within the course of 1 h at ambient temperature and lighting conditions.
Example 13. Compatibility of reconstituted Compound 1 formulation with sterilization filters [0370] The feasibility of aseptic processing was evaluated and three different filter materials were tested for compatibility with the reconstituted Compound 1 formulation.
Aseptic processing is the generally suggested method for sterilization of Compound 1, since Compound 1 comprises a decreased stability at elevated temperature and only dry sterilization cycles (T= 160 C, t = 120 min) are applicable for lyophilized drug product as a terminal sterilization option.
[0371] Filter compatibility of the reconstituted Compound 1 drug product was tested with different filter material (Table 17) composed of polyethersulfone (PES), nylon, and polyvinylidene fluoride (PVDF). For this a volume of Vfilter pass = 10 mL was passed through the respective filter and the first as well as the last 10 vol% of the filtered volume were assayed for recovery of Compound 1 (Table 12).
Table 12. Assessment of compatibility with sterilization filters c(Compound Avg. Avg. Avg. Avg.
Conditions 1, Compound 1 Compound 1 c(Compound % Compound FB, Theor.) Retention Peak Area 1, FB, Obs.) 1 [mg/mL] Time ImAU21 Img/mL] Recovery [min]
Sample Soln. 0.95* 4.14 4296856 0.95 100*
(pre-filtration) PES, first 10% 0.95 4.15 4285782 0.94 100 PES, last 10% 0.95 4.14 4296190 0.95 100 Nylon, first 10% 0.95 4.15 4255708 0.94 99 Nylon, last 10% 0.95 4.14 4297770 0.95 100 PVDF, first 10% 0.95 4.13 4306693 0.95 100 PVDF, last 10% 0.95 4.13 4305766 0.95 100 *%recovery(Compound 1) 100%, since Vfin solution = VDIwater, reconst [0372] The average values of %recovery are relative to the reconstituted drug product that has not been in contact with the tested materials. No increase in back-pressure was observed with any of the tested filters. At the studied filter pass volumes and concentrations no significant loss in Compound 1 recovery was observed.
Example 14. Compatibility of reconstituted Compound 1 formulation with infusion bags and IV systems [0373] The compatibility of the reconstituted Compound 1 formulation with two infusion bags (different volumes and material) and two IV lines was tested (Table 13) at c(Compound 1) = 0.1 mg/mL. After injection of the reconstituted drug product solution into infusion bags filled with NS, the recovery of Compound 1 was measured i) directly after mixing with the infusion vehicle (to, Table 14) and ii) after At = 10 min of contact time with the infusion bag (Table 15). Additionally, storage in an infusion bag at ambient temperature and lighting conditions was assessed for At = 6 h (Table 15). The average values of %recovery are .. relative to the reconstituted drug product that has not been in contact with the tested materials.
Table 13. Tested infusion bag and IV system material Size Article #1 Material [mL] Manufact. Description Catalog #
Lot #
0.9% Sodium Chloride Inf. bag #1 500 Baxter Injection USP (500 mL FE1323 14J15E3D
Viaflo Bag) 0.9% Sodium Chloride Inf. bag #2 50 Baxter Injection USP (50 mL 2B1301 P326306 Viaflex Bag) Clearlink/Interlink, Non-IV system --- Baxter DEHP solution set, Duo-vent EMS3110 R14H27059 #1 spike IV system --- Baxter Clearlink system, continuo- 2C8519S R14J10060 #2 Flo solution set Table 14. Assessment of compatibility with infusion bags at to.
c(Compound Avg. Avg. Avg. StDev. Avg.
Conditions 1, Compound Compound c(Compoundc(Compound %
FB, Theor.) 1 1 1, FB, Obs.) 1, FB, Obs.) Compound [mg/mL] Retention Peak Area Img/mL] 1 Time ImAU2] Recovery [min]
Sample soln. 0.09* 4.19 441971 0.09 1.3E-01 100*
(water) infus. bagl, to 0.09 4.19 423961 0.09 1.8E-04 96 infus. bag2, to 0.09 4.19 393294 0.08 7.1E-05 88 *%recovery(Compound 1) 100%, since Vfin solution = VDIwater, reconst Table 15. Assessment of compatibility with infusion bags at t = 10 min and 6 h storage in infusion bag c(Compound Avg. Avg. Avg. StDev. Avg.
Conditions 1, Compound Compound c(Compoundc(Compound %
FB, Theor.) 1 1 1, FB, Obs.) 1, FB, Obs.) Compound Img/mL] Retention Peak Area [mg/mL] 1 Time ImAU2] Recovery [min]
infus. bagl, to 0.09* 4.18 436470 0.09 2.7E-04 100*
infus. bagl, 0.09 4.18 436694 0.09 3.6E-04 100 t=l0min infus. bagl, 0.09 4.19 436411 0.09 2.0E-04 100 t=6h infus. bag2, to 0.08* 4.18 401640 0.08 1.1E-04 100*
infus. bag2, 0.08 4.18 401638 0.08 5.2E-05 100 t=l0min infus. bag2, 0.08 4.19 400252 0.08 4.2E-04 100 t=6h *%recovery(Compound 1) d4 100%, since Vfin solution= VDIwater, reconst [0374] The two IV systems were evaluated for compatibility with the reconstituted drug .. product solution by filling the IV lines with the diluted (NS) drug product solution and flowing Vflow through (FT) = 101 mL through the respective IV system at a flow rate of 5 mL/min.
Flow-through samples of Vsample = 1 mL were collected i) immediately (VFT = 0 mL), ii) after VFT = 10 mL and iii) after VFT = 100 mL. Flow through samples were assayed for recovery of Compound 1 and compared to the infusion solution in the reservoir at to (Table 16).
Table 16. Assessment of compatibility with IV systems c(Compound Avg. Avg. Avg. StDev. Avg.
Conditions 1, FB, Compound Compoundc(Compoundc(Compound %
Theor.) 1 1 1, FB, Obs.) 1, FB, Obs.) Compound Img/mL] Retention Peak Area [mg/mL] 1 Time ImAU21 Recovery [mini infus. bag, to 0.09* 4.18 436470 0.09 2.7E-04 100*
(IV#1) IV#1, VFT = 0.09 4.18 436836 0.09 100 0 mL
IV#1, VFT = 0.09 4.18 438353 0.09 100 10 mL
IV#1, VFT = 0.09 4.18 440111 0.09 100 100 mL
infus. bag, tO 0.09* 4.18 436640 0.09 1.1E-04 100*
(IV#2) IV#2, VFT = 0.09 4.18 436142 0.09 100 0 mL
IV#2, VFT = 0.09 4.18 436115 0.09 100 mL
IV#2, VFT = 0.09 4.19 436142 0.09 100 100 mL
*%recovery(Compound 1) 100%.
103751 The tested infusion bags and IV system material is compatible with the reconstituted Compound 1 drug product at the tested concentrations and exposure times.
While storage in the infusion bags up to 6 h does not change the concentration of Compound 5 1 in the respective infusion vehicle compared to to (approximately 1 min after exposure), it seems to be the case that some Compound 1 material is adsorbed from the infusion bag material immediately after contact. Thereby, the observed changes in Compound 1 recovery do not correlate with the surface area of the tested infusion bags but seem to be dependent on the infusion bag material. Infusion bag #1 (Viaflo) shows a lesser extent of Compound 1 10 adsorption than infusion bag #2 (Viaflex).
103761 Both IV systems appear to be inert towards binding of Compound 1; no changes in Compound 1 recovery were observed after flowing the Compound 1 solution derived from dilution of the reconstituted drug product solution through either IV test system.
Example 15. Materials and Equipment Table 17. Materials Material Supplier/Manufactur Part Number Lot # / Serial #
0.9% Sodium Chloride Injection Baxter 2B1301 P326306 USP (50 mL Viaflex Bag) 0.9% Sodium Chloride Injection Baxter FE1323 14J15E3D
USP (500 mL Viaflo Bag) Acetic Acid (glacial) BDH UN2789 Acetonitrile Fisher Scientific A998-4 146154/151811 Cannulas (Precision Glide Becton Dickinson 305175 614499 Needle D-D20G1)) Captisol (beta cyclodextrin CyDex Inc. NC-sulfobutyl ethers, sodium salts) Citric acid anhydrous Spectrum C1131 XCO269 Clearlink system, continuo-Flo Baxter 2C8519S R14J10060 solution set Clearlink/Interlink, Non-DEHP Baxter EMS3110 R14H27059 solution set, Duo-vent spike Crimp Seals (Afton Ready-To- Afton Scientific 54202258 1745-15 Fill Sterilized Seals) Deionized water (ultra pure) In-house, Nanopure Infinity (Barnstead) water DSC pans (Pan + Lid, Hermetic TA Instruments T131003/T14060 900796.901/
Alodined) 3 900790.901 Ethanol (dehydrated, 200 proof, Spectrum ET107 ZT0426 Undenatured, USP) Halo C18 HPLC column MAC-MOD 92814-602 AH142237/
HPLC (vials clear) VWR 46610-722 24108033 HPLC vials (amber) VWR 46610-726 24107863 Hydrochloric Acid Fisher Scientific A144-500 48038830 Hydrogen Peroxide 35%, w/w, Alfa Aesar L14000 W03A029 stab.
Hydroxypropy1-13-cyclodextrin Spectrum H2690 1D60239 Lactose Monohydrate Spectrum LA106 R00212 Lyophilization bottles (Wheaton, 20 mL, Serum Wheaton 223762 1550400 bottles, Borosilicate glass, amber) Lyophilization stoppers (Wheaton, 20 mm, STPR, 3- Wheaton W224100-202 1539836 Leg, Lyo, 13x20, GRY, BTYL, SLZD) Lyophilization vials (Wheaton, mL vials, serum, Type I Wheaton 223685 Borosilicate glass, clear) Lyophilization vials (Wheaton, 5 mL vials, serum, Type I Wheaton 223695 1548721 Borosilicate glass, amber) Magnetic Stir Bars (various VWR
sizes) Maleic acid Spectrum M1075 VG1288 Marmitol (USP) Spectrum MA165 XE1369 Manufacturing stoppers, sterile West Pharmaceutical (20 mm Lyo NovaPure RP Services, Inc. 19700311 D000039730 V10- F597W 4432/50 West ready pack) Manufacturing vials, sterile Afton Scientific (via (Ready- to-fill Sterilized Vials, West Pharmaceutical 68000369 5ML 20MM S/L FNT W/BB Services, Inc.) Osmometry Std. 100 mOsm/kg Fisher Scientific 12-827-12 (Precision Systems No. 2101) Osmometry Std. 300 mOsm/kg Fisher Scientific 12-827-13 (Precision Systems No. 2103) Osmometry Std. 500 mOsm/kg Fisher Scientific 12-827-14 (Precision Systems No. 2105) pH Standard (pH 10.000) Ricca Chemical 1602-16 250 1A26 Company pH Standard (pH 4.000) Ricca Chemical 1502-16 2410B96 Company pH Standard (pH 7.000) Ricca Chemical 1552-16 2410761 Company Phosphoric acid Sigma Aldrich 438081-Polyethylene glycol 400, NF Spectrum P0110 ZQ0106 (PEG 400) Polysorbate 80, NF Spectrum P01138 2DJ0314 Prominence Autosampler Vial Shimadzu 228-45454-Closures Sodium acetate anhydrous EMD 7510 1775B65 Sodium citrate=2H20 Acros Organics 446330010 A0342566 Sodium hydroxide solution VWR BDH7247-1 410417 N
Sodium hydroxide solution Fisher Scientific SS276-1 100160 Sodium phosphate dibasic Spectrum S0138 WG0695 anhydrous Sodium phosphate dibasic Spectrum S1108 VM0472 dihydrate Sodium phosphate monobasic Spectrum S0187 VK1125 anhydrous Sucrose (NF) Spectrum 5U103 RB0137 Syringe filters (0.2 p.m, 25 mm, Pall 4436 11961095 Acrodisc, Nylon) Syringe filters (0.2 p.m, 25 mm, Pall 4405 12491302 Acrodisc, Supor EKV) Syringe filters (0.22 p.m, 25 Millipore SLGVM33RS
mm, Milles GV, PVDF) Syringes Luer-Lock TIP (60 ml, 8107397/
10 mL, 5 mL) BD 309653/-04/-46 5026529/
TGA Pans (ceramic) TA Instruments T060516 952323.902 Trifluoroacetic acid EMD TX1276-6 48038830 TWEEN 20 Fisher Scientific BP337-500 117274 Weighing pans Fisher Scientific NC0184742 n/a (Aluminum,12 mm) Table 18. Equipment Equipment Description Analytical Balance Mettler Toledo MX-5, S/N #1126472420 Bath¨type Sonicator Fisher Scientific, F530 (100W, 42 kHz), S/N #RTA12119995B
Biological Safety NuAire Class II, Type A/B3, Model: Nu-425-600, S/N
Cabinet #12757041800 Crimper Wheaton, 20 mm, 224323 Decrimper Wheaton, 20 mm, W225353 Differential Scanning TA Instrument, DSC Q100 Calorimeter Digital Timer VWR Laboratory Timer, Product #62344-641, S/N # 101445261 Environmental ThermoForma 3911, S/N #40759-101 Chambers ThermoForma 3911, S/N #57484-132 HIAC Pacific Scientific, HIAC Royco Model 9703 Liquid Particle Counting System, Sensor: HRLD400CE (serial# F06211); Pharm Spec Software Controller Unit: Shimadzu Prominence CBM-20A
Pump System: Shimadzu Prominence LC-20 AD
Autosampler: CTC HTS PAL
Degasser: Shimadzu Prominence DGU-20As LC-MS/MS System MS Detector: Applied Biosystems API 4000 Column Oven: Shimadzu Prominence CTO-20A
Software: Applied Biosystems/MSD SCIEX
Instruments: Analyst Software Lyophilizer VirTis 25L Genesis SQ Super XL lyophilizer, S/N #214950;
Encore iFIX Software V. 3.5 Magnetic Stir Plate Barnstead/Thermolyne, Cimarec 2 (S46725) Micro Osmometer Precision Systems, u0smette, Mode1:5004 Micro-pipettes Rainin Instrument Co., Pipetmen P-10, P-20, P-100, P-200, P-1000 and P- 5000 pH-Meter/ pH- Thermo Scientific Orion Star A211, S/N #127 Electrode VWR Symphony semi-micro pH-electrode (epoxy) BNC, #89231-576 Thermo Scientific, Part #9810BN, Lot # SS1 Photostability Caron Photostability Chamber 6540-1, S/N #011607-6540-1-Chamber Refrigerator GE Refrigerator GTS18FBMFRWW, S/N #FF759776 Jordon Scientific Refrigerator Repeater Pipette Eppendorf Repeater Plus, incl. CombiTips Plus (10 mL, 5 mL, 2.5 mL) Rotisserie Barnstead 415110, S/N #1105060242886, incl. sample holder for 15 mL conical tubes Tabletop Centrifuge Eppendorf Centrifuge 5414D (24-place fixed-angle rotor for 1.5-2.0 mL tubes/F-24-45-11) Thermogravimetric TA Instruments, TGA Q500 Balance Pump System: Shimadzu Prominence LC-20 AT
Auto-sampler: Shimadzu Prominence SIL-20AC
Degasser: Shimadzu Prominence DGU-20As Detector: Shimadzu Prominence SPD-20A
UV-HPLC System 12 Column Oven: Shimadzu Prominence CTO-20A
Software: Shimadzu Class VP Client/Server V7.4 Column: MAC-MOD Halo C18, Part #: 92814-602, SN#: AH142237/ U5RG003098 Vortex Mixer National Labnet Co. Inc, VX100 (S01100) Diffractometer: Rigaku MiniFlex, #2005G302, S/N
#CD04539 (30 kV/50 mA, Cu-Ka) Cooling unit: Haskris WA1 XRD Equipment Sample Holder Six-Position Sample Changer with Sample Mount: Spinner ASC-6, #2455E431 Sample Holder: Zero Background Sample Holder ¨ 100 micron indent, round, #SH-LBSI511-RNDB
Example 16. Long -Term Stability Studies [0377] Exemplary long-term stability studies of the Compound 1 lyophilized drug product are shown in FIGS. 7-9 for T = -80 C, T = -20 C, and T= 2-8 C, respectively. The studies were initiated by collecting data of an initial time point (to) and subjecting the required amount of sample to the respective testing conditions. Stability of the Compound 1 lyophilized drug product was evaluated after t = 1 month, 3 month, 6 month, 9 month, and 12 month. The tests include appearance, reconstitution time, reconstitution appearance, recovery & impurity (HPLC assay), pH, and LPC (HIAC, particulates).
Example 17. Compounding process for Compound 1 liquid injectable formulation .. [0378] Compounding process for liquid formulations of Compound 1, designed for dilution into infusion vehicles was developed with 3.0 mg/mL of Compound 1 (or 3.13 mg/mL
Compound 1 free base equivalent), phosphate buffer solution (PBS), and pH of 6.4-7.2. The compounding process was applied over a wide range of scales (25-500 mL).
[0379] The compounding of the drug product required a neutralization step using 0.5N
sodium hydroxide solution and buffering with PBS to adjust the pH to values compatible with an IV infusion. The compounding process also required a filtration step, which also served as aseptic processing. Either a minimal loss or no loss of Compound 1 was observed.
[0380] The compounded formulations were diluted into infusion vehicles: normal saline, 5%
dextrose in water (D5W), and lactated Ringer's solution (buffered and unbuffered). The dilution into normal saline was carried out at 100-fold and 600-fold dilution.
[0381] Compound 1 formulations were stable at 2-8 C for at least one week with nominal degradation of < 4%. The observed Compound 1 was within the error range of sample preparation, so it is feasible that no measurable degradation was occurring during the studied time frame. When Compound 1 formulation was diluted into normal saline, the resulting infusate solution at c(Compound 1) = 0.03 mg/mL was stable at ambient temperature for at least 48 hours. The pH was constant over 48 hours and no significant loss in Compound 1 recovery was observed. The purity for Compound 1 appeared unchanged for over 48 hours and the chromatographic trace recorded after 48 hours did not reveal additional peaks or growth of observed degradants (FIG. 10).
Example 18. Efficacy study of Compound 1 in a hound cardiopulmonary bypass model [0382] The objective of this study was to demonstrate the efficacy of Compound compared to the Standard of Care (SOC), heparin, for preventing activation of blood coagulation components while using the Cardiopulmonary Bypass (CPB) circuit during an extended run time on Day 1 in a mixed breed hound dog model. The study design is shown in Table 19:
Table 19. Experimental Design (Target Doses of Compound lb) IV IV
IV Bolus Infusion Dose Dose Loading Dose Dose Dose Infusion Concentration Compound No. of Dose Volume Concentration Level Rate for IV 1 in Prime Group Animals (mg/kg) (mL/kg) for IV Bolus (mg/kg/hr) (mL/kg/hr) Infusion Solution 1 3 NA NA NA 3 5 0.6 mg/mL
NA
0.6 [tg/mL and 0.01 2 2 3 1 3 5 0.6 [tg/mL
3 mg/mLa mg/mL
3 2 10 1 10 mg/mL 10 5 2.0 mg/mL
0.01 mg/mL
4 2 10 1 10 mg/mL 10 5 2.0 mg/mL
0.01 mg/mL
2 10 1 10 mg/mL 10 5 2.0 mg/mL 0.01 mg/mL
NA ¨ Not Applicable a Animal No. 1001 received 0.6 [tg/mL and Animal No. 1004 received 3 mg/mL.
b Doses shown are targets for the dosing on this study; actual dose values are shown in the 5 results section.
[0383] The following parameters and endpoints were evaluated in this study:
mortality, body weight, physical, clinical pathology parameters (hematology and coagulation), coagulation time, and bioanalytical parameters.
Experimental Design Administration [0384] The vehicle and test article were administered via intravenous (IV) infusion once on Day 1 for 135 minutes (initiated 30 minutes prior to starting the Cardiopulmonary Bypass (CPB) and continuing for 105 minutes of CPB). Group 2 animals received a 0.6 [tg/mL or 3.0 mg/mL IV bolus dose immediately prior to the start of IV infusion. Group 3, 4, and 5 animals received a 10 mg/kg IV bolus dose prior to the start of the IV
infusion; with the CPB
machine primed with test article at 10 [tg/mL.
Surgical Procedure [0385] Group 1 had an infusion pump setup with an open system/reservoir.
Infusion of the Compound 1 was started 30 minutes prior to the animal being placed on the CPB
pump. The CPB pump was primed with 0.9% saline.
[0386] Groups 2, 3, and 4 had an infusion pump setup with an open system/reservoir.
Venous and arterial sheaths were flushed with the Compound 1 at a concentration of 10 g/mL. An IV bolus dose of the test article was administered immediately prior to the start of the infusion. Infusion of Compound 1 was started 30 minutes prior to the animal being placed on the CPB pump. The CPB patient was primed with 10 g/mL of the Compound 1 prior to initiation of the CPB pump.
[0387] Group 5 had an infusion pump setup with a closed system/"bag." Venous and arterial sheaths were then flushed with Compound 1 at 10 g/mL. An IV bolus dose of the Compound 1 was administered immediately prior to the start of the infusion.
Infusion of Compound 1 was started 30 minutes prior to the animal being placed on the CPB
pump.
Results [0388] FIG. 11 shows pressure gradients assessed across the membrane oxygenator.
Studies previously conducted with no anticoagulant demonstrated that the pressure across the membrane oxygenator built within 15 minutes of pump start and exponentially increased over the next 30 minutes such that the oxygenator was occluded and the circulation was stopped, whereas with Compound 1 at multiple doses, the pressure gradient across the membrane oxygenator stayed consistent through the entire run, indicating that the test article successfully maintained anticoagulation allowing the continuation of the pump run for the entirety of the protocol.
[0389] FIG. 12 shows a correlation between Compound 1 plasma concentration and aPTT.
All animals survived to study termination. Overall, Compound 1 was not associated with any increases in morbidity or mortality at the dose levels used in this study during the Cardiopulmonary bypass/ECMO protocol.
[0390] During Compound 1 infusion and prior to CPB, aPTT was moderately to markedly prolonged in all animals (FIG. 13). Prolongations in aPTT persisted throughout Compound 1 infusion and CPB. In groups that received a loading dose of Compound 1 (Groups 2 through 5), prolongations in aPTT were most pronounced prior to (Group 3 through 5) or during the first 30 minutes of CPB (Group 2), but then improved slightly before reaching steady-state.
Group 1 animals did not receive an Compound 1 loading dose, and prolongations in aPTT
remained relatively consistent at all measured timepoints during Compound 1 infusion in this group. In all groups following cessation of Compound 1 infusion and CPB, aPTT
trended towards baseline values, but remained moderately prolonged at the conclusion of the study.
Conclusions [0391] Administration of the Compound 1 to the model was successful in preventing the activation of blood coagulation in components of cardiopulmonary bypass. The anticoagulant effects of Compound 1 were selective to inhibition of activated partial .. thromboplastin time (aPTT). Additionally, the data demonstrated that adding a bolus dose immediately prior to starting the infusion enabled targeted plasma levels of Compound 1 to rapidly be achieved, along with desired steady state levels, and was sufficient to achieve a successful 105-minute CPB run and prevent coagulation in most of the circuit components.
[0392] Overall, these data indicate that Compound 1 may be an acceptable alternative to heparin in preventing blood coagulation in components of cardiopulmonary bypass.
Samples of Compound 1 at c(Compound 1) = 0.1 mg/mL were prepared in standard buffers (Table 2) at a buffer strength of c(buffer) = 100 mM and incubated at either T = 4 C or T
=40 C
(exclusion from light during incubation and analysis). The concentration of Compound 1 was assessed in such samples via HPLC analysis at an initial time point (to) and on days 1, 2, 3, 4, 7 and 10 (At = day x 24 h). The pH was monitored at identical time points during the 10-day period.
[0339] Over the 10-day period for both temperatures the pH of the sample solutions (FIG. 2A
& FIG. 2B) was monitored and the recovery (R%) of Compound 1 (FIG. 3A & FIG.
3B) was calculated via:
R% = (c(Compound 1,theor.)) ____________________________________________ = 100 (1) c(Compound1,actual) whereas c(Compound 1, theor.) = 0.1 mg/mL and c(Compound 1, actual) is determined by HPLC analysis via integration of the Compound 1 parent peak areas.
[0340] Compound 1 is stable in buffered aqueous solutions over a broad pH-range (pH = 2-8) when stored in the dark at 4 C. At elevated temperature (T = 40 C, in the dark) significant degradation is observed. The trend of the stability/pH-correlation is clear with Compound 1 tending to be more stable towards a low pH and less stable towards a higher pH.
It can be excluded that the differences observed in stability can be attributed to changes in pH
since the pH-values of the studies solutions remained constant within the 10 days of the experiment. All solutions were clear throughout the course of the experiment;
no precipitation of the drug compound could be observed.
Example 5. Solid state characterization of Compound 1.1-1C1 [0341] An exemplary sample of the solid state of Compound 1=FIC1 was assessed by powder X-ray diffractometry (XPRD) using a Rigaku Miniflex X-ray diffractometer (Cu-Ka source, NaI-Scintillation Counter, U = 30kV, I = 15 mA).
[0342] The solid Compound 1=FIC1 (m = 15-20 mg) was analyzed in a zero-background holder silicon (Si). Scanning was carried out in FT-mode with a 20-scan (20 =
3 ¨>40 , A20 =
0.05 , tcoont = 20s). The obtained diffractogram is displayed in FIG. 4A on a 20-scale and as specimen dimensions in real-space (d-scale) as shown in FIG. 4B. Additionally, representative peaks from an exemplary XRD pattern of Compound 1=FIC1 can be indicated by their values of 20, d-spacing, and relative intensities, for example, in Table 4 below. At low d the indication of a plateau of total reflection indicated the proper sample alignment.
[0343] The defined peak pattern obtained for Compound 1=HC1 shows the drug compound as crystalline, which makes likely that a crystalline drug product will result from solely pairing the drug compound with crystalline excipients like mannitol during a lyophilization process. The use of amorphous excipients on the other hand might shift a crystallization process towards an amorphous drug product potentially comprising enhanced properties regarding reconstitution, dissolution and solubility.
Table 4. Selected experimental powder XRD pattern data for Compound 1=HC1 20 (degrees) d-spacing (A) Relative Intensity (%) 3.744 23.5791 100 7.539 11.7173 13.7 13.295 6.654 11.7 14.343 6.1703 19 16.256 5.4483 24.8 18.751 4.7284 21.2 19.151 4.6307 12.5 20.157 4.4018 17.2 23.539 3.7764 16.6 26.702 3.3358 19.1 Example 6. Experimental setup and details for testing of vehicles [0344] Two additional vehicles: sodium citrate (50 mM) and PBS (commercial) were formulated at different concentrations (Table 5, Table 6). Both vehicles at any concentration were compounded using the appropriate final sodium hydroxide concentration (0.1 M NaOH
stock solution).
Table 5. Compounding information for citrate and PBS formulations Sample c(Compound 1, V Buffer c(HC1) Target final Osml.
FB) Conditions [mL] Stock mM pH
pH [mOsm/
[mg/mL] Conc. kg]
26 0.5 PBS, after 4 10X 7.00 7.00 311 compounding 27 0.5 PBS 4 10X 1.69 6.80 6.78 309 Sample c(Compound 1, V Buffer c(NaOH) Target final Osml.
FB) Conditions [mL] Stock mM pH
pH [mOsm/
[mg/mL] Conc. kg]
28 1.0 Citrate 5 10X 3.75 6.80 7.08 154 29 10.0 Citrate 2 10X 37.5 6.80 6.82 216 Table 6. Concentration and recovery for citrate and PBS formulations (HPLC
analysis) Sample c(Comp Avg. Avg. Avg. StDev. Avg.
# Conditions ound 1, Compou Compou c(Compou c(Compou % pH
FB, nd 1 nd 1Peak nd 1, FB, nd 1, FB, Compoun (Meas.) Theor.) Retentio Area Obs.) Obs.) d 1 Img/mL n Time ImAU2] Img/mL] Recovery [min]
After 0.5 4.21 483261 0.5 1.6E-03 103 7.00 compounding 26 After filtration 0.5 4.21 482115 0.5 2.2E-03 103 n/a 27 After 0.5 4.21 487381 0.5 1.2E-03 104 6.78 compounding 27 After filtration 0.5 4.21 483822 0.5 2.2E-03 103 n/a 28 After 1.0 4.19 505228 1.1 0.00 106 7.08 compounding 28 After filtration, 1.0 4.19 502493 1.1 0.02 105 n/a to 28 t = 12h 1.0 4.19 506190 1.1 0.01 106 7.08 28 t = 12h, 1.0 4.18 500765 1.1 0.00 105 n/a +filtration 28 t = 24h 1.0 4.18 485904 1.0 0.01 101 7.01 28 t = 24h, 1.0 4.19 480614 1.0 0.00 100 n/a +filtration 29 After 10.0 4.18 478936 10.0 0.03 100 6.82 compounding 29 After filtration, 10.0 4.19 467520 9.7 0.03 97 n/a 29 t = 12h 10.0 4.18 472523 9.8 0.04 98 6.86 29 t = 12h, 10.0 4.18 464674 9.6 0.02 96 n/a +filtration 29 t = 24h 10.0 4.18 484808 10.1 0.39 101 6.79 29 t = 24h, 10.0 4.18 465309 9.7 0.01 97 n/a +filtration [0345] The PBS vehicle was compounded to two different pH-values while the citrate vehicle was compounded at different concentrations at the same target pH and tested for its stability over the course of 24 h (rt, exclusion from light). To evaluate the potential occurrence of particles from precipitation, a filtration step (0.2 p.m micro centrifugal filters) was included at each time point.
[0346] In case of Sample #27 the amount of HC1(aq.) (0.1 M stock) added instead of the NaOH-solution was mixed with the 10X PBS buffer and added to the aqueous solution of Compound 1 in a single step.
[0347] In the case of PBS formulations at a low concentration of Compound 1 with c(Compound 1) = 0.5 mg/mL, the concentrations of HC1(aq.) or Na0H(aq.) were carefully determined in iterative compounding titrations (see above). Stability of Compound 1 in citrate buffer was confirmed for at = 24 h; losses are comparable to the degradation generally observed for Compound 1 under the applied conditions (ambient temperature).
Precipitation of Compound 1 was not observed within this time frame.
Example 7. Development of the lyophilization process [0348] A conservative lyophilization cycle (FIG. 5) was developed for lyophilization of the Compound 1 target formulation. The lyophilization cycle comprises an annealing step and a primary drying time of 20 h. During cycle development the annealing temperature as well as the primary drying temperature (shelf temperature) were varied to achieve optimal drying properties and economic use of time. FIG. 5 shows the shelf temperature (Tshelf) of the lyophilizer as well as the exemplary parameters of an early stage formulation of Compound 1 .. with Tg' as the glass transition temperature, T(melt, onset) as the onset temperature of melting and T(freeze) as the freezing temperature of the formulation as measured by differential scanning calorimetry (DSC).
[0349] Due to the evaporation enthalpy of the aqueous phase during the drying process (100 mTorr) the product temperature Tproduct is generally lower than the shelf temperature of the lyophilizer; below a temperature of T = -40 C the water vapor over ice is close to zero.
Variation of the shelf temperature was performed to achieve a slow primary drying with a primary drying temperature below the Tg' (amorphous product) or the eutectic melting temperature (Teu, crystalline product) of the formulation but above a Tproduct > -40 C. During test lyophilizations the product vials were equipped with temperature sensors to record Tproduct, in the final cycle a Tproduct = -38.5 C was observed at Tsheir = -35 C (FIG. 6). The end of primary drying was determined by measuring the water vapor release over time as a function of the pressure differences between the product chamber and the vacuum circuit of the lyophilizer (FIG. 6). It is noted that in the presence of certain excipients (e.g., mannitol) and at certain concentrations of those excipients primary drying can be accomplished well above a Tg' or Teu.
[0350] Parameters of the optimized lyophilization cycle can be found in Table 7. The residual moisture content of lyophilized formulation vehicles was determined by thermogravimetric analysis (TGA) with approximately 1.5-1.7% (w/w).
Table 7. Details of the lyophilization cycle program Step Set Point, Ramp Rate Pressure Step Total Phase Type (Tshelf) 1 C] 1 C/h]
[mTorr] Time Time [h]
[min]
0 Loading 5 atm 1 Freeze Hold 5 0.0 atm 60 1.00 2 Freeze Rate -50 20.0 atm 165 3.75 3 Freeze Hold -50 atm 180 6.75 4 Freeze/Anneal Rate -8 20.0 atm 174 9.65 Freeze/Anneal Hold -8 atm 240 13.65 6 Freeze/Anneal Rate -35 20.0 atm 81 15.00 7 Freeze/Anneal Hold -35 atm 60 16.00 8 Primary Drying Hold -35 100 1200 36.00 Secondary drying Rate 20 2.5 100 1300 57.67 11 Secondary drying Hold 20 100 360 63.67 [0351] The developed lyophilization cycle was successfully applied to Compound formulations.
5 .. Example 8. Exemplary formulations [0352] The target product profile (TPP) was defined as:
= c(Compound 1) = 10 mg/mL
= Sodium phosphate buffer, pH = 6.8, cp = 270-320 mOsm/kg = Minimal number and minimal concentration of excipients (bulking agents, solubilizing 10 agents) that facilitate robust preparation of a lyophilized drug product = Neutralization of the Compound 1=FIC1 during liquid compounding during preparation of the lyophilization fill solutions [0353] A limited formulation matrix of 108 formulations was created. The matrix comprised bulking agents, co-solvents, cyclodextrins at varying concentrations (Table 8); the concentration of sodium phosphate (10 mM) and the API (10 mg/mL) were kept constant.
Table 8. Excipients evaluated in the limited formulation testing matrix Approx. Conc.
Excipient Category [%], w/w Mannitol bulking aent 4.0, 3.5, 3.0, 2.5 Lactose bulking agent 8.0, 7.0, 6.0, 5.0, 1.5 HPPCD bulking/solubilizing 5.0, 2.1, 0.7, 0.0 (encapsulating) agent Captisol bulking/solubilizing (Sulfobutyl ether (encapsulating) agent 5.6, 2.4, 0.8, 0.0 P-cyclodextrin) PEG 400 solubilizing agent 0.05, 0.00 (cosolvent) TWEEN 20 solubilizing agent 0.01, 0.00 (cosolvent) [0354] Formulations always contained mannitol or lactose as a bulking agent and varying amounts of cyclodextrins and cosolvents. Usually the concentration of the bulking agent was varied to maintain an osmolality in the appropriate range. Lyophilization at an increased total volume concordant with a lower concentration of all formulation components compared to the .. final reconstitution strength was evaluated.
[0355] The 108 formulations were compounded from stock solutions including neutralization of Compound 1=FIC1 and lyophilized in triplicates and duplicates on a 1 mL
scale using 5 mL lyophilization vials. The concentration of excipients denoted in percent w/w is relative to the weight of Compound 1. The concentration of excipients denoted in percent (w/w or w/v) can only be considered to be approximate and do not reflect absolute w/w or w/v percentages, since neutralization compounding from stock solutions involves dilutions that do not account for defined mass or volume-ratios.
[0356] The following formulations represent the top, equally well-performing candidates with the mannitol containing formulation providing a more elegant cake structure and the .. lactose formulation achieving a cleaner, less foamy reconstitution.
= Formulation 1: 10 mg/mL Compound 1, 10 mM sodium phosphate, pH = 6.8,5%
HPOCD, 3% Marmitol = Formulation 2: 10 mg/mL Compound 1, 10 mM sodium phosphate, pH = 6.8, 5%
HPOCD, 3% Marmitol, 0.05 % PEG400 = Formulation 3: 10 mg/mL Compound 1, 10 mM sodium phosphate, pH= 6.8,5%
HPOCD, 5% Lactose = Formulation 4: 10 mg/mL Compound 1, 10 mM sodium phosphate, pH= 6.8,5%
HPOCD, 5% Lactose, 0.05 % PEG400 = Formulation 5: 10 mg/mL Compound 1, 10 mM sodium phosphate, pH = 6.8, 3.5%
HPOCD, 3% Mannitol = Formulation 6: 10 mg/mL Compound 1, 10 mM sodium phosphate, pH= 6.8, 3.5%
HPOCD, 5% Lactose Example 9. Preparation of Formulation 5 at an increased bench scale [0357] Formulation 5 was prepared to the target concentration of c(Compound 1) = 10 mg/mL on a 210 mL scale. First, a liquid fill solution was compounded including neutralization of the Compound 1=FIC1 component before lyophilization containers were filled and lyophilization was performed. Amber lyophilization containers at Vcontamer = 20 mL
and a fill volume of Vfitt = 5 mL were applied.
[0358] The fill solution was compounded from the following stock solutions at the given multifold concentration:
i. Aq. Compound 1 stock solution, c(Compound 1) = 40 mg/mL, [4X]
ii. 10 % aq. mannitol stock solution(w/v), [3.33X]
iii. 28% aq. HPPCD stock solution (w/w), [8X]
iv. 500 mM aq. sodium hydroxide stock solution [12.82X]
v. 100 mM aq. sodium phosphate buffer, pH = 6.8 [10X].
[0359] For preparation of the fill solution the residual volume of water to reach the target concentrations was added to the Compound 1 stock solution under constant stirring.
Subsequently the mannitol and HPPCD stock solutions were dispensed into the mixture before the sodium hydroxide stock solution was added to yield a final c(NaOH) = 39 mM. In the last step the 10X sodium phosphate buffer was added and the solution was allowed to cool to ambient temperature.
[0360] The mannitol, HPPCD and buffer stock solutions were filtered (0.2 p.m PES
membrane, 20 mm syringe filter, Acrodisc Supor EKV) prior to compounding without observing any difficulties. The ready-compounded lyophilization fill solution was likewise filtered (0.2 p.m PES membrane, 20 mm syringe filter, Acrodisc Supor EKV) before dispensing into lyophilization vials under best clean conditions.
[0361] The 40 resulting lyophilization vials were arranged densely packed at the center of the lyophilization and placed at the center shelf of the lyophilizer product chamber. Product vials were surrounded by vials filled with buffer solution. The developed lyophilization cycle from Example 7 was applied for lyophilization of the product vials; vials were stoppered manually after vacuum release to ambient air.
Example 10. Reconstitution and reconstitution stability of the lyophilized Compound 1 drug product [0362] The lyophilized Compound 1 drug product was subjected to testing of reconstitution and to stability testing for 6 h after reconstituted with DI water VDtwater =
5 mL.
[0363] The lyophilization cake readily reconstituted within 10-20 s. The solution during reconstitution appeared quite foamy and contained many bubbles, which cleared within approximately 2 min addition of the reconstitution solution. Residual micro-bubbles on the container wall can be removed by vortexing (2 s) or sonication (2 s). The reconstituted solution appears clear and colorless. The pH of the reconstituted solution was measured with pH = 6.81; the osmolality was determined to cp = 295 mOsm/kg. The reconstituted solution was practically free of particulates as determined by liquid particle counting (LPC, HIAC: Vsamme = 5 mL, nmas = 4, 1st run discarded, fammen = 10, Vnommal, container = 2 ml) with a cumulative count of 3200 particles at a size of 10 p.m and 667 particles at a size of 25 p.m.
[0364] The recovery of Compound 1 was monitored for 24 h after reconstitution to test for the in-use stability of the reconstituted solution (Table 9) Table 9. Excipients evaluated in the limited formulation testing matrix c(Compoun Avg. Avg. Avg. StDev. Avg.
Condition d 1, Compoun Compoun c(Compoun c(Compoun % pH
s FB, Theor.) d 1 d 1 Peak d 1, FB, d 1, FB, Compoun (Meas.
Img/mL] Retention Area Obs.) Obs.) d 1 Time ImAU21 [mg/mL] Recovery [min]
Reconst. to 9.65* 4.22 464901 9.65 0.78 100*
6.80 Reconst, 9.65 4.22 456448 9.47 0.12 98 6.79 t=lh Reconst, 9.65 4.22 444244 9.20 0.09 95 6.80 t=2h Reconst, 9.65 4.21 8501104 9.19 0.28 95 6.79 t=4h Reconst, 9.65 4.22 448263 9.28 0.06 96 6.79 t=6h Reconst, 9.65 4.21 434893 8.99 0.01 93 6.85 t=24h *%recovery(Compound 1) 100 %, since Vfm solution = VDIwater, reconst ; #different dilution was applied for preparation of the HPLC sample [0365] The current phosphate-based formulation containing HPPCD and mannitol shows a loss in Compound 1 recovery of approximately 7% over the course of 24 h.
Example 11. Compatibility with infusion vehicles and in use storage of reconstituted Compound 1 formulation [0366] The compatibility of the reconstituted Compound 1 formulation with two infusion vehicles, normal saline (NS) and 5% dextrose in water (D5W) was tested after At = 4 h for two concentration (high/low) at c(Compound 1, target) = 0.1 mg/mL and c(Compound 1, target) = 1.0 mg/mL and at ambient conditions (Table 10). The average values of % recovery are relative to the dilution of the reconstituted drug product into DI water at to.
Table 10. Assessment of compatibility with infusion vehicles c(Compound Avg. Avg. Avg. StDev. Avg.
Conditions 1, Compound Compound c(Compoundc(Compound %
FB, Theor.) 1 1 1, FB, Obs.) 1, FB, Obs.) Compound Img/mL] Retention Peak Area [mg/mL] 1 Time ImAU21 Recovery [min]
Water, to 0.09* 4.22 449346 0.09 6.10-Water, t=4h 0.09 4.22 448417 0.09 4.10-NS, t=4h 0.09 4.21 450839 0.09 5.10-D5W, t=4h 0.09 4.21 445119 0.09 2.10-Water, to 0.92* 4.22 445348 0.92 3.10-Water, t=4h 0.92 4.22 444601 0.92 6.104 NS, t=4h 0.92 4.21 446396 0.92 3.10-D5W, t=4h 0.92 4.21 446458 0.92 1.10'3 *%recovery(Compound 1) d4 100%, since Vfin solution= VDIwater, reconst.;
[0367] Both infusion, NS, and D5W are compatible with the reconstituted Compound 1 drug product at the tested concentrations and within the course of 4 h at ambient temperature and lighting conditions.
Example 12. Compatibility of reconstituted Compound 1 formulation with vials and stoppers [0368] The compatibility of the reconstituted Compound 1 formulation with sterile manufacturing vials and stoppers (Table 17) was tested for a contact time of At = 1 h at c(Compound 1, target) = 10 mg/mL at ambient conditions. The average values of %recovery are relative to the reconstituted drug product that has not been in contact with the tested materials.
Table 11. Assessment of compatibility with vials and stoppers for manufacturing c(Compound Avg. Avg. Avg. StDev. Avg.
Conditions 1, FB, Compound Compoundc(Compoundc(Compound %
Theor.) 1 1 1, FB, Obs.) 1, FB, Obs.) Compound Img/mL] Retention Peak Area [mg/mL] 1 Time ImAU21 Recovery [min]
Reconst. Soln., 9.32* 4.21 450793 9.32 0.02 100*
Vial, t = lh 9.32 4.21 449081 9.28 0.02 100 Stopper, t = lh 9.32 4.20 449072 9.28 0.01 100 *%recovery(Compound 1) d4 100%, since Vol solution = VDIwater, reconst [0369] Table 11 shows the tested vial and stopper material is compatible with the reconstituted Compound 1 drug product at the tested concentrations and within the course of 1 h at ambient temperature and lighting conditions.
Example 13. Compatibility of reconstituted Compound 1 formulation with sterilization filters [0370] The feasibility of aseptic processing was evaluated and three different filter materials were tested for compatibility with the reconstituted Compound 1 formulation.
Aseptic processing is the generally suggested method for sterilization of Compound 1, since Compound 1 comprises a decreased stability at elevated temperature and only dry sterilization cycles (T= 160 C, t = 120 min) are applicable for lyophilized drug product as a terminal sterilization option.
[0371] Filter compatibility of the reconstituted Compound 1 drug product was tested with different filter material (Table 17) composed of polyethersulfone (PES), nylon, and polyvinylidene fluoride (PVDF). For this a volume of Vfilter pass = 10 mL was passed through the respective filter and the first as well as the last 10 vol% of the filtered volume were assayed for recovery of Compound 1 (Table 12).
Table 12. Assessment of compatibility with sterilization filters c(Compound Avg. Avg. Avg. Avg.
Conditions 1, Compound 1 Compound 1 c(Compound % Compound FB, Theor.) Retention Peak Area 1, FB, Obs.) 1 [mg/mL] Time ImAU21 Img/mL] Recovery [min]
Sample Soln. 0.95* 4.14 4296856 0.95 100*
(pre-filtration) PES, first 10% 0.95 4.15 4285782 0.94 100 PES, last 10% 0.95 4.14 4296190 0.95 100 Nylon, first 10% 0.95 4.15 4255708 0.94 99 Nylon, last 10% 0.95 4.14 4297770 0.95 100 PVDF, first 10% 0.95 4.13 4306693 0.95 100 PVDF, last 10% 0.95 4.13 4305766 0.95 100 *%recovery(Compound 1) 100%, since Vfin solution = VDIwater, reconst [0372] The average values of %recovery are relative to the reconstituted drug product that has not been in contact with the tested materials. No increase in back-pressure was observed with any of the tested filters. At the studied filter pass volumes and concentrations no significant loss in Compound 1 recovery was observed.
Example 14. Compatibility of reconstituted Compound 1 formulation with infusion bags and IV systems [0373] The compatibility of the reconstituted Compound 1 formulation with two infusion bags (different volumes and material) and two IV lines was tested (Table 13) at c(Compound 1) = 0.1 mg/mL. After injection of the reconstituted drug product solution into infusion bags filled with NS, the recovery of Compound 1 was measured i) directly after mixing with the infusion vehicle (to, Table 14) and ii) after At = 10 min of contact time with the infusion bag (Table 15). Additionally, storage in an infusion bag at ambient temperature and lighting conditions was assessed for At = 6 h (Table 15). The average values of %recovery are .. relative to the reconstituted drug product that has not been in contact with the tested materials.
Table 13. Tested infusion bag and IV system material Size Article #1 Material [mL] Manufact. Description Catalog #
Lot #
0.9% Sodium Chloride Inf. bag #1 500 Baxter Injection USP (500 mL FE1323 14J15E3D
Viaflo Bag) 0.9% Sodium Chloride Inf. bag #2 50 Baxter Injection USP (50 mL 2B1301 P326306 Viaflex Bag) Clearlink/Interlink, Non-IV system --- Baxter DEHP solution set, Duo-vent EMS3110 R14H27059 #1 spike IV system --- Baxter Clearlink system, continuo- 2C8519S R14J10060 #2 Flo solution set Table 14. Assessment of compatibility with infusion bags at to.
c(Compound Avg. Avg. Avg. StDev. Avg.
Conditions 1, Compound Compound c(Compoundc(Compound %
FB, Theor.) 1 1 1, FB, Obs.) 1, FB, Obs.) Compound [mg/mL] Retention Peak Area Img/mL] 1 Time ImAU2] Recovery [min]
Sample soln. 0.09* 4.19 441971 0.09 1.3E-01 100*
(water) infus. bagl, to 0.09 4.19 423961 0.09 1.8E-04 96 infus. bag2, to 0.09 4.19 393294 0.08 7.1E-05 88 *%recovery(Compound 1) 100%, since Vfin solution = VDIwater, reconst Table 15. Assessment of compatibility with infusion bags at t = 10 min and 6 h storage in infusion bag c(Compound Avg. Avg. Avg. StDev. Avg.
Conditions 1, Compound Compound c(Compoundc(Compound %
FB, Theor.) 1 1 1, FB, Obs.) 1, FB, Obs.) Compound Img/mL] Retention Peak Area [mg/mL] 1 Time ImAU2] Recovery [min]
infus. bagl, to 0.09* 4.18 436470 0.09 2.7E-04 100*
infus. bagl, 0.09 4.18 436694 0.09 3.6E-04 100 t=l0min infus. bagl, 0.09 4.19 436411 0.09 2.0E-04 100 t=6h infus. bag2, to 0.08* 4.18 401640 0.08 1.1E-04 100*
infus. bag2, 0.08 4.18 401638 0.08 5.2E-05 100 t=l0min infus. bag2, 0.08 4.19 400252 0.08 4.2E-04 100 t=6h *%recovery(Compound 1) d4 100%, since Vfin solution= VDIwater, reconst [0374] The two IV systems were evaluated for compatibility with the reconstituted drug .. product solution by filling the IV lines with the diluted (NS) drug product solution and flowing Vflow through (FT) = 101 mL through the respective IV system at a flow rate of 5 mL/min.
Flow-through samples of Vsample = 1 mL were collected i) immediately (VFT = 0 mL), ii) after VFT = 10 mL and iii) after VFT = 100 mL. Flow through samples were assayed for recovery of Compound 1 and compared to the infusion solution in the reservoir at to (Table 16).
Table 16. Assessment of compatibility with IV systems c(Compound Avg. Avg. Avg. StDev. Avg.
Conditions 1, FB, Compound Compoundc(Compoundc(Compound %
Theor.) 1 1 1, FB, Obs.) 1, FB, Obs.) Compound Img/mL] Retention Peak Area [mg/mL] 1 Time ImAU21 Recovery [mini infus. bag, to 0.09* 4.18 436470 0.09 2.7E-04 100*
(IV#1) IV#1, VFT = 0.09 4.18 436836 0.09 100 0 mL
IV#1, VFT = 0.09 4.18 438353 0.09 100 10 mL
IV#1, VFT = 0.09 4.18 440111 0.09 100 100 mL
infus. bag, tO 0.09* 4.18 436640 0.09 1.1E-04 100*
(IV#2) IV#2, VFT = 0.09 4.18 436142 0.09 100 0 mL
IV#2, VFT = 0.09 4.18 436115 0.09 100 mL
IV#2, VFT = 0.09 4.19 436142 0.09 100 100 mL
*%recovery(Compound 1) 100%.
103751 The tested infusion bags and IV system material is compatible with the reconstituted Compound 1 drug product at the tested concentrations and exposure times.
While storage in the infusion bags up to 6 h does not change the concentration of Compound 5 1 in the respective infusion vehicle compared to to (approximately 1 min after exposure), it seems to be the case that some Compound 1 material is adsorbed from the infusion bag material immediately after contact. Thereby, the observed changes in Compound 1 recovery do not correlate with the surface area of the tested infusion bags but seem to be dependent on the infusion bag material. Infusion bag #1 (Viaflo) shows a lesser extent of Compound 1 10 adsorption than infusion bag #2 (Viaflex).
103761 Both IV systems appear to be inert towards binding of Compound 1; no changes in Compound 1 recovery were observed after flowing the Compound 1 solution derived from dilution of the reconstituted drug product solution through either IV test system.
Example 15. Materials and Equipment Table 17. Materials Material Supplier/Manufactur Part Number Lot # / Serial #
0.9% Sodium Chloride Injection Baxter 2B1301 P326306 USP (50 mL Viaflex Bag) 0.9% Sodium Chloride Injection Baxter FE1323 14J15E3D
USP (500 mL Viaflo Bag) Acetic Acid (glacial) BDH UN2789 Acetonitrile Fisher Scientific A998-4 146154/151811 Cannulas (Precision Glide Becton Dickinson 305175 614499 Needle D-D20G1)) Captisol (beta cyclodextrin CyDex Inc. NC-sulfobutyl ethers, sodium salts) Citric acid anhydrous Spectrum C1131 XCO269 Clearlink system, continuo-Flo Baxter 2C8519S R14J10060 solution set Clearlink/Interlink, Non-DEHP Baxter EMS3110 R14H27059 solution set, Duo-vent spike Crimp Seals (Afton Ready-To- Afton Scientific 54202258 1745-15 Fill Sterilized Seals) Deionized water (ultra pure) In-house, Nanopure Infinity (Barnstead) water DSC pans (Pan + Lid, Hermetic TA Instruments T131003/T14060 900796.901/
Alodined) 3 900790.901 Ethanol (dehydrated, 200 proof, Spectrum ET107 ZT0426 Undenatured, USP) Halo C18 HPLC column MAC-MOD 92814-602 AH142237/
HPLC (vials clear) VWR 46610-722 24108033 HPLC vials (amber) VWR 46610-726 24107863 Hydrochloric Acid Fisher Scientific A144-500 48038830 Hydrogen Peroxide 35%, w/w, Alfa Aesar L14000 W03A029 stab.
Hydroxypropy1-13-cyclodextrin Spectrum H2690 1D60239 Lactose Monohydrate Spectrum LA106 R00212 Lyophilization bottles (Wheaton, 20 mL, Serum Wheaton 223762 1550400 bottles, Borosilicate glass, amber) Lyophilization stoppers (Wheaton, 20 mm, STPR, 3- Wheaton W224100-202 1539836 Leg, Lyo, 13x20, GRY, BTYL, SLZD) Lyophilization vials (Wheaton, mL vials, serum, Type I Wheaton 223685 Borosilicate glass, clear) Lyophilization vials (Wheaton, 5 mL vials, serum, Type I Wheaton 223695 1548721 Borosilicate glass, amber) Magnetic Stir Bars (various VWR
sizes) Maleic acid Spectrum M1075 VG1288 Marmitol (USP) Spectrum MA165 XE1369 Manufacturing stoppers, sterile West Pharmaceutical (20 mm Lyo NovaPure RP Services, Inc. 19700311 D000039730 V10- F597W 4432/50 West ready pack) Manufacturing vials, sterile Afton Scientific (via (Ready- to-fill Sterilized Vials, West Pharmaceutical 68000369 5ML 20MM S/L FNT W/BB Services, Inc.) Osmometry Std. 100 mOsm/kg Fisher Scientific 12-827-12 (Precision Systems No. 2101) Osmometry Std. 300 mOsm/kg Fisher Scientific 12-827-13 (Precision Systems No. 2103) Osmometry Std. 500 mOsm/kg Fisher Scientific 12-827-14 (Precision Systems No. 2105) pH Standard (pH 10.000) Ricca Chemical 1602-16 250 1A26 Company pH Standard (pH 4.000) Ricca Chemical 1502-16 2410B96 Company pH Standard (pH 7.000) Ricca Chemical 1552-16 2410761 Company Phosphoric acid Sigma Aldrich 438081-Polyethylene glycol 400, NF Spectrum P0110 ZQ0106 (PEG 400) Polysorbate 80, NF Spectrum P01138 2DJ0314 Prominence Autosampler Vial Shimadzu 228-45454-Closures Sodium acetate anhydrous EMD 7510 1775B65 Sodium citrate=2H20 Acros Organics 446330010 A0342566 Sodium hydroxide solution VWR BDH7247-1 410417 N
Sodium hydroxide solution Fisher Scientific SS276-1 100160 Sodium phosphate dibasic Spectrum S0138 WG0695 anhydrous Sodium phosphate dibasic Spectrum S1108 VM0472 dihydrate Sodium phosphate monobasic Spectrum S0187 VK1125 anhydrous Sucrose (NF) Spectrum 5U103 RB0137 Syringe filters (0.2 p.m, 25 mm, Pall 4436 11961095 Acrodisc, Nylon) Syringe filters (0.2 p.m, 25 mm, Pall 4405 12491302 Acrodisc, Supor EKV) Syringe filters (0.22 p.m, 25 Millipore SLGVM33RS
mm, Milles GV, PVDF) Syringes Luer-Lock TIP (60 ml, 8107397/
10 mL, 5 mL) BD 309653/-04/-46 5026529/
TGA Pans (ceramic) TA Instruments T060516 952323.902 Trifluoroacetic acid EMD TX1276-6 48038830 TWEEN 20 Fisher Scientific BP337-500 117274 Weighing pans Fisher Scientific NC0184742 n/a (Aluminum,12 mm) Table 18. Equipment Equipment Description Analytical Balance Mettler Toledo MX-5, S/N #1126472420 Bath¨type Sonicator Fisher Scientific, F530 (100W, 42 kHz), S/N #RTA12119995B
Biological Safety NuAire Class II, Type A/B3, Model: Nu-425-600, S/N
Cabinet #12757041800 Crimper Wheaton, 20 mm, 224323 Decrimper Wheaton, 20 mm, W225353 Differential Scanning TA Instrument, DSC Q100 Calorimeter Digital Timer VWR Laboratory Timer, Product #62344-641, S/N # 101445261 Environmental ThermoForma 3911, S/N #40759-101 Chambers ThermoForma 3911, S/N #57484-132 HIAC Pacific Scientific, HIAC Royco Model 9703 Liquid Particle Counting System, Sensor: HRLD400CE (serial# F06211); Pharm Spec Software Controller Unit: Shimadzu Prominence CBM-20A
Pump System: Shimadzu Prominence LC-20 AD
Autosampler: CTC HTS PAL
Degasser: Shimadzu Prominence DGU-20As LC-MS/MS System MS Detector: Applied Biosystems API 4000 Column Oven: Shimadzu Prominence CTO-20A
Software: Applied Biosystems/MSD SCIEX
Instruments: Analyst Software Lyophilizer VirTis 25L Genesis SQ Super XL lyophilizer, S/N #214950;
Encore iFIX Software V. 3.5 Magnetic Stir Plate Barnstead/Thermolyne, Cimarec 2 (S46725) Micro Osmometer Precision Systems, u0smette, Mode1:5004 Micro-pipettes Rainin Instrument Co., Pipetmen P-10, P-20, P-100, P-200, P-1000 and P- 5000 pH-Meter/ pH- Thermo Scientific Orion Star A211, S/N #127 Electrode VWR Symphony semi-micro pH-electrode (epoxy) BNC, #89231-576 Thermo Scientific, Part #9810BN, Lot # SS1 Photostability Caron Photostability Chamber 6540-1, S/N #011607-6540-1-Chamber Refrigerator GE Refrigerator GTS18FBMFRWW, S/N #FF759776 Jordon Scientific Refrigerator Repeater Pipette Eppendorf Repeater Plus, incl. CombiTips Plus (10 mL, 5 mL, 2.5 mL) Rotisserie Barnstead 415110, S/N #1105060242886, incl. sample holder for 15 mL conical tubes Tabletop Centrifuge Eppendorf Centrifuge 5414D (24-place fixed-angle rotor for 1.5-2.0 mL tubes/F-24-45-11) Thermogravimetric TA Instruments, TGA Q500 Balance Pump System: Shimadzu Prominence LC-20 AT
Auto-sampler: Shimadzu Prominence SIL-20AC
Degasser: Shimadzu Prominence DGU-20As Detector: Shimadzu Prominence SPD-20A
UV-HPLC System 12 Column Oven: Shimadzu Prominence CTO-20A
Software: Shimadzu Class VP Client/Server V7.4 Column: MAC-MOD Halo C18, Part #: 92814-602, SN#: AH142237/ U5RG003098 Vortex Mixer National Labnet Co. Inc, VX100 (S01100) Diffractometer: Rigaku MiniFlex, #2005G302, S/N
#CD04539 (30 kV/50 mA, Cu-Ka) Cooling unit: Haskris WA1 XRD Equipment Sample Holder Six-Position Sample Changer with Sample Mount: Spinner ASC-6, #2455E431 Sample Holder: Zero Background Sample Holder ¨ 100 micron indent, round, #SH-LBSI511-RNDB
Example 16. Long -Term Stability Studies [0377] Exemplary long-term stability studies of the Compound 1 lyophilized drug product are shown in FIGS. 7-9 for T = -80 C, T = -20 C, and T= 2-8 C, respectively. The studies were initiated by collecting data of an initial time point (to) and subjecting the required amount of sample to the respective testing conditions. Stability of the Compound 1 lyophilized drug product was evaluated after t = 1 month, 3 month, 6 month, 9 month, and 12 month. The tests include appearance, reconstitution time, reconstitution appearance, recovery & impurity (HPLC assay), pH, and LPC (HIAC, particulates).
Example 17. Compounding process for Compound 1 liquid injectable formulation .. [0378] Compounding process for liquid formulations of Compound 1, designed for dilution into infusion vehicles was developed with 3.0 mg/mL of Compound 1 (or 3.13 mg/mL
Compound 1 free base equivalent), phosphate buffer solution (PBS), and pH of 6.4-7.2. The compounding process was applied over a wide range of scales (25-500 mL).
[0379] The compounding of the drug product required a neutralization step using 0.5N
sodium hydroxide solution and buffering with PBS to adjust the pH to values compatible with an IV infusion. The compounding process also required a filtration step, which also served as aseptic processing. Either a minimal loss or no loss of Compound 1 was observed.
[0380] The compounded formulations were diluted into infusion vehicles: normal saline, 5%
dextrose in water (D5W), and lactated Ringer's solution (buffered and unbuffered). The dilution into normal saline was carried out at 100-fold and 600-fold dilution.
[0381] Compound 1 formulations were stable at 2-8 C for at least one week with nominal degradation of < 4%. The observed Compound 1 was within the error range of sample preparation, so it is feasible that no measurable degradation was occurring during the studied time frame. When Compound 1 formulation was diluted into normal saline, the resulting infusate solution at c(Compound 1) = 0.03 mg/mL was stable at ambient temperature for at least 48 hours. The pH was constant over 48 hours and no significant loss in Compound 1 recovery was observed. The purity for Compound 1 appeared unchanged for over 48 hours and the chromatographic trace recorded after 48 hours did not reveal additional peaks or growth of observed degradants (FIG. 10).
Example 18. Efficacy study of Compound 1 in a hound cardiopulmonary bypass model [0382] The objective of this study was to demonstrate the efficacy of Compound compared to the Standard of Care (SOC), heparin, for preventing activation of blood coagulation components while using the Cardiopulmonary Bypass (CPB) circuit during an extended run time on Day 1 in a mixed breed hound dog model. The study design is shown in Table 19:
Table 19. Experimental Design (Target Doses of Compound lb) IV IV
IV Bolus Infusion Dose Dose Loading Dose Dose Dose Infusion Concentration Compound No. of Dose Volume Concentration Level Rate for IV 1 in Prime Group Animals (mg/kg) (mL/kg) for IV Bolus (mg/kg/hr) (mL/kg/hr) Infusion Solution 1 3 NA NA NA 3 5 0.6 mg/mL
NA
0.6 [tg/mL and 0.01 2 2 3 1 3 5 0.6 [tg/mL
3 mg/mLa mg/mL
3 2 10 1 10 mg/mL 10 5 2.0 mg/mL
0.01 mg/mL
4 2 10 1 10 mg/mL 10 5 2.0 mg/mL
0.01 mg/mL
2 10 1 10 mg/mL 10 5 2.0 mg/mL 0.01 mg/mL
NA ¨ Not Applicable a Animal No. 1001 received 0.6 [tg/mL and Animal No. 1004 received 3 mg/mL.
b Doses shown are targets for the dosing on this study; actual dose values are shown in the 5 results section.
[0383] The following parameters and endpoints were evaluated in this study:
mortality, body weight, physical, clinical pathology parameters (hematology and coagulation), coagulation time, and bioanalytical parameters.
Experimental Design Administration [0384] The vehicle and test article were administered via intravenous (IV) infusion once on Day 1 for 135 minutes (initiated 30 minutes prior to starting the Cardiopulmonary Bypass (CPB) and continuing for 105 minutes of CPB). Group 2 animals received a 0.6 [tg/mL or 3.0 mg/mL IV bolus dose immediately prior to the start of IV infusion. Group 3, 4, and 5 animals received a 10 mg/kg IV bolus dose prior to the start of the IV
infusion; with the CPB
machine primed with test article at 10 [tg/mL.
Surgical Procedure [0385] Group 1 had an infusion pump setup with an open system/reservoir.
Infusion of the Compound 1 was started 30 minutes prior to the animal being placed on the CPB
pump. The CPB pump was primed with 0.9% saline.
[0386] Groups 2, 3, and 4 had an infusion pump setup with an open system/reservoir.
Venous and arterial sheaths were flushed with the Compound 1 at a concentration of 10 g/mL. An IV bolus dose of the test article was administered immediately prior to the start of the infusion. Infusion of Compound 1 was started 30 minutes prior to the animal being placed on the CPB pump. The CPB patient was primed with 10 g/mL of the Compound 1 prior to initiation of the CPB pump.
[0387] Group 5 had an infusion pump setup with a closed system/"bag." Venous and arterial sheaths were then flushed with Compound 1 at 10 g/mL. An IV bolus dose of the Compound 1 was administered immediately prior to the start of the infusion.
Infusion of Compound 1 was started 30 minutes prior to the animal being placed on the CPB
pump.
Results [0388] FIG. 11 shows pressure gradients assessed across the membrane oxygenator.
Studies previously conducted with no anticoagulant demonstrated that the pressure across the membrane oxygenator built within 15 minutes of pump start and exponentially increased over the next 30 minutes such that the oxygenator was occluded and the circulation was stopped, whereas with Compound 1 at multiple doses, the pressure gradient across the membrane oxygenator stayed consistent through the entire run, indicating that the test article successfully maintained anticoagulation allowing the continuation of the pump run for the entirety of the protocol.
[0389] FIG. 12 shows a correlation between Compound 1 plasma concentration and aPTT.
All animals survived to study termination. Overall, Compound 1 was not associated with any increases in morbidity or mortality at the dose levels used in this study during the Cardiopulmonary bypass/ECMO protocol.
[0390] During Compound 1 infusion and prior to CPB, aPTT was moderately to markedly prolonged in all animals (FIG. 13). Prolongations in aPTT persisted throughout Compound 1 infusion and CPB. In groups that received a loading dose of Compound 1 (Groups 2 through 5), prolongations in aPTT were most pronounced prior to (Group 3 through 5) or during the first 30 minutes of CPB (Group 2), but then improved slightly before reaching steady-state.
Group 1 animals did not receive an Compound 1 loading dose, and prolongations in aPTT
remained relatively consistent at all measured timepoints during Compound 1 infusion in this group. In all groups following cessation of Compound 1 infusion and CPB, aPTT
trended towards baseline values, but remained moderately prolonged at the conclusion of the study.
Conclusions [0391] Administration of the Compound 1 to the model was successful in preventing the activation of blood coagulation in components of cardiopulmonary bypass. The anticoagulant effects of Compound 1 were selective to inhibition of activated partial .. thromboplastin time (aPTT). Additionally, the data demonstrated that adding a bolus dose immediately prior to starting the infusion enabled targeted plasma levels of Compound 1 to rapidly be achieved, along with desired steady state levels, and was sufficient to achieve a successful 105-minute CPB run and prevent coagulation in most of the circuit components.
[0392] Overall, these data indicate that Compound 1 may be an acceptable alternative to heparin in preventing blood coagulation in components of cardiopulmonary bypass.
Claims (96)
1. An aqueous pharmaceutical composition comprising a compound of Formula (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and an excipient.
2. The pharmaceutical composition of claim 1, wherein the cyclodextrin is selected from the group consisting of alkyl cyclodextrin, hydroxyalkyl cyclodextrin, carboxyalkyl cyclodextrin, and sulfoalkyl ether cyclodextrin.
3. The pharmaceutical composition of claim 1 or 2, wherein the cyclodextrin is hydroxypropy113-cyclodextrin.
4. The pharmaceutical composition of claims 1 or 2, wherein the cyclodextrin is sulfobutyl ether 0-cyc1odextrin.
5. The pharmaceutical composition of any one of claims 1 to 4, wherein the excipient is a sugar (e.g., a saccharide (e.g., monosaccharide, disaccharide, or polysaccharide)) or a sugar alcohol.
6. The pharmaceutical composition of any one of claims 1 to 5, wherein the excipient is sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, or mannitol, or a combination thereof
7. The pharmaceutical composition of any one of claims 1 to 6, wherein the excipient is mannitol.
8. The pharmaceutical composition of any one of claims 1 to 6, wherein the excipient is lactose.
9. The pharmaceutical composition of any one of claims 1 to 8, further comprising a buffer.
10. The pharmaceutical composition of claim 9, wherein the buffer is a monoprotic acid or a polyprotic acid or a combination thereof
11. The pharmaceutical composition of claim 9 or 10, wherein the buffer is a solution of one or more substances.
12. The pharmaceutical composition of any one of claims 9 to 11, wherein the buffer is a solution of a salt of a weak acid and a weak base.
13. The pharmaceutical composition of any one of claims 9 to 11, wherein the buffer is a solution of a salt of the weak acid with a strong base.
14. The pharmaceutical composition of any one of claims 9 to 13, wherein the buffer is selected from the group consisting of a maleate buffer, a citrate buffer, and a phosphate buffer.
15. The pharmaceutical composition of any one of claims 9 to 14, wherein the buffer is a phosphate buffer.
16. The pharmaceutical composition of claim 15, wherein the phosphate buffer is a solution of monosodium phosphate, disodium phosphate, trisodium phosphate, or a combination thereof
17. The pharmaceutical composition of any one of claims 1 to 17, further comprising a solubilizing agent.
18. The pharmaceutical composition of claim 17, wherein the solubilizing agent is a polyoxyethylene sorbitan ester (e.g, TWEENO 20) or a polyethylene glycol (e.g., PEG400).
19. The pharmaceutical composition of any one of claims 1 to 18, wherein the pH of the composition is from about 2 to about 8.
20. The pharmaceutical composition of any one of claims 1 to 19, wherein the pH of the composition is about 6.8.
21. The pharmaceutical composition of any one of claims 1 to 20, wherein the concentration of the compound of Formula (I-A) is from about 0.1 mg/mL to about 100 mg/mL.
22. The pharmaceutical composition of any one of claims 1 to 21, wherein the concentration of the compound of Formula (I-A) is about 10 mg/mL.
23. The pharmaceutical composition of any one of claims 9 to 22, wherein the concentration of the buffer is from about 1 mM to about 500 mM.
24. The pharmaceutical composition of any one of claims 9 to 23, wherein the concentration of the buffer is about 10 mM.
25. The pharmaceutical composition of claim 23 or 24, wherein the buffer is a phosphate buffer.
26. The pharmaceutical composition of any one of claims 1 to 25, wherein the cyclodextrin is in an amount of from about 0.1% to about 10% (e.g., about 0.5%
to about 6%
(e.g., about 0.7% to about 5.6% (e.g., about 2.1 % to about 5%))) by weight relative to weight of the compound of Formula (I-A).
to about 6%
(e.g., about 0.7% to about 5.6% (e.g., about 2.1 % to about 5%))) by weight relative to weight of the compound of Formula (I-A).
27. The pharmaceutical composition of any one of claims 1 to 26, wherein the cyclodextrin is in an amount of about 3.5% by weight relative to weight of the compound of Formula (I-A).
28. The pharmaceutical composition of any one of claims 1 to 26, wherein the cyclodextrin is in an amount of about 5% by weight relative to weight of the compound of Formula (I-A).
29. The pharmaceutical composition of any one of claims 26 to 28, wherein the cyclodextrin is hydroxypropyl 0-cyc1odextrin.
30. The pharmaceutical composition of any one of claims 1 to 29, wherein the excipient is in an amount of from about 0.1% to about 10% by weight relative to weight of the compound of Formula (I-A).
31. The pharmaceutical composition of any one of claims 1 to 30, wherein the excipient is in an amount of about 3% by weight relative to weight of the compound of Formula (I-A).
32. The pharmaceutical composition of any one of claims 1 to 30, wherein the excipient is in an amount of about 5% by weight relative to weight of the compound of Formula (I-A).
33. The pharmaceutical composition of any one of claims 30 to 32, wherein the excipient is mannitol.
34. The pharmaceutical composition of any one of claims 30 to 32, wherein the excipient is lactose.
35. A pharmaceutical composition comprising particles, wherein the particles comprise a compound of Formula (I-A) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and a bulking agent.
36. The pharmaceutical composition of claim 35, wherein the cyclodextrin is selected from the group consisting of alkyl cyclodextrin, hydroxyalkyl cyclodextrin, carboxyalkyl cyclodextrin, and sulfoalkyl ether cyclodextrin.
37. The pharmaceutical composition of claim 35 or 36, wherein the cyclodextrin is hydroxypropy113-cyclodextrin.
38. The pharmaceutical composition of claim 35 or 36, wherein the cyclodextrin is sulfobutyl ether 0-cyc1odextrin.
39. The pharmaceutical composition of any one of claims 35 to 38, wherein the bulking agent is a sugar (e.g., a saccharide (e.g., monosaccharide, disaccharide, or polysaccharide)) or a sugar alcohol.
40. The pharmaceutical composition of any one of claims 35 to 39, wherein the bulking agent is sucrose, lactose, trehalose, dextran, erythritol, arabitol, xylitol, sorbitol, or mannitol, or a combination thereof
41. The pharmaceutical composition of any one of claims 35 to 40, wherein the bulking agent is mannitol.
42. The pharmaceutical composition of any one of claims 35 to 40, wherein the bulking agent is lactose.
43. The pharmaceutical composition of any one of claims 35 to 42, wherein the bulking agent is a lyoprotectant.
44. The pharmaceutical composition of any one of claims 35 to 43 wherein the concentration of the compound of Formula (I-A) is from about 0.1 to about 10%
by weight of the composition.
by weight of the composition.
45. The pharmaceutical composition of any one of claims 35 to 44, wherein the concentration of the compound of Formula (I-A) is about 1% by weight of the composition.
46. The pharmaceutical composition of any one of claims 35 to 44, wherein the concentration of the compound of Formula (I-A) is about 0.3% by weight of the composition.
47. The pharmaceutical composition of any one of claims 35 to 46, wherein the cyclodextrin is in an amount of from about 0.1% to about 10% (e.g., about 0.5%
to about 6%
(e.g., about 0.7% to about 5.6% (e.g., about 2.1 % to about 5%))) by weight relative to weight of the compound of Formula (I-A).
to about 6%
(e.g., about 0.7% to about 5.6% (e.g., about 2.1 % to about 5%))) by weight relative to weight of the compound of Formula (I-A).
48. The pharmaceutical composition of any one of claims 35 to 47, wherein the cyclodextrin is in an amount of about 3.5% by weight relative to weight of the compound of Formula (I-A).
49. The pharmaceutical composition of any one of claims 35 to 47, wherein the cyclodextrin is in an amount of about 5% by weight relative to weight of the compound of Formula (I-A).
50. The pharmaceutical composition of any one of claims 47 to 49, wherein the cyclodextrin is hydroxypropyl 0-cyc1odextrin.
51. The pharmaceutical composition of any one of claims 35 to 50, wherein the bulking agent is in an amount of from about 0.1% to about 10% by weight relative to weight of the compound of Formula (I-A).
52. The pharmaceutical composition of any one of claims 35 to 51, wherein the bulking agent is in an amount of about 3% by weight relative to weight of the compound of Formula (I-A).
53. The pharmaceutical composition of any one of claims 35 to 51, wherein the bulking agent is in an amount of about 5% by weight relative to weight of the compound of Formula (I-A).
54. The pharmaceutical composition of any one of claims 51 to 53, wherein the bulking agent is mannitol.
55. The pharmaceutical composition of any one of claims 51 to 53, wherein the bulking agent is lactose.
56. A process for preparing an aqueous pharmaceutical composition from the pharmaceutical composition of any one of claims 35 to 55, the process comprising reconstituting the pharmaceutical composition into an aqueous medium, thereby forming the aqueous composition.
57. The process of claim 56, wherein the aqueous medium is deionized water.
58. The process of claim 56 or 57, wherein the aqueous medium comprises sodium chloride.
59. The process of claim 56 or 57, wherein the aqueous medium comprises about 5%
dextrose.
dextrose.
60. The process of any one of claims 56 to 59, wherein the composition is prepared to be suitable for parenteral administration to a subject in need thereof
61. The process of any one of claims 56 to 59, wherein the composition is prepared to be suitable for intramuscular, subcutaneous or intravenous administration to a subject in need thereof
62. A method of treating a thromboembolic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition of any one of claims 1-34, wherein the blood of the subject is contacted with an artificial surface.
63. A method of reducing the risk of a thromboembolic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition of any one of claims 1-34, wherein the blood of the subject is contacted with an artificial surface.
64. A method of prophylaxis of a thromboembolic disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition of any one of claims 1-34, wherein the blood of the subject is contacted with an artificial surface.
65. The method of any one of claims 62-64, wherein the artificial surface is in contact with blood in the subject's circulatory system.
66. The method of any one of claims 62-65, wherein the artificial surface is an implantable device, a dialysis catheter, a cardiopulmonary bypass circuit, an artificial heart valve, a ventricular assist device, a small caliber graft, a central venous catheter, or an extracorporeal membrane oxygenation (ECMO) apparatus.
67. The method of any one of claims 62-66, wherein the artificial surface causes or is associated with the thromboembolic disorder.
68. The method of any one of claims 62-67, wherein the thromboembolic disorder is a venous thromboembolism, deep vein thrombosis, or pulmonary embolism.
69. The method of any one of claims 62-67, wherein the thromboembolic disorder is a blood clot.
70. The method of any one of claims 62-69, further comprising conditioning the artificial surface with a separate dose of a pharmaceutical composition of any one of claims 1-34 prior to contacting the artificial surface with blood in the circulatory system of the subject.
71. The method of any one of claims 62-69, further comprising conditioning the artificial surface with a separate dose of a pharmaceutical composition of any one of claims 1-34 prior to or during administration of the pharmaceutical composition to the subject.
72. The method of any one of claims 62-69, further comprising conditioning the artificial surface with a separate dose of a pharmaceutical composition of any one of claims 1-34 prior to and during administration of the pharmaceutical composition to the subject.
73. The method of any one of claims 62-72, wherein the artificial surface is a cardiopulmonary bypass circuit.
74. The method of any one of claims 62-72, wherein the artificial surface is an extracorporeal membrane oxygenation (ECMO) apparatus.
75. The method of claim 74, wherein the ECMO apparatus is venovenous ECMO
apparatus or venoarterial ECMO apparatus.
apparatus or venoarterial ECMO apparatus.
76. A method of preventing or reducing a risk of a thromboembolic disorder in a subject during or after a medical procedure, comprising:
(i) administering to the subject an effective amount of a pharmaceutical composition of any one of claims 1-34, before, during, or after the medical procedure; and (ii) contacting blood of the subject with an artificial surface;
thereby preventing or reducing the risk of the thromboembolic disorder during or after the medical procedure.
(i) administering to the subject an effective amount of a pharmaceutical composition of any one of claims 1-34, before, during, or after the medical procedure; and (ii) contacting blood of the subject with an artificial surface;
thereby preventing or reducing the risk of the thromboembolic disorder during or after the medical procedure.
77. The method of claim 76, wherein the artificial surface is conditioned with a pharmaceutical composition of any one of claims 1-34 prior to administration of the pharmaceutical composition to the subject prior to, during, or after the medical procedure.
78. The method of claim 77, wherein the pharmaceutical composition for conditioning the artificial surface further comprises a solution, wherein the solution is selected from the group consisting of a saline solution, Ringer's solution, and blood.
79. The method of any one of claims 76-78, wherein the thromboembolic disorder is a blood clot.
80. The method of any one of claims 76-79, wherein the medical procedure comprises one or more of i) a cardiopulmonary bypass, ii) oxygenation and pumping of blood via extracorporeal membrane oxygenation, iii) assisted pumping of blood (internal or external), iv) dialysis of blood, v) extracorporeal filtration of blood, vi) collection of blood from the subject in a repository for later use in an animal or a human subject, vii) use of venous or arterial intraluminal catheter(s), viii) use of device(s) for diagnostic or interventional cardiac catherisation, ix) use of intravascular device(s), x) use of artificial heart valve(s), and xi) use of artificial graft(s).
81. The method of any one of claims 76-80, wherein the medical procedure comprises a cardiopulmonary bypass.
82. The method of any one of claims 76-80, wherein the medical procedure comprises an oxygenation and pumping of blood via extracorporeal membrane oxygenation (ECMO).
83. The method of claim 82, wherein the ECMO is venovenous ECMO or venoarterial ECMO.
84. The method of any one of claims 62-83, wherein the subject is in contact with the artificial surface for at least 1 day (e.g., about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 2 months, about 3 months, about 6 months, about 9 months, about 1 year).
85. A method of treating the blood of a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition of any one of claims 1-34.
86. The method of any one of claims 62-85, wherein the pharmaceutical composition is administered to the subject intravenously.
87. The method of any one of claims 62-85, wherein the pharmaceutical composition is administered to the subject subcutaneously.
88. The method of any one of claims 62-85, wherein the pharmaceutical composition is administered to the subject as a continuous intravenous infusion.
89. The method of any one of claims 62-85, wherein the pharmaceutical composition is administered to the subject as a bolus.
90. The method of any one of claims 62-89, wherein the subject is a human.
91. The method of any one of claims 62-90, wherein the subject has an elevated risk of a thromboembolic disorder.
92. The method of claim 91, wherein the thromboembolic disorder is a result of a complication in surgery.
93. The method of any one of claims 62-92, wherein the subject is sensitive to or has developed sensitivity to heparin.
94. The method of any one of claims 62-92, wherein the subject is resistant to or has developed resistance to heparin.
95. The method of any one of claims 62-94, wherein the subject is a pediatric subject.
96. The method of any one of claims 62-94, wherein the subject is an adult.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962798012P | 2019-01-29 | 2019-01-29 | |
US62/798,012 | 2019-01-29 | ||
PCT/US2020/015002 WO2020159824A1 (en) | 2019-01-29 | 2020-01-24 | Therapeutic compounds and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3128018A1 true CA3128018A1 (en) | 2020-08-06 |
Family
ID=71841895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3128018A Pending CA3128018A1 (en) | 2019-01-29 | 2020-01-24 | Therapeutic compounds and compositions |
Country Status (10)
Country | Link |
---|---|
US (2) | US20210361634A1 (en) |
EP (1) | EP3917910A4 (en) |
JP (1) | JP2022523712A (en) |
KR (1) | KR20210119432A (en) |
CN (1) | CN113784951A (en) |
AU (1) | AU2020216887A1 (en) |
BR (1) | BR112021014956A2 (en) |
CA (1) | CA3128018A1 (en) |
IL (1) | IL285167A (en) |
WO (1) | WO2020159824A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116444506A (en) | 2014-02-07 | 2023-07-18 | 艾克赛特赫拉制药有限责任公司 | Therapeutic compounds and compositions |
KR20200118088A (en) | 2018-02-07 | 2020-10-14 | 엑시테라 파마슈티컬스 인코퍼레이티드 | Therapeutic compounds and compositions |
KR20210084581A (en) * | 2018-10-30 | 2021-07-07 | 엑시테라 파마슈티컬스 인코퍼레이티드 | Therapeutic compounds and compositions |
TW202345825A (en) * | 2022-03-30 | 2023-12-01 | 大陸商四川海思科製藥有限公司 | Pharmaceutical composition for injection comprising cyclic lactam compound and method for preparing same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006108039A2 (en) * | 2005-04-04 | 2006-10-12 | Daiamed, Inc. | Substituted azetidinones |
CN116444506A (en) * | 2014-02-07 | 2023-07-18 | 艾克赛特赫拉制药有限责任公司 | Therapeutic compounds and compositions |
WO2018118705A1 (en) * | 2016-12-23 | 2018-06-28 | Exithera Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
-
2020
- 2020-01-24 CA CA3128018A patent/CA3128018A1/en active Pending
- 2020-01-24 AU AU2020216887A patent/AU2020216887A1/en active Pending
- 2020-01-24 WO PCT/US2020/015002 patent/WO2020159824A1/en unknown
- 2020-01-24 BR BR112021014956-2A patent/BR112021014956A2/en unknown
- 2020-01-24 JP JP2021544181A patent/JP2022523712A/en active Pending
- 2020-01-24 EP EP20748002.1A patent/EP3917910A4/en active Pending
- 2020-01-24 CN CN202080019754.5A patent/CN113784951A/en active Pending
- 2020-01-24 KR KR1020217025742A patent/KR20210119432A/en unknown
-
2021
- 2021-07-27 IL IL285167A patent/IL285167A/en unknown
- 2021-07-29 US US17/388,859 patent/US20210361634A1/en active Pending
-
2023
- 2023-04-19 US US18/136,734 patent/US20230270731A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3917910A4 (en) | 2022-11-09 |
KR20210119432A (en) | 2021-10-05 |
BR112021014956A2 (en) | 2021-09-28 |
WO2020159824A1 (en) | 2020-08-06 |
US20210361634A1 (en) | 2021-11-25 |
CN113784951A (en) | 2021-12-10 |
EP3917910A1 (en) | 2021-12-08 |
JP2022523712A (en) | 2022-04-26 |
IL285167A (en) | 2021-09-30 |
US20230270731A1 (en) | 2023-08-31 |
AU2020216887A1 (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230270731A1 (en) | Therapeutic compounds and compositions | |
US20210261524A1 (en) | Therapeutic compounds and compositions | |
US20210253550A1 (en) | Therapeutic compounds and compositions | |
RU2707887C2 (en) | Dihydroindolysinone derivative | |
JP5993933B2 (en) | Otamixerban formulation with improved stability | |
AU2019217366B2 (en) | Therapeutic compounds and compositions | |
RU2813780C2 (en) | Therapeutic compounds and compositions | |
AU2021343468A1 (en) | Therapeutic compounds, compositions, and methods of use thereof | |
CN116782911A (en) | Therapeutic compounds, compositions, and methods of use thereof | |
EP2258364A1 (en) | Preventive and/or remedy for vascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220912 |
|
EEER | Examination request |
Effective date: 20220912 |
|
EEER | Examination request |
Effective date: 20220912 |
|
EEER | Examination request |
Effective date: 20220912 |
|
EEER | Examination request |
Effective date: 20220912 |
|
EEER | Examination request |
Effective date: 20220912 |